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GenerAl intrODuctiOn AnD Outline Of this thesis
Colorectal cancer is one of the most common cancers in Europe and the incidence is still 
growing. It is the third most common diagnosed cancer in males, and the second in females. 
Besides, it is the second most important cause of cancer death in Europe.1 The incidence 
rates vary across Europe, with higher rates in developed countries, as compared to develop-
ing countries.2 These geographic differences appear to be attributable to the differences in 
dietary and environmental exposures. In the Netherlands the incidence is high as compared 
to other European countries with an incidence of over 57 per 100 000 per year (European 
Standardized Rate).
Age is a major risk factor for colorectal cancer. The highest incidence is between 70 and 79 
years of age, which makes it a disease of the elderly patient (see figure 1). Together with the 
fact that our population is ageing it is anticipated that the number of elderly patients with 
colorectal cancer will grow during the coming years.3 
Approximately two thirds of the colorectal cancer incidence occurs in the colon, and about one 
third occurs in the rectosigmoid and rectum. Stage of disease is based on the growth of the 
tumour into the wall of the intestine, tumour growth in lymph nodes, and tumour growth into 
other organs.4 About 25% of the patients will present with lymph node metastases without 















figure 1: Crude number of new cases per 5-year age group from 2005 until 2010
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cancer. Furthermore, approximately 20 to 25% of the patients with colorectal cancer will have 
distant metastases at time of diagnosis, most often in the liver and/or longs, also called stage 
IV colorectal cancer. Patients without distant and lymph node metastases have stage I or stage 
II disease, depending on the growth of the tumour in the wall of the intestine and surrounding 
structures.
Over the past decades survival has improved as a result of several changes in the therapy 
of colorectal cancer. The EUROCARE working group has shown improvement in survival of 
colorectal cancer patients in Europe, Survival substantially increased over time in all European 
regions. In general, increases were more pronounced in younger than in older patients, for 
earlier than for more advanced cancer stages and for
rectum than for colon cancer.5 With all the multidisciplinary approaches to treat colorectal 
cancer, it has to be emphasized that surgery remains the mainstay of curative colorectal 
cancer. To improve the overall outcome of colorectal cancer, one can focus on improvement of 
treatment or enhancement of quality of care; both parts will be discussed in this thesis. 
PArt i cOlOrectAl cAncer; treAtment AnD survivAl
Since colon and rectal cancer are treated as different entities, they will be discussed separately 
in this thesis. In the treatment of early colon cancer, the first step is the surgical removal of the 
tumour and loco regional lymph nodes. Nowadays the classical abdominal resection is increas-
ingly replaced by laparoscopic surgery. Besides, for early stages of colon cancer advanced 
endoscopic techniques such as endoscopic mucosal resection, endoscopic submucosal dis-
section, or even endoscopic mucosal ablation are described as less invasive experimental 
alternatives of colectomy.6-8 Additionally, advances have been made in perioperative care 
with the implementation of fast track programmes for colorectal surgery.9,10 
In the beginning of the 1990’s Moertel et al showed in a randomised clinical trial that stage 
III patients treated with adjuvant chemotherapy have a significant decrease in recurrence and 
an improvement in survival.11 Since then, the use of adjuvant chemotherapy has been incor-
porated in guidelines. Since the mid 2000’s the use of adjuvant chemotherapy for high risk 
stage II patients has been implemented in the Dutch guidelines.12 High risk stage II patients 
are defined as patients with a T4 tumour, poor differentiation, perforation or obstruction at 
time of diagnosis, less than 10 lymph nodes examined, and/or angio-invasion. The time trends 
in the use and costs of adjuvant chemotherapy, and survival for stage III colon cancer patients 
in the Netherlands from 1990-2008 are shown in Chapter 2. Factors associated with omitting 
adjuvant chemotherapy in these patients are described in Chapter 3. 
The improvement in survival over time is accompanied by changes in treatment, although in 
subgroups, such as elderly patients and patients with comorbidities, these changes in treat-
ment have occurred in a lesser extent. 13 Chapter 4 consists of a retrospective study comparing 
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the survival improvement of younger, middle-aged, and elderly over time. In general, survival 
of elderly colorectal cancer patients is worse as compared to younger patients. Chapter 5 
shows the importance of the first postoperative year on the survival differences between 
older and younger colorectal cancer patients. 
As in colon cancer, surgical removal of the tumour is the main curative treatment for rectal can-
cer patients. Phil Quirke in 1986 identified that there was a high positive predictive value of 
the circumferential resection margin involvement for the subsequent development of locally 
recurrent cancer and poor survival.14 Conventional resection consisted of blunt dissection, 
which failed to clear the pelvis of mesorectal disease and resulted in an increased risk of 
positive lateral margins.15 Consequently, the total mesorectal excision (TME) technique, which 
is defined by embryological planes, and with a sharp dissection, has been introduced.16 Since 
introducing the TME technique, the local recurrences have decreased from 15-50% to below 
10%.17-21 
The preferred type of resection depends on the anatomical location of the tumour, all using 
TME resection. Tumours located in the lower rectum, near the anal sphincter, should undergo 
an abdominal perineal resection (APR) in most cases, resulting in a permanent colostomy. For 
tumours in the middle or upper part of the rectum, a low anterior resection (LAR) is indicated. 
With this surgical method the anal sphincter remain will be preserved.
In the Swedish Rectal Cancer trial patients included from 1987 until 1990 had a significant 
lower local recurrence rate when treated with preoperative, short course, 5 x 5 Gy radiotherapy 
(27% in surgery only compared with 11% for patients treated with preoperative radiotherapy 
followed by immediate surgery).22 In the 1990’s the Dutch Colorectal Cancer Group designed 
a trial using standardised TME surgery; the Dutch TME trial.23 After the Swedish Rectal Cancer 
trial had demonstrated the beneficial effect of radiotherapy, the remaining question was 
whether radiotherapy was still beneficial in combination with standardised, good, TME sur-
gery.22,24 The results of the Dutch TME trial demonstrated improved local control, with an even 
lower local recurrence rate for patients treated with preoperative radiotherapy. For patients 
with a negative resection margin, the effect of radiotherapy was irrespective of the distance 
from the anal verge and led to an improved cancer-specific survival, which was nullified by 
an increase in other causes of death, resulting in an equal overall survival. Nevertheless, 
preoperative short term radiotherapy significantly improved ten year survival in patients with 
a negative circumferential margin and TNM stage III.25 Since the introduction of preopera-
tive radiotherapy, the interval between short course radiotherapy has been discussed as this 
could result in differences in outcome. Chapter 6 addresses the impact of the interval between 
preoperative short course radiotherapy and surgery on outcome of rectal cancer patients in 
two time periods. 
Besides radiotherapy, also chemoradiation (45-50 Gy of radiotherapy combined with chemo-
therapy) is often used as preoperative treatment for locally advanced rectal cancer patients. 
In contrast to short course radiotherapy followed by immediate surgery, chemoradiation 
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followed by surgery in six to eight weeks does induce downstaging.26,27 For locally advanced 
rectal cancer and patients with more than four lymph nodes expected to be positive the Dutch 
guidelines recommends chemoradiation.12 
Since the use of adjuvant chemotherapy in stage III colon cancer patients is recommended, 
the National Institute of Health (NIH) recommend that adjuvant chemotherapy should be used 
in rectal cancer patients as well, based upon the results of a few small trials in the USA.28-30 
These conclusions have been criticised since the trials are well underpowered, patients were 
included before the TME technique was introduced, and radiotherapy, if given, was delivered 
postoperatively. Nowadays, preoperative radiotherapy or preoperative chemoradiation, 
depending on the mesorectal fascia involvement, is considered to be the gold standard.31 
Although the effect of adjuvant chemotherapy could be similar in rectal as in colon cancer, 
there is little direct evidence to support this since the introduction of preoperative treatment. 
A recent Cochrane review has shown that rectal cancer patient treated without preoperative 
treatment do benefit from adjuvant chemotherapy, while for rectal cancer patients treated 
with preoperative treatment, this remains unknown.32
PArt ii internAtiOnAl cOmPArisOns in cOlOrectAl cAncer 
treAtment AnD survivAl
Quality of health care has a high priority on the political agenda of most European countries. 
Surgical quality assurance program, also called surgical audit, is a quality instrument that col-
lects detailed clinical data from different health care providers, which can be adjusted for 
baseline risk and subsequently fed back to individual hospitals or surgeons. Major improve-
ments have been achieved with national audits.33-35 However, although all the national audits 
achieved excellent results, differences in treatment and outcome remain between European 
countries.36 This suggests that further improvement is possible. To reduce the differences 
between the countries by identifying and spreading ‘best practice’, the European CanCer 
Organisation (ECCO) initiated an international, multidisciplinary, outcome-based quality 
improvement program: European Registration of Cancer Care (EURECCA). The goal is to cre-
ate a multidisciplinary European registration structure for patient, tumour, and treatment 
characteristics linked to outcome registration.37 The EURECCA project makes use of existing 
national audit registrations and started with colorectal cancer, at this moment European audit 
projects of other solid tumour types, such as breast cancer, gastric cancer, oesophageal cancer, 
and pancreatic cancer, are developed. Chapter 7 describes the ‘core dataset’ (variables that 
are included by at least 8 of the 9 audit registries) of EURECCA colorectal. The cumulative 
experience of EURECCA’s participants could be used to identify a ‘core dataset’ that covers 
all important aspects needed for high quality auditing and at the same time lacking needless 
data items that only consumes administrative effort. After defining the ‘core dataset’, the next 
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step is to compare treatment and survival between countries. The first EURECCA analyses are 
described in Chapter 8, which is a comparison of the use of preoperative treatment for rectal 
cancer patients between Norway, Sweden, Denmark, Belgium and the Netherlands. 
Currently, randomised controlled trials (RCT’s), systematic reviews, and meta-analyses are 
seen as the highest level of evidence. Unfortunately, randomised controlled trials are costly, 
time consuming, subgroups may be underrepresented in trials, and certain research ques-
tions remain unanswered by randomised clinical trials. A relatively new analysis in medicine 
is an instrumental variable analysis. In randomised controlled trials the type of treatment is 
assigned randomly, which makes sure that both treatment groups are comparable. Therefore, 
the results of both treatment arms can be compared in a randomised controlled trial. Since 
in observational studies the type of treatment is not randomly assigned to the patients, but 
probably based on patients’ characteristics, treatment results cannot be compared without 
confounding by indication is most cases. An instrumental variable is a factor which is not 
related to both patients’ characteristics and prognosis, and therefore can function as a pseudo 
randomisation.38,39 The prognosis of different treatment strategies can then be compared. In 
Chapter 9 a new preoperative treatment for rectal cancer used in a specialised clinic in Canada 
has been compared with standard of care in a specialised clinic in the Netherlands. This study 
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Use of adjuvant chemotherapy for stage III colon cancer has increased since several trials have 
shown the beneficial effect on survival. In this population-based study we show time trends 
in the administration and costs of chemotherapy and relative survival of patients with stage 
III colon cancer.
Methods
All patients surgically treated for adenocarcinoma of the colon stage III between 1990 and 
2008 in the Netherlands were included. Relative survival (using period analyses) and Relative 
Excess Risks of death (RER) were calculated. The costs of chemotherapy were estimated.
Results
A total of 24,111 colon cancer patients with stage III were included in the cohort. The admin-
istration (from 9.5% in 1990 to 61.8% in 2008; p<0.001) and costs of chemotherapy (from 
€ 38,467 in 1990 to € 3,876,150 in 2008) increased during the study period. Multivariable 
relative survival improved for patients receiving adjuvant chemotherapy (RER 0.93; 95% CI 
0.92-0.94; p<0.001). In contrast, relative survival remained stable for patients, younger than 
80 years, who did not receive chemotherapy (RER 1.00; 95% CI 1.00-1.01; p=0.3). Patients 
aged 80 years and older without chemotherapy, relative survival increased during the study 
period (RER 0.98; 95% CI 0.97-0.99; p<0.001). 
Conclusion 
Both the administration, the costs of chemotherapy and the survival of patients with stage 
III colon cancer increased over time. Whereas the costs and administration of chemotherapy 
increased extensively, relative survival increased to a lesser extent. For patients treated with 
adjuvant chemotherapy relative survival increased equally in all age groups.
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intrODuctiOn
Colorectal cancer is one of the most frequently diagnosed cancers in the Netherlands with 
more than 12,000 new patients annually. Approximately, two thirds of the patients are diag-
nosed with colon cancer and approximately a quarter of these patients are diagnosed with 
stage III disease.1 After potentially curative surgery without adjuvant treatment, 50-60% of 
these patients will relapse.2 Over 50% of the patients diagnosed with colon cancer are aged 
70 years or older.
Moertel et al. were first to show a significant decrease in recurrence and improvement in 
survival of stage III colon cancer patients with the use of adjuvant fluorouracil and levami-
sole.3 Afterwards, several studies have shown that levamisole can be replaced by folinic acid, 
whereas low dose folinic acid is as effective as high dose. Besides, it was shown that adjuvant 
chemotherapy for half a year achieves similar results in terms of relapse and improvement 
of survival as chemotherapy for one year.4,5 In 2004 the MOSAIC-trial was published, which 
randomised between fluorouracil and folinic acid with or without oxaliplatin. The addition 
of oxaliplatin showed a significant increase in disease-free survival and overall survival for 
stage III colon cancer patients.6 A meta-analysis of recent trials showed no difference between 
oral or intravenous fluorouracil, and one trial included in the meta-analysis showed a trend 
towards an advantage in disease-free survival for oral fluorouracil (capecitabine).7 
In the Netherlands adjuvant chemotherapy for stage III colon cancer patients was incorpo-
rated in the guidelines in the mid-1990s without age limits.8 The guidelines advised half a 
year of fluorouracil in combination with folinic acid as adjuvant treatment. Revisions of the 
guidelines were made in 2004, when FOLFOX (a combination of fluorouracil, folinic acid and 
oxaliplatin) was advised. Since 2008 the guidelines included that intravenous fluorouracil 
could be replaced with oral fluorouracil (capecitabine). Furthermore, in case of high age and/
or comorbidities, the medical oncologist can choose for monotherapy with oral fluorouracil.8 
In the aforementioned adjuvant trials, treatment was shown to be cost-effective, but elderly 
patients were usually not included. A large proportion of the elderly patients with stage III 
colon cancer do not receive adjuvant chemotherapy, although some studies showed a benefit 
for the elderly in terms of recurrence and survival.9,10 In this population-based study we show 
time trends for young and elderly patients in the administration and costs of chemotherapy, 
and the survival of stage III colon cancer patients.
PAtients AnD methODs
Patients and follow-up
Patients were selected from the Netherlands Cancer Registry (NCR). The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the registry of 
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histo- and cytopathology (PALGA-system). The national hospital discharge databank, which 
receives discharge diagnoses of admitted patients from all Dutch hospitals, completed case 
ascertainment. Information on patient characteristics, such as gender and date of birth, as 
well as tumour characteristics, such as date of diagnosis, anatomical location (International 
Classification of Diseases for Oncology (ICD-O)), histology, stage (clinical and pathological 
TNM classification), grade, and primary treatment, were obtained routinely from the medical 
records, around nine months after diagnosis. The information about the primary treatment 
included whether patients received chemotherapy, but no information about the number 
of cycles or which drugs were retrieved. Completeness of data was estimated to be at least 
95%.11 The vital status was obtained either directly from medical records or through linkage 
of the cancer registry data with the municipal population registry which registers information 
on inhabitants’ vital status. 
Stage was based on pathological TNM classification (5th edition); if pathological stage was 
unknown, clinical TNM-stage was used. In approximately 1.2% of the patients the pN-stage 
were missing, resulting in the use of cN-stage. From 2003 the percentage of missing pN-stage 
decreased to approximately 0.2% per year. Patients were divided in four age groups (<60, 
60-69, 70-79, and ≥80 years). Tumour localization was categorized into the following ana-
tomical locations: proximal colon; consisting of caecum, appendix, ascending colon, hepatic 
flexure, and transverse colon (ICD-O C18.0-C18.4), distal colon; consisting of splenic flexure, 
descending colon, and sigmoid colon (ICD-O C18.4-C18.7), and Not Otherwise Specified 
(NOS); consisting of unknown location or overlapping anatomical locations of the colon (ICD-O 
C18.8 and C18.9). Type of hospital was divided into two groups. Most patients were treated in 
non-university hospitals.
Patients with their first primary invasive colon cancer (adenocarcinoma; ICD-O C18) stage III 
(T1-4, N1-3, M0) diagnosed between January 1st 1990 and December 31st 2008 and surgically 
treated were selected from the NCR (n=24,111). At least 98.8% of the included patients were 
treated with curative surgery. 
Statistical analyses
Differences between the age groups were tested with a Chi-Square test. Statistical signifi-
cance was defined as p<0.05. Follow-up time was calculated as the time from diagnosis to 
death, last date of follow-up or last date of linkage with the municipal population registry 
(January 1st 2010). For survival analyses, overall survival and relative survival were calculated. 
Overall survival analyses were carried out by the Kaplan-Meier method and multivariable 
Cox proportional hazard models with any death as event. Relative survival was calculated by 
the Hakulinen method, as the ratio of the observed survival among the cancer patients and 
the survival that would have been expected based on the corresponding (age, sex, and year) 
general population. National life tables were used to estimate the expected survival. Relative 
Excess Risks of death (RER) were estimated using a multivariable generalized linear model 
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with a Poisson distribution, based on collapsed relative survival data, using exact survival 
times. Period analysis was conducted for patients diagnosed between 2005 and 2008.12 
The multivariable relative survival analysis was stratified for age groups and adjuvant che-
motherapy, as the model showed statistical interaction between year of diagnosis, adjuvant 
chemotherapy, and age.
Costs of chemotherapy per vial or tablet were retrieved from the pharmacy at the Leiden 
University Medical Center for three years: 1990, 1999, and 2008. The costs presented in 
this study are solely the costs of the chemotherapy and were calculated per average person 
(height of 1.70 m, weight of 76 kg, 1.90 m2 body surface). The number of patients receiving 
chemotherapy was retrieved from the present dataset. The different types of chemotherapy 
and completion rate were unknown in the dataset retrieved from the NCR and were therefore 
retrieved from the ‘Quality Information System Colorectal Cancer’ project from the Compre-
hensive Cancer Centre the Netherlands, location Leiden, and extrapolated to the dataset from 
the NCR. The ‘Quality Information System Colorectal Cancer’ project was a project from 2004 
until 2006 collecting detailed information about chemotherapy (type, dose and completion) 
of colorectal cancer patients in this region. Percentages from this project have been used to 
calculate the results in the current study, assuming that this region is representative for all the 
Netherlands. Patients who did not complete their chemotherapy were calculated to have had 
half of the courses of chemotherapy. 
results
A total of 24,111 colon cancer patients with stage III were included in the cohort. Median age 
of the patients at diagnosis was 70 (range 11-100) years. The age distribution was stable over 
time from 1990 to 2008 (p=0.7). The sex distribution was different within the age groups, 
with more females in the elderly age group (p<0.001, table 1). The distribution of anatomical 
tumour location changed with age, younger patients were more often diagnosed with distal 
tumours, while elderly patients were more often diagnosed with proximal tumours (p<0.001). 
With increasing age, patients were more often diagnosed with higher T-stage (p<0.001) and 
lower N-stage (p<0.001). 
Administration of chemotherapy
The administration of chemotherapy increased from 22.2% in 1990 to 92.3% in 2008 for 
patients younger than 60 years; from 12.8% to 84.5% for patients aged 60 to 69 years; from 
4.2% to 58.8% for patients aged 70 to 79 years; and from 0.5% to 5.6% for patients of 
80 years and older (p<0.001 for each age group, figure 1). The odds of receiving adjuvant 
chemotherapy, adjusted for sex, age, anatomical location, differentiation, T-stage, N-stage, and 
hospital type, increased significantly in all age groups. The following factors were negatively 
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associated with the administration of chemotherapy in younger patients (<70 years): increas-
ing age, T4-stage, and tumours with unknown location. On the contrary, higher N-stage was 
associated with more frequent administration of adjuvant chemotherapy in younger patients. 
Patients aged 70 years or older received more frequently adjuvant chemotherapy with a 
higher N-stage, while in contrary, increasing age, female gender, and T4-stage were associated 
with less frequent administration of chemotherapy.
In 1990, less than 10% of all patients (all ages) received chemotherapy. As shown in table 
2, a higher percentage of patients aged younger than 60 years were treated with adjuvant 
table 1: Patient characteristics
  <60 years % 60-70 years % 70-80 years % ≥80 years % p-value
sex <0.001
Male 2621 50.9 3420 53.7 3730 47.1 1564 33.5
Female 2524 49.1 2943 46.3 4198 52.9 3111 66.5
Period 0.7
1990-1996 1532 29.8 1881 29.6 2341 29.5 1415 30.3
1997-2002 1647 32.0 2000 31.4 2579 32.5 1455 31.1
2003-2008 1966 38.2 2482 39.0 3008 38.0 1805 38.6
Grade <0.001
I 339 6.6 450 7.1 473 6.0 270 5.7
II 3193 62.1 4078 64.1 4950 62.4 2752 58.9
III 1197 23.3 1394 21.9 1912 24.1 1303 27.9
Unknown 416 8.1 441 6.9 593 7.5 350 7.5
Anatomical location <0.001
Proximal 2301 44.7 3081 48.4 4399 55.5 2895 61.9
Distal 2742 53.3 3170 49.8 3397 42.8 1697 36.3
NOS* 102 2.0 112 1.8 132 1.7 83 1.8
t-stage <0.001
1 66 1.3 73 1.2 61 0.8 41 0.9
2 385 7.5 487 7.6 589 7.4 274 5.9
3 3875 75.3 4787 75.2 5904 74.5 3416 73.1
4 805 16.6 997 15.7 1351 17.0 932 19.9
Unknown 14 0.3 19 0.3 23 0.3 12 0.2
n-stage <0.001
1 3589 69.8 4520 71.0 5796 73.1 3453 73.9
2 1435 27.9 1706 26.8 1986 25.1 1123 24.0
3 121 2.3 137 2.2 146 1.8 99 2.1
chemotherapy <0.001
Yes 3775 73.4 4066 63.9 2822 35.6 142 3.0
No 1370 26.6 2297 36.1 5106 64.4 4533 97.0
total 5145 21.3 6363 26.4 7928 32.88 4675 19.4  
* Not Otherwise Specified and unknown location




















<60 years 60-69 years 70-79 years ≥80 years 
Years of diagnosis <60 years 60-69 years 70-79 years ≥80 years
OR over time* (95%CI) 1.23 (1.22-1.25) 1.22 (1.21-1.24) 1.19 (1.18-1.21) 1.17 (1.13-1.22)
p-value <0.001 <0.001 <0.001 <0.001
* Adjusted for sex, age, grade, anatomical location, T-stage, N-stage, and hospital type.
figure 1: Percentage of chemotherapy given per age group
table 2: Type of chemotherapy in 1990, 1999, and 2008, per age group
no. of patients in 1990 
(% of chemo)
no. of patients in 1999 
(% of chemo)
no. of patients in 2008 
(% of chemo)
total no. of patients < 60 years 185 271 338 
5-FU* 41 (22.2%) 229 (84.5%) 7 (2.0%)
FOLFOX-4 0 (0.0%) 0 (0.0%) 53 (15.7%)
CapOX 0 (0.0%) 0 (0.0%) 222 (65.7%)
Capecitabine mono 0 (0.0%) 0 (0.0%) 30 (8.9%)
total no. of patients with chemotherapy 41 (22.2%) 229 (84.5%) 312 (92.3%)
total no. of patients 60-69 years 251 322 504 
5-FU* 32 (12.8%) 235 (73%) 10 (2.0%)
FOLFOX-4 0 (0.0%) 0 (0.0%) 72 (14.2%)
CapOX 0 (0.0%) 0 (0.0%) 276 (54.8%)
Capecitabine mono 0 (0.0%) 0 (0.0%) 68 (13.5%)
total no. of patients with chemotherapy 32 (12.8%) 235 (73%) 426 (84.5%)
total no. of patients 70-79 years 284 477 563 
5-FU* 12 (4.2%) 162 (34%) 20 (3.5%)
FOLFOX-4 0 (0.0%) 0 (0.0%) 46 (8.2%)
CapOX 0 (0.0%) 0 (0.0%) 125 (22.2%)
Capecitabine mono 0 (0.0%) 0 (0.0%) 140 (24.9%)
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chemotherapy in 1990, and the percentage of patients receiving chemotherapy decreased 
with increasing age. In 1999 almost 50% of all patients received chemotherapy (all ages), 
which also decreased with increasing age.  In both 1990 and 1999 patients were only treated 
with a combination of fluorouracil and folinic acid. In 2008 over 60% of all patients (all ages) 
received adjuvant chemotherapy. Since the guidelines have been revised in 2004 and 2008, 
patients in 2008 were treated more often with FOLFOX, CapOx (combination of capecitabine 
and oxaliplatin) or capecitabine as monotherapy (table 2). With increasing age, patients more 
often received capecitabine as a monotherapy and less often a combination of capecitabine 
with oxaliplatin or FOLFOX.
Costs of chemotherapy 
Due to the low percentage of patients receiving chemotherapy in 1990 and the low costs 
for these chemotherapeutics (off patent), the costs were relatively low, € 38,467 (figure 2). 
The estimated costs per patient (total costs divided trough the number of patients treated) 
in 1990 were € 459 for patients younger than 60 years, € 445 for patients between 60 and 
69 years, € 427 for patients between 70 and 79 years, and € 285 for patients 80 years and 
older, as shown in attachment 1. With increasing age, fewer patients completed six months of 
chemotherapy, resulting in lower costs per patient with increasing age. Guidelines of adjuvant 
chemotherapy were widely incorporated in 1999, as is shown in figure 1. The costs for chemo-
therapy in the present dataset for 1999 were approximately € 262,040. The estimated costs 
of chemotherapy per person were between € 264 and € 426 for the different age groups. In 
2008, the costs of chemotherapy were higher due to the frequent use of capecitabine, an 
oral 5-fluorouracil analogue, which is still under a patent. Furthermore, oxaliplatin was widely 
incorporated as adjuvant chemotherapy in addition to fluorouracil and folinic acid (FOLFOX). 
The estimated costs per person in 2008 varied between € 1,933 and € 3,800 and total costs 
were estimated to be € 3,876,150.
table 2 (continued)
no. of patients in 1990 
(% of chemo)
no. of patients in 1999 
(% of chemo)
no. of patients in 2008 
(% of chemo)
total no. of patients with chemotherapy 12 (4.2%) 162 (34%) 331 (58.8%)
total no. of patients ≥80 years 190 271 357 
5-FU* 1 (0.5%) 10 (3.7%) 4 (1.1%)
FOLFOX-4 0 (0.0%) 0 (0.0%) 0 (0.0%)
CapOX 0 (0.0%) 0 (0.0%) 4 (1.1%)
Capecitabine mono 0 (0.0%) 0 (0.0%) 12 (3.4%)
total no. of patients with chemotherapy 1 (0.5%) 10 (3.7%) 20 (5.6%)
total no. of patients in each year with 
chemotherapy
86 (9.5%) 636 (47.4%) 1089 (61.8%)
* 5-FU in combination with folinic acid
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Survival
Five year overall survival for colon cancer patients with stage III increased over time from 
38.7% in 1990-1996, to 45.9% in 1997-2002, and to 51.6% in 2003-2008 (HR over inci-
dence periods=0.82; 95% CI=0.80-0.84; p<0.001). The five year relative survival increased 
from 47.3% in 1990-1996, to 55.3% in 1997-2002, and to 62.2% in 2003-2008 (RER over 
incidence periods=0.96; 95% CI=0.96-0.97; p<0.001, figure 3). The improvement of relative 
survival was less pronounced with increasing age with a RER of 0.94 (95% CI 0.93-0.95; 
p<0.001) for patients younger than 60 years, RER of 0.95 (95% CI 0.95-0.96; p<0.001) for 
patients 60-70 years, RER of 0.96 (95% CI 0.95-0.97; p<0.001) for patients between 70-80 
years and a RER of 0.99 (95% CI 0.98-1.00; p=0.01) for patients of 80 years and older. 
The multivariable relative survival analyses were adjusted for sex, age, grade, anatomical loca-
tion, T-stage, N-stage, and hospital. The multivariable relative survival of patients receiving 
chemotherapy increased for each age group over time (table below figure 3). However, the 
multivariable relative survival of in patients not receiving chemotherapy was less consistent 
over time. Whereas the survival of patients aged 60 to 69 years who did not receive chemo-
therapy decreased over time, the survival of patients aged 80 years or older has improved over 
time. Relative survival of the other age groups not receiving chemotherapy remained stable 
over time. Of the patients that did not receive adjuvant chemotherapy, female patients had a 
better relative survival. Relative survival decreased with higher grade, T-stage, and N-stage in 
both the group of patients receiving adjuvant chemotherapy, as well as the group of patients 
not receiving adjuvant chemotherapy (p<0.001). 
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figure 2: Changes of total costs of chemotherapy over time
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DiscussiOn
In this nationwide population-based study covering a period of 18 years, we showed that both 
administration of chemotherapy and survival of patients with stage III colon cancer increased 
during the study period. Whereas the administration of chemotherapy increased considerably 
during the period, survival increased to a lesser extent. New chemotherapeutics were intro-
duced during the study period, which led, together with the increased use of chemotherapy, 
to increasing costs of chemotherapy per patient. 
Administration of chemotherapy
The changes in administration of chemotherapy and survival of colon cancer found in this 



















<60 years 60-69 years 70-79 years ≥80 years 
chemotherapy no chemotherapy
rer (95% ci) p-value rer (95% ci) p-value
<60 years 0.93 (0.91-0.94) <0.001 1.01 (1.00-1.03) 0.2
60-69 years 0.94 (0.93-0.96) <0.001 1.02 (1.00-1.03) 0.01
70-79 years 0.92 (0.89-0.94) <0.001 1.00 (0.99-1.00) 0.3
≥80 years 0.83 (0.73-0.94) 0.003 0.98 (0.97-0.99) <0.001
* Adjusted for sex, age, grade, anatomical location, T-stage, N-stage, and hospital type.
figure 3: Relative survival over time per age group, with multivariable relative survival per age 
group in the table
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The results of randomized clinical trials published during the study period have been imple-
mented in guidelines and clinical practice, resulting in a large increase in the use of adjuvant 
chemotherapy. Our observation that elderly patients less frequently received chemotherapy 
as compared to younger patients is in line with previous studies.15,16 There are several rea-
sons why elderly patients are less likely to receive adjuvant chemotherapy; they include the 
presence of comorbidities, frailty, the absence of supportive caregivers, and a decrease in 
patients’ general condition and cognitive ability.17 In addition, elderly patients seem to be 
less willing to accept the negative side-effects of chemotherapy, resulting in more frequent 
patient refusal, and some medical oncologists will probably offer elderly less often adjuvant 
chemotherapy.18 However, fit elderly colon cancer patients may benefit equally from adjuvant 
chemotherapy without increased toxicity.9,10 Over time, patients were more often treated with 
FOLFOX, CapOx, or capecitabine mono therapy, according to the results of the MOSAIC trial, 
the NSABP C-07 trials, and the adjustments in the guidelines.6,8,19 The addition of oxaliplatin 
showed an improved disease-free survival for stage III colon cancer patients.6,19 Since sub-
groups analyses of these two studies have shown that elderly patients with an age of 70 years 
and older are less likely to benefit from the addition of oxaliplatin, elderly patients in our 
study indeed received less often oxaliplatin in addition to oral fluorouracil with folinic acid, or 
in addition to capecitabine.20,21 Furthermore, capecitabine monotherapy has shown to be as 
least as effective as intravenous fluorouracil in combination with folinic acid.7  
Costs of chemotherapy
The costs of chemotherapy are expected to be an underestimation since only the costs for 
the medication, and no hospital or material costs, were included. Furthermore, patients who 
did not complete the chemotherapy were calculated to have had fifty percent of the expected 
chemotherapy costs, which also might have led to an underestimation. Despite these limita-
tions, costs of chemotherapy have increased considerably during the study period, especially 
in the last period, due to the use of newer chemotherapeutics. Cost-effectiveness cannot be 
calculated with the design of this study. However, we observe high costs for the adjuvant 
chemotherapy (between € 1,933 and € 3,800 per person in 2008). Recently, Pandor et al. have 
shown in their systematic review that the use of oral fluorouracil is cost-effective, based on 
quality adjusted life years (QALY’s).22 
The end of the patent on oral fluorouracil, capecitabine, in December 2013, will probably 
result in lower costs per person. Furthermore, subset analyses of recent studies have shown 
that oxaliplatin might not be effective in elderly colon cancer patients20,21 which could 
decrease the costs in the coming years. 
Overall, the improvement in survival found in this study was accompanied by an approximately 
100-fold increase in costs of chemotherapy. Currently, the question is how much more costs 
can be accepted. The proportion between the improvement in survival and the increase in 
costs should be balanced. Perhaps, other ways to improve survival, such as perioperative care 
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or low-cost drugs such as aspirin23, should be implemented first, since these improvements 
might be relatively cheap and less toxic in comparison to new chemotherapeutics.
Survival
The considerable improvement in five year relative survival of patients who received che-
motherapy over time with 7% for patients younger than 60 years, 6% for patients between 
60 and 69 years, 8% for patients between 70 and 79 years, and 17% for patients 80 years 
and older, is thought to be at least in part attributable to the increased use of adjuvant che-
motherapy. Stage migration and improved perioperative care probably played an additional 
role, although these data were not available. Although the percentage of patients receiving 
chemotherapy increased most for patients younger than 60 years and less with increasing age, 
elderly patients who did receive chemotherapy had the highest increase in relative survival, 
indicating differences in the selection of patients receiving chemotherapy within each age 
group. 
In the adjuvant studies that demonstrated decreased colon cancer relapse and increased 
overall survival, the mean age was below 65 years and the small number of older patients does 
not allow drawing firm conclusions on the benefits of adjuvant therapy in elderly patients.10 
For patients not receiving adjuvant chemotherapy the relative survival remained almost 
stable, although there was an age disparity in time trends of relative survival. For patients 
aged younger than 80 years relative survival decreased or remained stable over time. The use 
of adjuvant therapy for these patients increased from approximately 10% to 80%. Hence, the 
selection of patients has changed over time from broad representation of unselected stage III 
patients who received no chemotherapy to a small group of highly selected patients for whom 
adjuvant therapy was not deemed beneficial for survival because of factors associated with an 
unfavourable outcome itself, such as comorbidities. 
For patients aged 80 years and older, relative survival increased over time for both those who 
did and those who did not receive adjuvant chemotherapy. Improved survival might be due 
to increased life expectancy and improved perioperative care. Besides, stage migration with 
improved detection of metastases during the preoperative work-up might have contributed as 
well.14,24 However, we have to interpret these retrospective data with caution. Nevertheless, 
these patients deserve more attention and research regarding adjuvant treatment.
Strengths and limitations
This population-based study has some limitations. Firstly, it lacks details concerning emergency 
surgery and the presence of comorbidities. Both are associated with increased postoperative 
complications and mortality and reduced administration of chemotherapy. Elderly patients are 
more likely to undergo emergency surgery and also the incidence of comorbidity increases 
with age.25 Secondly, the costs of chemotherapy and the number of patients completing 
chemotherapy per age group were estimated. Furthermore, the costs of complications and 
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additional costs, such as material and hospital stay, were not taken into account. This probably 
resulted in an underestimation of the actual costs of chemotherapy. 
Thirdly, stage migration probably played a role in the survival changes over time, as lymph 
node detection has improved and advanced diagnostic methods might have increased recog-
nition of metastases.14,24 It is unknown which part of the improvement in survival over time 
can be explained by stage migration, and which part can be attributed to changes in treatment. 
Nevertheless, this study has several strengths. It is a large population-based study, which used 
stratification according to age groups with comparison between younger and elderly patients 
and the receipt of chemotherapy over a long period of time, so that time trends could be 
studied. Furthermore, this is the first study to present the absolute costs of chemotherapy for 
colon cancer patients in the Netherlands.
cOnclusiOn
In conclusion, the administration of chemotherapy and costs increased considerably over 
time, although many elderly patients still do not receive adjuvant chemotherapy. The relative 
survival of patients receiving chemotherapy increased over time, while the relative survival of 
patients who did not receive chemotherapy remained almost stable. Although administration 
of chemotherapy increased considerably during the study period, relative survival increased 
to a lesser extent. In our study we show that elderly patients who did receive adjuvant che-
motherapy have at least equal improvement in relative survival as compared to younger stage 
III colon cancer patients, suggesting that there are differences in the selection of patients 
receiving adjuvant chemotherapy in each age group. Furthermore, the current results show 
the importance of selecting patients for whom chemotherapy is expected to be beneficial.
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Attachment 1: costs of chemotherapy in 1990, 1999, and 2008, per age group
no. in 1990 
(% of chemo)
costs (€) no. in 1999 
(% of chemo)
costs (€) no. in 2008 
(% of chemo)
costs (€)
< 60 years 185 (22.2%) 271 (84.5%) 338 (92.3%)
5-FU* 41 € 18,806.04 229 € 97,570.98 7 € 2,703.89
FOLFOX-4 0 € 0.00 0 € 0.00 53 € 142,184.60
CapOX 0 € 0.00 0 € 0.00 222 € 931,891.38
Capecitabine mono 0 € 0.00 0 € 0.00 30 € 108,917.76
total 41 € 18,806.04 229 € 97,570.98 312 € 1,185,697.63
Per patient € 458.68 € 426.07 € 3,800.31
60-69 years 251 (12.8%) 322 (73%) 504 (84.5%)
5-FU* 32 € 14,247.00 235 € 97,042.14 10 € 3,932.93
FOLFOX-4 0 € 0.00 0 € 0.00 72 € 187,349.12
CapOX 0 € 0.00 0 € 0.00 276 € 1,125,056.54
Capecitabine mono 0 € 0.00 0 € 0.00 68 € 240,526.72
total 32 € 14,247.00 235 € 97,042.14 426 € 1,556,865.31
Per patient € 445.22 € 412.95 € 3,654.61 
70-79 years 284 (4.2%) 477 (34%) 563 (58.8%)
5-FU* 12 € 5,128.92 162 € 64,782.90 20 € 7,374.24
FOLFOX-4 0 € 0.00 0 € 0.00 46 € 115,420.44
CapOX 0 € 0.00 0 € 0.00 125 € 493,354.26 
Capecitabine mono 0 € 0.00 0 € 0.00 140 € 487,784.32
total 12 € 5,128.92 162 € 64,782.90 331 € 1,094,933.26
Per patient € 427.41 € 399.89 € 3,307.96
≥80 years 190 (0.5%) 271 (3.7%) 357 (5.6%)
5-FU* 1 € 284.94 10 € 2,644.20 4 € 983.23
FOLFOX-4 0 € 0.00 0 € 0.00 0 € 0.00
CapOX 0 € 0.00 0 € 0.00 4 € 10,441.36
Capecitabine mono 0 € 0.00 0 € 0.00 12 € 27,229.44
total 1 € 284.94 10 € 2,644.20 20 € 38,654.03
Per patient € 284.94 € 264.42 € 1,932.70
total costs population 86 € 38,466.90 636 € 262,040.22 1089 € 3,876,150.23
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According to the Dutch guidelines, patients with stage III colon cancer are advised to 
receive adjuvant chemotherapy. Even though, only about 60% of the patients do receive 
this treatment. The present study compares characteristics and causes of death of patients 
who received adjuvant chemotherapy versus patients who did not. In addition, cumulative 
incidence of recurrence, with death as a competing risk was studied.
Methods
All patients from two hospitals in the mid-western part of the Netherlands, diagnosed with 
stage III colon cancer between 2000 and 2009 and treated with curative surgery were 
selected. Patient characteristics, including comorbidities and treatment preferences, tumour 
characteristics, and follow-up were extracted from the medical records. These characteris-
tics were compared between the treatment groups using chi-squared test. Competing-risks 
regression models were used to assess Sub Hazard Ratios (SHR) for recurrence rates between 
treatment groups with death as competing risk, adjusted for the possible confounding factors.
Results 
A total of 348 patients were included. Median age was 73 years (range 33 to 93). Over 
half of the patients have been treated with adjuvant chemotherapy (50.6%). Patients who 
received adjuvant chemotherapy were significantly younger (p<0.001), had less comorbidities 
(p<0.001), and were more often living together with a partner (p<0.001). Patients who received 
no adjuvant chemotherapy had a reduced overall survival, and cause of death was more often 
due to other causes than colon cancer. The cumulative incidence of colon cancer recurrence, 
with death as a competing risk, did not differ between the treatment groups (p=0.7).
Conclusion 
Patients who received no adjuvant chemotherapy had worse survival, but most of these 
patients died due to competing causes. Remarkably, cumulative incidence of recurrence, with 
death as competing risk was similar in both treatment groups.  Prospective research is needed 
to evaluate which patient characteristics predict risks and benefits of adjuvant chemotherapy.
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intrODuctiOn
In developed countries, colon cancer is one of the most common types of cancer. The incidence 
of colon cancer increases with age, and therefore the number of patients is expected to rise 
along with increasing life expectancy. In the Netherlands, colon cancer is diagnosed in over 
8000 persons annually, with node positive or stage III disease in approximately a quarter of 
these patients.1 Unfortunately, about 50% to 60% of the patients with stage III colon cancer 
have disease recurrence within five years of operation when treated with surgery only.2
Large randomised controlled trials have demonstrated relative risk reductions of 40% for 
recurrence and 33% relative risk reductions for mortality in patients with stage III colon 
cancer who received adjuvant chemotherapy.3-6 Subsequently, it has been shown that the 
addition of oxaliplatin further improves disease control.7,8 Since 1997 the Dutch guidelines 
recommend adjuvant chemotherapy for patients with stage III colon cancer after surgery. No 
age limitation is stated in these guidelines.9
Data from the Netherlands Cancer Registry indicate that administration of adjuvant chemo-
therapy has increased steadily over time. Still, only 62% of stage III colon cancer patients 
are treated with adjuvant chemotherapy.10 The percentage of patients that receives adjuvant 
chemotherapy after surgery for colon carcinoma with lymph node metastases declines with 
increasing age; while approximately 85% of patients under the age of 65 years receive adju-
vant chemotherapy, this is approximately 25% above 75 years of age.10,11 Several reasons 
have been suggested to explain why these patients do not receive adjuvant chemotherapy, 
including age and comorbidities. In order to study the reasons to withhold adjuvant chemo-
therapy, the characteristics of all patients with stage III colon cancer treated with surgery 
in two hospitals in the mid-western part of the Netherlands have been studied. Delivery of 
adjuvant chemotherapy, cancer recurrences, and additionally causes of death were studied.
methODs
Data collection
All patients with primary stage III colon cancer (Tumour Lymph Node Metastasis (TNM) clas-
sification from the UICC and C18.0 –C18.9 ICD-10) diagnosed between 2000 and 2009, 
treated with radical resection in a large teaching hospital and a university hospital in the 
mid-western part of the Netherlands were included in this study. Patients were identified from 
the Netherlands Cancer Registry (NCR). The NCR is based on notification of all new diagnosed 
malignancies in the Netherlands by the registry of histo- and cytopathology (PALGA-system). 
The national hospital discharge databank, which receives discharge diagnoses of admitted 
patients from all Dutch hospitals, completed case ascertainment. 
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The following data were collected from the medical records and registered on a CRF (case 
report form); date of birth, gender, date of diagnosis, clinical and pathological TNM-stage, 
grade, location of the tumour in the colon, number of lymph nodes resected and number 
positive, comorbidities, prescribed medication, housing situation, and marital status. 
Besides, treatment information such as ASA-score, surgical radicality, surgical complications 
(subdivided into anastomotic leakage, postoperative bleeding, infectious complications, 
cardiovascular complications, neurological complications, pneumonia, urinary tract infection, 
trombo-embolism, death, and other), administration and type of adjuvant chemotherapy, and 
complications from chemotherapy (subdivided into neuropathy, hand-foot-syndrome, fatigue 
and other), were collected. Comorbidity was counted as the number of comorbidities per 
person, and calculated as a Charlson comorbidity score.12 Polypharmacy was deemed pres-
ent when a patient used five or more prescribed medications at the time of colon cancer 
diagnosis. Marital status was divided into married, living together, or LAT-relationship; single 
or divorced; widowed; or unknown marital status. Housing situation was divided into together 
with partner; living alone; nursing home; other (including living with children or siblings); or 
unknown housing situation. Reasons to withhold adjuvant chemotherapy were collected from 
the record or medical correspondence. Follow-up information was collected including date 
of local and distant recurrences, location of recurrences, number of recurrences, vital status, 
date of vital status, and cause of death. Causes of death were divided into seven major groups; 
primary tumour, complications of surgery, complications of chemotherapy, second primary 
tumour, heart failure, and other causes of death. Death due to postoperative complications 
was defined as death and postoperative complication within 30 days of surgery. Death due 
to complications of chemotherapy was defined as death within 30 days after administration 
of chemotherapy or death as a result of prolonged complications after chemotherapy. Age at 
time of surgery was divided into four groups; <60 years, 60-69 years, 70-79 years, and ≥80 
years. 
Patients were excluded if there were no positive lymph nodes found (N0), if distant metasta-
ses were discovered before, during, or within four weeks after surgery (M1), if the carcinoma 
was located in the rectosigmoid (C19.0) or rectum (C20.0), if colon cancer was present in the 
medical history, or if the tumour was not an adenocarcinoma.  Figure 1 shows the selection of 
the patients included in current study. A total of 348 patients were included. 
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Stage III colon cancer patients with a complete CRF were included
n=500











Metastatic disease at time of 
diagnosis
n=92




Total patients included in study
n=348
figure 1: Flowchart for the inclusion of the patient population
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Statistical analyses
The characteristics were compared between the treatment groups using chi-squared test. 
Motives for suboptimal treatment and treatment adaptations were described. Time to recur-
rence was defined as time from date of surgery to date of recurrence. Follow-up for survival 
was calculated as time from date of surgery to date of death or last contact. In calculating 
recurrence rates we accounted for death as competing risk.13 Competing-risks regression 
models were used to assess Sub Hazard Ratios (SHR) for recurrence rates between treatment 
groups, adjusted for the following risk factors; age at surgery, gender, pathological tumour 
stage, nodal stage, and grade.  
results
Characteristics
A total of 348 patients were included in the study. In table 1 the patient characteristics are 
shown. Over 60% of the patients were aged 70 years or older, with a median age of 73 years 
(range from 33 years to 93 years). Slightly more than half of the patients included were 
female (51.4%). Almost two thirds of the included patients had one or more comorbidities 
at the time of colon cancer diagnosis (62.4%). The most common comorbid conditions were 
cardiovascular disease (36.5%), diabetes mellitus (17.0%), pulmonary disease (14.7%), and 
cerebrovascular disease (13.2%). Just over half of the patients had a Charlson comorbidity 
score of one or more (55.5%). The median Charlson comorbidity score was 1, with a range 
from 0 to 5. Almost a quarter of the patients underwent emergency surgery (23.3%). Patients 
who underwent emergency surgery more often had postoperative complications as compared 
to patients who underwent elective surgery (61.7% versus 28.7%). Besides, those patients 
slightly more often underwent reoperation (9.9% versus 6.4%).
Adjuvant treatment
Approximately half of the included patients received adjuvant chemotherapy (50.6%). In 
table 2, the characteristics of the treatment groups are compared. The median age of patients 
who received adjuvant chemotherapy was 66 years versus 80 years in the group who received 
no adjuvant chemotherapy. There were no significant differences between the patients in gen-
der, T-stage, N-stage, and occurrence of emergency surgery. However, patients who received 
adjuvant chemotherapy were more often married and living with their partner, as compared 
to patients who received no adjuvant chemotherapy, who were more often widowed and 
living alone or in a nursing home (p<0.001). Of the patients who received no adjuvant chemo-
therapy, 97 (75.8%)have had postoperative complications. Of patients who received adjuvant 
chemotherapy, only 31 (24.2%) have had postoperative complications.
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table 1: Patient characteristics 
number of patients Percentage
Age group
<60 years 63 18.1
60-69 years 73 21.0
70-79 years 124 35.6





Married, living together, or LAT-relationship 188 54.0




Together with partner 176 50.6
Living alone 105 30.2



















2 or 3 83 23.8







Elective surgery 251 72.1







table 2: Patient characteristics according to adjuvant chemotherapy
no adjuvant chemotherapy (n=172) Adjuvant chemotherapy (n=176) p-value
Number of patients Percentage Number of patients Percentage
Age group <0.001
<60 years 3 1.8 60 34.1
60-69 years 15 8.7 58 33.0
70-79 years 69 40.1 55 31.2
≥80 years 85 49.4 3 1.7
Gender 0.587
Men 81 47.1 88 50.0
Women 91 52.9 88 50.0
marital status <0.001
Married, living together, or LAT-
relationship
79 45.9 109 61.9
Single or divorced 17 9.9 18 10.2
Widowed 56 32.6 16 9.1
Unknown 20 11.6 33 18.8
housing situation <0.001
Together with partner 69 40.1 107 60.8
Living alone 73 42.5 32 18.2
Nursing home 20 11.6 2 1.1
Other 0 0.0 3 1.7
Unknown 10 5.8 32 18.2
t-stage 0.183
1 or 2 16 9.3 12 6.8
3 129 75.0 146 82.9
4 27 15.7 17 9.7
Unknown 0 0.0 1 0.6
n-stage 0.112
1 134 77.9 124 70.5
2 38 22.1 52 29.5
comorbidity <0.001
0 30 17.4 101 57.4
1 59 34.3 52 29.5
2 and more 83 48.3 20 11.4
Unknown 0 0.0 3 1.7
charlson comorbidity score <0.001
0 44 25.6 108 61.4
1 44 25.6 34 19.3
2 or 3 57 33.1 26 14.8
4 and more 27 15.7 5 2.8
Unknown 0 0.0 3 1.7
Polypharmacy <0.001
Yes 73 42.4 19 10.8
No 94 54.7 152 86.4
Unknown 5 2.9 5 2.8
emergency surgery 0.430
Elective surgery 120 69.8 131 74.4
Emergency surgery 45 26.1 36 20.5
Unknown 7 4.1 9 5.1
total 172 49.4 176 50.6
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Table 3 shows the type of complications and the percentage of patients with this complication 
stratified for the treatment with adjuvant chemotherapy.
The most common reasons to withhold adjuvant chemotherapy for patients who had survived 
at least 30 days after surgery were a combination of high age and comorbidity (67.3%), surgi-
cal complications (12.9%), or refusal by the patient or family (8.2%). 
Type of adjuvant chemotherapy was fluorouracil and leucovorin in the majority of patients, 
with or without oxaliplatin (22.2% and 52.8%, respectively); the remaining patients received 
either capecitabine monotherapy (12.5%), or a combination of capecitabine and oxaliplatin 
(8.5%). With increasing age, patients more often received capecitabine monotherapy. Almost 
half of the patients receiving adjuvant chemotherapy experienced a complication (83 patients, 
47.2%), resulting in dose reduction in 40 patients (22.7%), and in reduced numbers of cycles 
in 28 patients (15.9%). Complications of chemotherapy and changes in the dose and cycles of 
chemotherapy were not significantly associated with age (p=0.6) or the number of comorbidi-
ties (p=0.9).
table 3: Types of postoperative complications stratified by the prescription of adjuvant 
chemotherapy
no adjuvant chemotherapy (n=172) Adjuvant chemotherapy (n=176)
Number of patients Percentage Number of patients Percentage
none 79 45.9 144 81.8
Anastomotic leakage 11 6.4 4 2.3
Postoperative bleeding 5 2.9 1 0.6
infectious complication 15 8.7 13 7.3
cardiovascular 5 2.9 0 0.0
neurological 4 2.3 0 0.0
Pneumonia 9 5.2 1 0.6
urinary tract infection 6 3.5 4 2.3
trombo-embolism 1 0.6 1 0.6
Other 12 7.0 6 3.4
Death 24 14.0 0 0.0
unknown 1 0.6 2 1.1
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Outcome
Median follow-up was 3.5 years (range from 0 to 12.5 years).  The median follow-up for patients 
who received no adjuvant chemotherapy was 2.2 years (range from 0 to 12.5 years), while 
the median follow-up of those who received adjuvant chemotherapy was 5.1 years (range 
from 0.1 to 12.0 years). Table 4 and figure 2 show the causes of death according to adjuvant 
chemotherapy. The primary cause of death of patients who received adjuvant chemotherapy 
was colon cancer including recurrences (70.5%). In comparison, patients who received no 
adjuvant chemotherapy died due to colon cancer including recurrences (31.9%), complica-
tions of surgery (19.8%), cardiovascular disease (7.8%), and due to other causes, such as 
cerebral vascular event and sepsis. 
As shown in table 4, in total, 104 patients had recurrence of the disease during follow-up 
(29.9%). Slightly more patients treated with adjuvant chemotherapy had a recurrence during 
follow-up (58 out of 176, 33.0%), as compared to patients who received no adjuvant chemo-
therapy (46 out of 172, 26.7%, p=0.06). As shown above, patients who received no adjuvant 
chemotherapy died more often due to other causes of death than the primary tumour. Figure 
3 shows the cumulative incidence of recurrence with death as competing risk according to the 
use of adjuvant chemotherapy. The unadjusted SHR showed that there is no significant differ-
ence in the recurrence rate between the treatment groups, when death was taken into account 
as competing risk for recurrence (SHR 1.15; 95% CI 0.77-1.70; p=0.5). After adjustment for 
potential confounders such as age, gender, pathological tumour stage, nodal stage, and grade, 
the SHR did not materially change (SHR 1.09; 95% CI 0.64-1.86; p=0.7).






median follow-up (range) 2.2 years (0 – 12.5) 5.1 years (0.1 – 12.0)
recurrence 0.042
No 117 (68.0) 116 (65.9)
Yes 46 (26.8) 58 (33.0)
Unknown 9 (5.2) 2 (1.1)
Dead <0.001
No 56 (32.6) 115 (65.3)
Yes 116 (67.4) 61 (34.7)
causes of death <0.001
Colon cancer 37 (31.9) 43 (70.5)
Complications surgery 23 (19.8) 0 (0.0)
Complications chemotherapy 0 (0.0) 4 (6.5)
Other tumour 5 (4.3) 7 (11.5)
Heart failure 7 (6.0) 0 (0.0)
Other 28 (24.2) 5 (8.2)
Unknown 16 (13.8) 2 (3.3)






















































In this population-based cohort of stage III colon cancer patients, almost half of the patients 
received no guideline recommended adjuvant chemotherapy after radical surgery. Main rea-
sons for withholding adjuvant chemotherapy were surgical complications, comorbidities, and 
high age. Patient who received no adjuvant chemotherapy died more often due to competing 
causes, such as surgical complications, while patients who received adjuvant chemotherapy 
died more often due to the primary tumour. The cumulative incidence of recurrence was 
similar between the treatment groups, when death was taking into account as competing risk.
The Dutch guidelines recommend adjuvant chemotherapy for all patients with stage III colon 
cancer irrespective of age. The finding that only half of these patients received adjuvant 
chemotherapy in our cohort, is in line with previous studies, although slightly lower than in 
the national cohort.10,14,15 With increasing age and the presence of comorbidities, adjuvant 
chemotherapy was more frequently omitted, which also has been shown by others.14,16-19 
In line with other studies, almost two thirds of the patients had one or more comorbidities at 
time of the diagnosis (62.4%).11,20,21 Furthermore, postoperative complications were associ-
ated with withholding adjuvant chemotherapy both in our study and in the literature.22,23 
Besides age, comorbidities, and surgical complications, our study showed that marital status, 
and living status affected the initiation of adjuvant chemotherapy. Widowed patients and 
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figure 3: The cumulative incidence of recurrence according to adjuvant chemotherapy
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two studies, by our knowledge, have shown a relationship between marital status and living 
status and receipt of adjuvant chemotherapy in stage III colon cancer.24,25 Widowed patients 
or patients living alone might refrain from treatment since both doctors and the patients 
themselves are worried about dependency during chemotherapy. Improving professional 
support and out of hospital care during treatment might help these patients to benefit from 
adjuvant treatment, aiming to reduce their recurrence risk. 
The decision to start adjuvant chemotherapy should be made jointly by doctors and 
patients.26 Elderly patients seem to be less willing to accept the side-effects of chemotherapy, 
resulting in more frequent patient refusal. Patient refusal occurred in 8.2% of patients who 
received no adjuvant therapy. Refusal was more prevalent at higher age.  Besides, clinicians 
might less often discuss adjuvant chemotherapy with elderly patients.16,24,27 However, it has 
been demonstrated that fit elderly colon cancer patients may benefit equally from adjuvant 
chemotherapy without increased toxicity.3,26 
Most of the patients in the present study received a combination of fluorouracil and leucovo-
rin as adjuvant chemotherapy, as this was the guideline recommended treatment for stage III 
colon cancer until 2004.9 The addition of oxaliplatin was advised since 2004, and therefore, 
more patients received a combination of fluorouracil, leucovorin, and oxaliplatin by the end 
of our study. With increasing age, however, patients more often received fluorouracil with 
leucovorin or capecitabine as monotherapy.  Of note, benefits of the addition of oxaliplatin in 
patients over the age of 70 have recently been disputed.8,28
The goal of adjuvant therapy is to reduce recurrences and improve survival. In our study 
29.9% of the patients developed a recurrence, which is similar in other studies.29-31 For indi-
vidual patients, doctors must carefully weigh benefits and risks of adjuvant chemotherapy. 
The potential reduction in recurrence risk must be weighed against potential risk of severe 
side effects and toxicities. Additionally, they must be aware that competing causes of death 
obliterate the intended effect of adjuvant chemotherapy. Hence, increasing age and comor-
bidities are expected to decrease the potential benefit of adjuvant treatment. Even though 
colon cancer recurrences were more frequent among patients who received adjuvant chemo-
therapy as compared to those who received no adjuvant chemotherapy, it may be deducted 
that doctors and patients decide upon adjuvant treatment for those with the largest risk of 
recurrence. Cumulative incidence of recurrence was equal in those treated with adjuvant che-
motherapy and those without, however, from these results, it cannot be determined whether 
more patients could have profited from adjuvant treatment and survival would have been 
better with more liberal prescription of adjuvant chemotherapy. 
Furthermore, elderly patients are not only interested in their life expectancy, but also in 
quality of life including independent life expectancy.32 In order to improve care in our aging 
population, geriatric health problems should be specifically addressed and geriatric medicine 
should become an integral part of everyday oncology practice. Besides, the goal of future 
studies on this subject should be to minimize recurrences and to optimize quality of life.
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Strengths and limitations
This descriptive, population based study gives a clear insight in the reasons to withhold 
adjuvant chemotherapy in stage III colon cancer patients and provides insight in the outcome 
of these patients. However, since this is a retrospective, observational study, this resulted in 
certain limitations: not all characteristics could be retrieved from medical records, and some 
variables, such as the reason why patients received no adjuvant chemotherapy, were miss-
ing. Therefore, we have described the missing variables, and sensitivity analyses have been 
performed in order to decide whether the missing values affected the outcome. This study 
has compared the cumulative incidence of recurrence with death as a competing risk. We are 
aware that data on colon cancer recurrence might be underestimated with increasing age and 
increasing number of comorbidities as follow up for recurrences may be better in patients 
fit enough to undergo future treatments. Therefore, it is to be expected that the number of 
recurrences might be underestimated in patients who received no adjuvant chemotherapy. 
This would result in higher cumulative incidence of recurrence in the patient who received no 
adjuvant chemotherapy. 
cOnclusiOn
In conclusion, these results highlight that in a population based cohort of patients with stage 
III colon cancer, patients who received adjuvant chemotherapy differ with respect to age, 
comorbidities and living status from patients who received no adjuvant chemotherapy. A large 
part of patients with surgical complications subsequently received no adjuvant chemotherapy. 
Patient who received no adjuvant chemotherapy had worse survival, but most of these patients 
died due to competing causes. Interestingly, cumulative incidence of recurrence, with death 
as competing risk was similar in both treatment groups.  In all patients, but especially in those 
who are old or have comorbidities, benefits and disadvantages of adjuvant chemotherapy 
must be carefully weighed as the effectiveness of adjuvant therapy depends not only on drug 
activity, but also on side effects and life expectancy. In our aging society it will become even 
more important to develop tools to estimate remaining life expectancy in order to facilitate 
the selection of patients for adjuvant treatments. Risks and benefits of adjuvant treatment in 
elderly patients should be studied in prospective studies that relate outcome and quality of 
life to geriatric parameters and comorbidities.
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For several types of cancer, including colon cancer, the survival gap between middle-aged 
patients and elderly patients widened between 1988 and 1999 in Europe. The aim of our 
study was to describe treatments and compare survival rates over time (1991-2005) between 
middle-aged (<65 years), aged (65-74 years) and elderly (≥75 years) colon cancer patients in 
the mid-western part of the Netherlands to assess whether this survival gap further increased.
Methods
All 8926 patients with invasive colon cancer diagnosed between 1991 and 2005 were 
selected from the Comprehensive Cancer Centre West. Relative survival was calculated. Rela-
tive Excess Risks of death (RER) were estimated using a multivariable generalized linear model 
with a Poisson distribution. 
Results
There were no significant changes in the treatment for stage I and II colon. Patients with stage 
III and IV more often received chemotherapy over time (from 9.6% to 54.3% and from 7.5% to 
44.2% for all ages, respectively), while less stage IV patients were operated on (from 73.1% to 
55.2%). Relative five year survival increased significantly for middle-aged patients (RER=0.97, 
95%CI=0.95-0.98, p<0.001), borderline significantly (RER=0.98, 95% CI=0.97-0.99, p=0.05) 
for elderly patients and not significantly for aged patients (RER=0.99, 95%CI=0.97-1.00, 
p=0.08) after adjustment for sex, age, grade, stage, and treatment. 
Conclusion
The survival gap earlier found by the EUROCARE is confirmed for the mid-western part of 
the Netherlands, even after adjustment for age, sex, grade, stage and treatment. However, 
present study does not show an increase in the survival gap between middle-aged and elderly 
patients.
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intrODuctiOn
Colorectal cancer is the second most commonly diagnosed cancer in the Netherlands.1 The 
incidence in the Netherlands is more than 57 per 100 000 persons per year (European Stan-
dardized Rate) and increases with age. There is an incidence peak around 74-80 years and 
approximately half of colorectal patients are over 70 years of age. 
The EUROCARE Working Group has compared five-year relative survival between elderly 
(70–84 years) and middle-aged cancer patients (55–69 years).2 They observed a significant 
survival improvement between 1988 and 1999 for all cancers combined and for almost every 
cancer site including colon cancer. Survival increased at a slower rate in the elderly. As a result 
the gap in survival between middle-aged and elderly patients widened. In particular middle-
aged women showed more marked improvements than elderly women for colon cancer.2 Dif-
ferences in survival for colon cancer may be explained by variations in tumour factors, patient 
characteristics and therapy. Elderly patients receive adjuvant chemotherapy less frequently 
and more often discontinue treatment.3 Moreover, the administration of adjuvant treatment 
for elderly stage III colon cancer patients is influenced by socioeconomic status, gender, and 
comorbidity.4 Besides, comorbidity also influences surgical eligibility and other treatment 
options. 
In recent years the focus on elderly colon cancer patients has increased. Several studies have 
concluded that age per se is not a contraindication for more aggressive or adjuvant treatment.5 
Therefore, the past ten years more elderly patients are considered for extensive therapy in 
routine clinical practice.5 As a consequence an improved outcome for elderly patients might 
be expected. We hypothesized that the gap in survival between middle-aged and elderly 
patients as observed in the EUROCARE data between 1988 and 1999 might be decreasing. 
Hence, the aim of our study was to describe treatments and compare survival rates over time 
between middle-aged (<65 years), aged (65-74 years) and elderly (≥75 years) colon cancer 
patients. 
PAtient AnD methODs 
Patients and follow-up
Patients were selected from the regional cancer registry of the Comprehensive Cancer Cen-
tre West (CCCW) covering the mid-western part of the Netherlands. The nationwide Dutch 
network and registry of histo- and cytopathology (PALGA) regularly submits reports of all 
diagnosed malignancies to the cancer registries. The national hospital discharge databank, 
which receives discharge diagnoses of admitted patients from all Dutch hospitals, completes 
case ascertainment. After notification, trained registry personnel collects data on diagnosis, 
staging, and treatment from the medical records, including pathology and surgery reports, 
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using the registration and coding manual of the Dutch Association of Comprehensive Cancer 
Centres. Cancer registry data show actual variations in patterns of staging, treatment and 
survival by age. Therefore, these data offer a scope for improvement of care and for creating 
guidelines, in addition to randomized clinical trials.6
From the regional cancer registry, patients with their first primary invasive colon cancer were 
selected (International Classification of Diseases for Oncology (ICD-O) code C18.0), diagnosed 
between 1991 and 2005 (n = 8926). CCCW established vital status either directly from 
the patients’ medical record or through linkage of cancer registry data with the municipal 
population registries which record information on their inhabitants’ vital status (last linkage at 
December 31st 2009). Stage was based on pathological information; clinical information was 
used if pathology data were missing.  
Statistical analyses
Patients were divided into middle-aged (younger than 65 years), aged (65-74 years) and 
elderly (75 years and older). We chose to divide the patients into those three age groups, 
so differences between middle-aged and elderly patients would be more pronounced. Dif-
ferences between age groups were tested with Chi-Square tests. Statistical significance was 
defined as p≤0.05. The study period was divided into three five year strata for the analyses 
of the treatment data; 1991-1995, 1996-2000, and 2001-2005. Treatment was divided into 
no treatment, surgery only, surgery and chemotherapy, chemotherapy only, and other (radio-
therapy, in combination with surgery and/or chemotherapy). Changes over time were assessed 
for stage at diagnosis and age. 
For survival analyses, relative survival is the preferred way to describe the prognosis of elderly 
cancer patients, as it takes into account the risk of dying from other causes than the cancer 
of interest.6 Relative survival was calculated by the Hakulinen method as the ratio of the 
observed survival among the cancer patients and the survival that would have been expected 
based on the corresponding (age, sex and year) general population. National life tables 
were used to estimate expected survival. Patients diagnosed between 1991 and 2004 were 
selected for five years survival analyses (n=8197). Patients diagnosed in 2005 were excluded 
from survival analyses by year, because five year follow-up was not available. Relative Excess 
Risks of death (RER) were estimated using a multivariate generalized linear model with a Pois-
son distribution, based on collapsed relative survival data, using exact survival times. Relative 
Excess Risks of death over time were calculated according to age and according to year of 
incidence stratified for age groups, with their 95% confidence interval (95%CI). The RER was 
adjusted for sex, age, grade, and stage. Models with and without adjustment for treatment are 
shown to assess the effect of therapy on the RER. Model fit was assessed for each multivariable 
analysis. Based on the model fit, continuous or categorical data were selected for the analyses. 




Between 1991 and 2005, 8926 patients with incident primary colon cancer were registered in 
the database of the Comprehensive Cancer Centre West (CCCW) in the Netherlands. The char-
acteristics of the patients are shown in table 1. The male to female ratio changed over time 
from 0.8 to 1.0. The age distribution was stable from 1991 to 2005 (p=0.08). The distribution 
between men and women changed with age, with relatively more elderly women diagnosed 
than men. The median age at diagnosis was 72 years (range 7-101 years) and stable over time. 
Patients between 65 and 75 years at time of diagnosis were more often diagnosed with grade 
II, and less often with unknown grade (p<0.001). Stage distribution was associated with age, 
with more elderly patients having an unknown stage of disease. Elderly patients did not have 
table 1: Characteristics of patients diagnosed in the period 1991-2005 according to age. 
Age groups
<65 years % 65-74 years % ≥75 years % p-value 
sex <0.001
Male 1311 51.0 1328 51.8 1571 41.4
Female 1259 49.0 1236 48.2 2221 58.6
Year 0.08
1991-1995 794 30.9 829 32.3 1162 30.6
1996-2000 791 30.8 844 32.9 1240 32.7
2001-2005 985 38.3 891 34.8 1390 36.7
Grade <0.001
I 151 5.9 158 6.2 219 5.8
II 1466 57.0 1610 62.8 2212 58.3
III 428 16.7 396 15.4 649 17.1
Unknown 525 20.4 400 15.6 712 18.8
stage <0.001
I 320 12.5 386 15.1 480 12.7
II 799 31.1 922 36.0 1502 39.6
III 644 25.1 634 24.7 819 21.6
IV 619 24.1 488 19.0 590 15.6
Unknown 188 7.3 134 5.2 401 10.6
surgery <0.001
No 271 10.5 242 9.4 630 16.6
Yes 2299 89.5 2322 90.6 3162 83.4
chemotherapy <0.001
No 1760 68.5 2125 82.9 3661 96.6
Yes 810 31.5 439 17.1 131 3.4
















































































































Stage I (p=0.3) Stage II (p=0.1) Stage III (p<0.001) Stage IV (p<0.001) 
None Only surgery Surgery + chemotherapy Only chemotherapy  Other*  
figure 1: Changes in treatment over the years according to age: (a) Middle-aged patients (<65 
years, (b) Aged patients (65-74 years), and (c) Elderly patients (75 years and older)
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more advanced disease at time of diagnosis. Elderly patients were less frequently operated on 
their colon cancer compared with middle-aged and aged patients, while use of chemotherapy 
gradually declined over the age strata. 
Treatment
Changes in treatment over time for the three age groups are shown in figure 1. During the 
study period, almost all patients with stage I to III colon cancer underwent resection of their 
primary tumour (98.5%). Over time, there were no significant changes in treatment for stage 
I and II in all age groups. Patients with stage III colon cancer received significantly more often 
surgery with adjuvant chemotherapy over time: from 31% to 85% among the middle-aged 
patients (p<0.001), from 8% to 59% among the aged patients (p<0.001), and from 2% to 
13% for the oldest patients (p<0.001). Resection rates of stage IV colon cancer patients 
(with or without chemotherapy) decreased over time: from 73% to 60% among middle-aged 
patients (p=0.02), from 73% to 64% among aged patients (p=0.2), and from 67% to 51% 
among elderly patients (p=0.004). The use of chemotherapy only for stage IV colon cancer 
increased: from 10% to 26% in the middle-aged patients (p<0.001), from 6% to 17% in 
the aged patients (p=0.002), and from 0% to 7% in the elderly patients (p<0.001). Elderly 
patients with stage IV colon cancer received more often no treatment compared to middle-
aged patients, 17% in the middle-aged and aged group compared to 38% in the elderly group 
(p<0.001).
Survival
Overall, there was a significant increase in the five year relative survival from 54.9% in 1991-
1995, to 56.5% in 1996-2000, and to 57.9% in 2001-2004 (p=0.03). The five year relative 
survival of men increased from 52.5% in 1991-1995 to 58.9% in 2001-2004(p=0.02), the 
five year relative survival of women remained stable in the same period from 56.7% to 57.0% 
(p=0.5). After adjustment for age (as a continuous variable in the model), grade, and stage, 
men showed a significant increase in five year relative survival over time with a RER of 0.98 
(95%CI=0.97-0.99, p<0.001). Women did not show a significant increase in their five year 
relative survival with a RER of 0.99 (95%CI=0.98-1.00, p=0.1). After additional adjustment for 
treatment, both men and women showed a small, but significant increase in five year relative 
survival over time with a RER of 0.99 (95%CI=0.97-1.00, p=0.02) for men and a RER of 0.99 
(95%CI=0.98-1.00, p=0.03) for women.
Stratified for stage, relative survival did not increase for stage I colon cancer (figure 2). In stage 
II colon cancer both aged and elderly showed a significant improvement in their unadjusted 
relative survival. After adjusting for sex, age, and grade, only aged patients still showed a sig-
nificant improvement in their relative survival, while after additional adjustment for treatment, 
both aged and elderly patients showed an improved relative survival. In stage III colon cancer 
for all age groups unadjusted relative survival increased significantly. After adjustment for sex, 
Chapter 464
age, and grade both middle-aged and elderly patients showed an increased relative survival, 
and after additional adjustment for treatment, only elderly patients showed an increased 
relative survival. Unadjusted relative survival in stage IV colon cancer did not increase in any 
of the age groups, after adjustment for sex, age and grade only middle-aged patients had an 
increased relative survival, which remained after additional adjustment for treatment.
For comparison with the EUROCARE study, which showed a widening survival gap between 
1988 and 1999, we calculated the adjusted RER over time, with 1991 as reference, stratified 
by age groups. (figure 3(a)) None of the age groups showed a significant increase in their 
adjusted relative survival between 1991 and 2004 after adjustment for sex, age, grade, and 
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.96 0.95 0.94
65-74 years 0.93 0.88 0.99
≥ 75 years 0.97 0.97 0.97
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.97 0.96 0.96
65-74 years 0.95 * 0.95 * 0.95 *
≥ 75 years 0.97 * 0.97 0.97 *
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.94 * 0.94 * 0.98
65-74 years 0.97 * 0.97 1.02
≥ 75 years 0.97 * 0.96 * 0.97 *
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.99 0.98 * 0.97 *
65-74 years 0.99 0.98 0.99





























































<65 years 65-74 years ≥75 years 
* p≤0.05  
(1) adjusted for sex, age, and grade  
(2) adjusted for sex, age, grade, and treatment 
figure 2: Unadjusted relative 5-year survival per stage and per age group in 3-year moving means, 
combined with tables with unadjusted and adjusted RER






























RER = 0.99 
RER = 0.99 
RER = 0.99 
* p≤0.05 
figure 3a: Adjusted RER and 95% CI per age group over time, with 1991 of each age group as a 
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1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
RE
R 
< 65 year 
RER = 0.97* 
RER = 0.99 
RER = 0.98* 
* p≤0.05 
figure 3b: Adjusted RER and 95% CI per age group over time, with 1991 of each age group as a 
reference. Adjusted for sex, age, grade, stage, and treatment
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stage. After additional adjustment for treatment (figure 3(b)) both middle-aged patients (< 65 
years) and elderly patients (≥ 75 years) showed a significant increase in their adjusted relative 
survival between 1991 and 2004 (RER=0.97, 95%CI=0.95-0.98, p<0.001 and RER=0.98, 95% 
CI=0.97-0.99, p=0.05, respectively). There was no significant increase in adjusted relative 
survival for patients aged between 65 and 75 years (RER=0.99, 95%CI=0.97-1.00, p=0.08).
We calculated the RERs over time per age group adjusted for sex, grade, and stage without 
treatment (table 2a) and with treatment (table 2b), with middle-aged patients (<65 years) 
as reference. Aged and elderly patients always showed a lower survival than middle-aged 
patients in all years. When there is a significant difference in the RERs, the survival of the 
aged or elderly patients is significant worse than the survival of the middle-aged patients. 
The higher the RER is, the larger the difference in survival between age groups. Looking at 
the study period of the EUROCARE, until 1999, we see a gap between the survival of middle-
aged patients and elderly patients, which is the largest in 1997 and 1998. In more recent 
years, the gap between middle-aged and elderly patients is still present, with 2001 and 2002 
comparable with 1997 and 1998, even when adjusted for treatment, but the gap has not 
further increased. 
DiscussiOn
In this population-based study covering the mid-western region of the Netherlands over a 
period of 15 years, substantial changes in treatment of colon cancer were found. Adjuvant 
chemotherapy for patients with stage III disease increased over time, resection rates remained 
stable over time for patients with stage I, II, and III disease in all age groups, while resection 
rates among metastatic patients decreased, and administration of chemotherapy for stage IV 
colon cancer patients increased for all age groups. Moreover, survival increased significantly 
over time for middle-aged and elderly patients after adjusting for age, sex, grade, stage and 
treatment. The adjusted survival of aged patients did not increase significantly over the years. 
However, the present study did not show a further increase in the survival gap between 
middle-aged and elderly patients.
Treatment 
During the study period, some major changes in the adjuvant treatment of colon cancer 
have occurred. After Moertel et al.7 published the first clinically important survival benefit 
of one year adjuvant therapy with fluorouracil and levamisole for patients with stage II and 
III colon cancer, the United States quickly adopted this as standard therapy for stage III colon 
cancer patients. However, in the Netherlands adjuvant chemotherapy for stage III colon cancer 
was incorporated in the guidelines from the mid 1990’s and since 2005 the guideline also 
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for treating patients with colon cancer are visible in the data; in the period 1996-2000, for 
all age groups a large increase in the adjuvant treatment of stage III colon cancer patients 
was visible (from 31% to 68%, from 8% to 47%, and from 2 to 10% for middle-aged, aged, 
and elderly patients respectively), although this showed much smaller survival benefit in the 
cohort than expected. During the study period stage IV colon cancer patients were increas-
ingly treated with chemotherapy and less often with surgery. Over the past three decades, 
stage IV colon cancer has turned from a lethal, incurable disease, into a potentially curable 
disease for a selected group of patients.9 
The surgical technique for colon cancer has not changed in the Netherlands during the study 
period. However, in 2009 Hohenberger et al. presented their promising results about the com-
plete mesocolic excision for patients with colon cancer.10 Possibly with use of this technique 
local recurrence rates might decrease and five year survival rates might increase further in the 
future. Also centralisation and auditing are relatively new for colon cancer in the Netherlands 
which might improve survival in the future.11 
Survival 
Overall we found a small increase in relative survival for colon cancer patients over the years. 
However, stage migration could have influenced this study. More advanced diagnostic tools 
have been used in the recent years,12,13 possibly leading to detecting a more advanced stage 
of disease. Furthermore, a more extensive search for affected lymph nodes could have had a 
similar effect. The harvesting of more lymph nodes could also have contributed directly to an 
improved survival.14,15 Another factor that might have influenced the survival results, is the 
improvement of perioperative care.16 With the hypothesis that survival would not increase 
over time when adjusted for sex, age, grade, stage, and treatment, the data in this paper show 
that there are residual influences related to outcome. Even after adjusting for sex, age, grade, 
stage, and treatment, a significant improvement was found in relative survival of elderly 
patients with stage III and of middle-aged patients with stage IV colon cancer. 
Changes in treatment and improvements in survival of colon cancer in the mid-western region 
of the Netherland found in this study, are in line with the results of a previous study cover-
ing national data.17 Notable is that the improvement in survival and the increase in use of 
adjuvant treatment are more visible in middle-aged patients than in aged and elderly patients. 
One of the main problems found in the treatment of elderly patients is that current guidelines 
are based on randomized controlled trials, in which elderly patients or patients with severe 
comorbidity are underrepresented or excluded. The improvement in survival of middle-aged 
colon cancer patients over time has mostly been due to a decrease in operative mortality and 
an increase in the resection rate, possibly coupled with a more aggressive approach to the 
treatment of local and distant recurrences.18-21 Elderly patients on the other hand usually 
present with more advanced stage and tend to undergo more emergency surgery. Although, 
in the present study we could not confirm the higher stage at diagnosis, but more elderly 
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patients were registered with an unknown stage of disease which could include undiagnosed 
stage III and IV. Elderly patients are also less likely to receive adjuvant treatment and receive 
“suboptimal” management.22-27 Adjuvant chemotherapy has shown to be an effective 
treatment for elderly patients with stage III colon cancer, but the benefit is lower with older 
age.18,28,29 However, elderly patients do not necessarily experience greater chemotherapy-
related toxicity.19,29  
Gap in survival between younger and elderly
EUROCARE recently reported that for colon cancer, as well as other cancer types, the survival 
gap between elderly (70-84 years) and middle-aged (55-69 years) patients was widening 
in the period between 1988 and 1999.2 Due to the information available in the EUROCARE 
study, adjusting for several factors, like stage, was not possible. In the present study we were 
able to adjust for sex, age, grade, stage, and treatment. Besides, we were able to analyse more 
recent data. Patients were divided into three age groups instead of two; this would make the 
difference between middle-aged and elderly patients more visible. We found a significant 
difference in survival between patients middle-aged and elderly patients over all the years, 
even after adjusting for sex, age, grade, stage, and treatment. The largest difference in survival 
was between 1997 and 1998 and between 2001 and 2002. Besides the gap between 1997 
and 1998, which is similar to the gap shown by the EUROCARE, we also show a more recent 
survival gap in 2001 and 2002, which is similar in size to the gap in 1997 and 1998. However, 
the survival differences between middle-aged and elderly patients are not consistent over 
time. The survival gap is mainly caused by an increase in survival of middle-aged patients and 
a stable survival of elderly patient. In the present study, this gap did not widen any further, 
but is stabilising. Hopefully in the future aged and elderly patients will also benefit of the 
increased survival, possibly due to improved treatment. 
Stage distribution differs between several countries in Europe.13 As tumour stage is one of the 
most important prognostic factors in most cancer types, survival rates for several countries are 
difficult to compare. A new initiative is needed and founded in EURECCA, which aims to collect 
prospective information about colorectal cancer patients in several countries in Europe.30
cOnclusiOn
In the mid-western region of the Netherlands no changes in treatment have occurred for stage 
I and II colon cancer during the study period. Patients with stage III and IV were treated with 
significantly more adjuvant chemotherapy over time, although less prominent for elderly 
patients, while the resection rate of patients with stage IV decreased for all age groups. The 
survival gap earlier found by the EUROCARE is confirmed for the mid-western part of the 
Netherlands, even after adjusting for several confounders. However, the present study did not 
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show a further increase in the survival gap between middle-aged and elderly patients. The 
near future will have to show if a more extensive and hopefully better tailored treatment can 
help elderly to close this gap.
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Elderly colorectal cancer patients have worse prognosis than younger patients. Age-related 
survival differences may be cancer or treatment related, but also due to death from other 
causes. This study aims to compare population-based survival data for young (<65 years), 
aged (65–74 years), and elderly (≥75 years) colorectal cancer patients.
Methods 
All patients operated for stage I–III colorectal cancer between 1991 and 2005 in the western 
region of the Netherlands were included. Crude survival, relative survival, and conditional 
relative survival curves, under the condition of surviving one year, were made for colon and 
rectal cancer patients separately. Furthermore, 30-day, 1 year, and 1 year excess mortality data 
were compared.
Results 
A total of 9,397 stage I–III colorectal cancer patients were included in this study. Crude survival 
curves showed clear survival differences between the age groups. These age-related differ-
ences were less prominent in relative survival and disappeared in conditional relative survival 
(CRS). Only in stage III disease did elderly patients have worse CRS than young patients. 
Furthermore, significant age-related differences in 30-day and 1 year excess mortality were 
found. Thirty-day mortality vastly underestimated one year mortality for all age groups.
Conclusion 
Elderly colorectal cancer patients who survive the first year have the same cancer-related 
survival as younger patients. Therefore, decreased survival in the elderly is mainly due to 
differences in early mortality. Treatment of elderly colorectal cancer patients should focus on 
perioperative care and the first postoperative year.
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intrODuctiOn
The number of elderly people in the population and the incidence of colorectal cancer are 
increasing. Therefore, it is to be expected that the number of elderly colorectal cancer patients 
will further increase. Various population-based studies show that survival of elderly colorectal 
cancer patients is worse compared with younger patients. Differences in survival by age group 
in colorectal cancer may be explained by variations in tumour factors, patient characteristics, 
and therapy. Elderly colorectal cancer patients tend to have more advanced disease stage.1 
Besides, they have more comorbidity and are treated less aggressively than their younger 
counterparts.2 Comorbidity influences surgical eligibility and other treatment options.3 Fur-
thermore, it represents a greater risk of non-cancer-related mortality. Elderly patients less 
frequently receive adjuvant chemotherapy and more often discontinue treatment before 
completion.4
Notwithstanding all these differences, several studies found similar disease-specific survival 
for elderly and young colorectal cancer patients.5-7 This would indicate that the excess mortal-
ity in elderly colorectal cancer patients is due to competing causes of death. To gain better 
insight into survival differences between age groups, the present study aims to compare 
population-based survival data of colorectal cancer patients for different age groups. It con-
siders not only overall and relative survival but also conditional relative survival under the 
condition of surviving one year. Furthermore, this study focuses on age-related differences in 
30-day and one year mortality.
PAtients AnD methODs
Patient and follow-up
Patients were selected from the regional cancer registry of the Comprehensive Cancer Centre 
West (CCCW) covering the western part of the Netherlands. The nationwide Dutch Network 
and Registry of histo- and cytopathology (PALGA) regularly submits reports of all diagnosed 
malignancies to the cancer registries. The national hospital discharge databank, which 
receives discharge diagnoses of admitted patients from all Dutch hospitals, completes case 
ascertainment. After notification, trained registry personnel collect data on diagnosis, stag-
ing, and treatment from medical records, including pathology and surgery reports, using the 
registration and coding manual of the Dutch Association of Comprehensive Cancer Centers. 
Cancer registry data show actual variations in patterns of staging, treatment, and survival by 
age and therefore offer scope for improvement of care and for creating guidelines, in addition 
to randomized clinical trials.8
From the regional cancer registry, patients diagnosed between 1991 and 2005 with their first, 
primary, stage I, II or III colon or rectal cancer who were surgically treated were selected. Vital 
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status was established either directly from the patient’s medical record or through linkage of 
cancer registry data with the municipal population registries which record information on their 
inhabitants’ vital status. Stage was based on pathological information; clinical information was 
used if pathology data were missing.
Statistical analyses
Patients were divided into younger than 65 years, 65–74 years, and 75 years and older. Dif-
ferences between characteristics were tested with chi-squared tests. Overall survival was 
calculated with death due to any cause as event. Relative survival is the preferred way to 
describe the prognosis of elderly cancer patients, as it takes into account the risk of dying from 
causes other than the disease of interest.8 Relative survival was calculated by the Hakulinen 
method as the ratio of the survival observed among the cancer patients and the survival that 
would have been expected based on the corresponding (age, sex, and year) general popula-
tion. National life tables were used to estimate expected survival. Conditional relative survival 
was calculated for patients who survived the first year. Relative excess risks of death (RER) 
were estimated using a multivariate generalized linear model with a Poisson distribution, 
based on collapsed relative survival data, using exact survival times. Finally, 30-day and one 
year overall mortality were calculated as well as the one year excess mortality as (observed − 
expected deaths)/(number of patients).
results
From 1 January 1991 through 31 December 2005 in the CCCW region 9,611 stage I–III 
colorectal cancer patients were diagnosed and 9,397 (97.8%) were operated, being 6,405 
patients with colon cancer and 2,992 with rectal cancer. These patients had median age of 72 
years (range 7–100 years) for colon cancer and 69 years (range 18–98 years) for rectal cancer 
patients. Patient characteristics according to age group for colon and rectum separately are 
shown in table 1. The percentage of female patients was significantly higher in the oldest 
age groups, especially for colon cancer patients. The number of treated colon cancer patients 
increased over the years. Tumour grade was evenly divided for rectal cancer but not for colon 
cancer patients, with more grade III in the elderly. In this cohort, younger patients had higher 
tumour stage than the elderly, although the percentage of patients with unknown stage of 
disease was higher in the elderly (data not shown). Use of adjuvant chemotherapy decreased 
with advancing age groups. Radiotherapy for rectal cancer patients was comparable for the 
young and aged groups and was lower in the elderly group.
Figure 1 shows survival curves for overall survival (a), relative survival (b), and conditional 
relative survival (c) for colon and rectal cancer patients in the different age groups. Differences 
in survival between age groups for colorectal cancer patients disappeared when a correction 





























































































































































































































































































































































































































































































































































































































































































was made for death from other causes under the condition of surviving one year. As shown in 
table 2, the elderly patients had a RER of 1.6 (95% confidence interval (CI) 1.4–1.9; p<0.001) 
as compared with the young patients for colon cancer and 1.4 (95% CI 1.2–1.7; p<0.001) for 
rectal cancer. When relative survival was calculated for patients who survived the first year, 
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figure 1c:  Conditional relative survival (conditioning on patients who survived 1 year) according 
to age for stage I -III patients operated for colon and rectal cancer
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Going into more detail by considering different stages, a significant difference in conditional 
relative survival remained for stage III patients for both colon and rectal cancer.
Table 3 shows overall 30-day, 1 year, and 1 year excess mortality according to type of tumour 
in reference to baseline factors. Gender was a significant factor for first-year mortality in rectal 
cancer, with more male patients dying. Age was the most significant factor for all three mortal-
ity endpoints for both colon and rectal cancer patients. Tumour grade did not influence 30-day 
mortality but was a significant factor for one year mortality for both colon and rectal cancer 
patients. Tumour stage also influenced 30-day mortality for colon cancer patients, but not for 
rectal cancer patients. Thirty-day and one year mortality rates decreased over the years (data 
not shown). For colon cancer patients this was only significant (p<0.05) for one year mortality 
rates for all age groups (lowest RER 0.94). For rectal cancer patients, 30-day mortality was 
significantly reduced (p<0.01) for the elderly (RER 0.89). One year mortality for the young 
and aged patients (lowest RER 0.93) was significantly improved (p=0.03), however not for the 
elderly patients (p=0.3; RER 0.98).
table 2: Patients stage I-III who received surgery
colon cancer All stages stage i stage ii stage iii
RS CS RS CS RS CS RS CS






























p-value <0.001 0.2 0.7 0.99 <0.001 0.1 <0.001 0.003
rectal cancer All stages stage i stage ii stage iii
RS CS RS CS RS CS RS CS


































p-value <0.001 0.3 0.2 0.5 0.009 0.1 <0.001 0.002
RS=relative survival, CS=conditional survival, N.A.=not addressed due to small numbers
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DiscussiOn
Crude survival is a solid outcome measure that shows evident age-related differences. 
However, crude survival will overestimate the impact of cancer on survival, because it also 
includes mortality due to other causes. To adjust for this, relative survival is used, defined as 
the ratio of observed to expected survival. This reduces age-related differences in colorectal 
cancer survival. However, the results of age-related relative survival are still largely influenced 
by early mortality (defined as mortality in the first postoperative year). Postoperative com-
plications are a more probable cause for early mortality than the colorectal cancer itself in 
stage I–III patients (who, in general, had curative surgery). Therefore, to get a clear image of 
the impact of colorectal cancer on survival for different age groups, we used conditional rela-
tive survival under the condition of surviving one year. As a result, age-related differences in 
survival disappeared, indicating that probably colorectal cancer itself is not the main cause of 
age-related differences in survival. This is in line with earlier studies that found no age-related 
differences in cancer-specific survival.5-7 However, this remains intriguing, since many papers 
indicate that differences in survival between the young and the elderly can be attributed 
to undertreatment in the elderly.1,9 Our study confirms these variations in treatment and 
that conditional survival in stage III patients is indeed significantly worse in the elderly. 
table 3: Overall 30-day and 1-year mortality and relative 1-year mortality according to type of 
tumour 
colon cancer rectal cancer 
Overall mortality excess 
mortality 
Overall mortality excess 
mortality 
n † ≤30 d † 1st year † 1st year n † ≤30 d †1st year † 1st year
sex
Male 2976 4.6 15.7 11.3 1639 2.1 13.2 9.4
Female  3429 4.1 14.5 10.9 1353 1.3 9.9 6.9
Age
<65 years 1740 1.4 6.8 6.1 1047 0.2 5.1 4.4
65-75 years 1916 2.4 10.8 8.5 892 1.4 9.5 7.2
≥75 years 2749 7.5 23.2 16.0 1053 3.7 20.1 13.1
Grade 
I 436 2.1 9.9 6.0 162 3.1 8.0 4.9
II 4284 4.4 12.6 8.5 2140 1.8 10.2 6.6
III 1065 4.7 25.2 21.3 440 1.6 22.3 19.5
Unknown 620 4.8 18.2 14.8 250 1.2 8.4 5.2
stage 
I 1179 1.7 8.0 4.0 1023 1.5 7.6 3.8
II 3143 5.0 13.5 9.2 966 2.4 12.7 9.1
III 2083 4.8 21.4 18.0 1003 1.5 14.9 12.1
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Nonetheless, the excess mortality in the first postoperative year was the main determining 
factor for age-related survival differences.
Postoperative Mortality
The 30-day mortality rates for the different age groups in the present study are in accordance 
with earlier findings by other studies.10,11 However, the most striking finding of this analysis 
is the fact that 30-day mortality vastly underestimates one year mortality for all age groups. 
Apparently, the impact and consequences of treatment have a prolonged effect on mortality. 
This effect is very strong even for patients in the youngest group. With increasing age, also 
the excess mortality increases. It has been shown earlier that, with increasing age, not only 
mortality but also postoperative morbidity increases.12-14 Furthermore, Manku et al. showed 
that in-hospital complications had prognostic significance.15 In 517 patients who underwent 
noncardiac surgery, they found that postoperative complications caused mortality up to 3 
months after surgery, with a sustaining effect on survival. Greenblatt et al. studied stage I–III 
colon cancer patients from the Surveillance, Epidemiology, and End Results–Medicare data-
base and found that readmission was strongly associated with one year mortality.16 The same 
variables that predicted readmission in this study also predicted one year mortality (male 
gender, comorbidity, emergent admission, prolonged hospital stay, blood transfusion, ostomy, 
and discharge to a nursing home). Kunitake et al. showed that patients older than 80 years 
were readmitted almost twice as much as patients younger than 65 years.17 Furthermore, in 
their study, 75% of readmissions were not related to the surgery itself. With the present study, 
all these studies seem to imply that, for a significant number of patients, the assault of surgery 
has delayed effects that can cause mortality beyond the scope of the surgery.
Stage III Patients
Only in stage III patients were age-related differences found in conditional relative survival. 
Here, differences in (neo)adjuvant therapy between the age groups were most apparent. This 
is in line with earlier studies that show that elderly patients are undertreated.4 This under-
treatment of elderly patients could explain the age-related differences in conditional relative 
survival for stage III patients. However, also in stage III patients, first-year mortality remains a 
crucial factor for survival. The difference in conditional relative survival between young and 
elderly stage III patients was 10.4% for colon and 5.6% for rectal cancer, while the differences 
in one year excess mortality rates were 17.2% and 12.0%, respectively.
Limitations
An obvious limitation of this study is the lack of information on emergency surgery and 
comorbidity. Both are associated with increased postoperative complications and mortality. 
They will not only have had a prominent influence on early mortality for all age groups, but 
they probably account for the differences between the age groups as well. Elderly patients are 
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more likely to undergo emergency surgery, and also the incidence of comorbidity increases 
with age.10 Nevertheless, the strength of this study is that it shows the essence of age-related 
survival and early mortality differences in a large population-based cohort.
Clinical Implications
The results of this study could provide a focus for future studies and have implications for 
the clinical setting. As age-related differences in mortality are most apparent for the first 
postoperative year, this is where the focus must be in treating elderly colorectal cancer 
patients. Although some risk factors may not be modifiable, others relate to care processes. 
More attention should be given to patient selection and careful preoperative evaluation, fol-
lowed by medical optimization, proper timing of surgery, and planning of perioperative care. 
Furthermore, appropriate referral to high-volume or dedicated centers should be considered 
if it is anticipated that patients will require a higher level of resources and care following 
surgery. Quality enhancement programs could focus on particular complications. These should 
not only try to prevent the occurrence of perioperative complications but also focus on early 
identification and adequate treatment of complications to avoid related mortality.18
The excess mortality of the first postoperative year forms a clear indication of the prolonged 
impact of the perioperative period, especially when complications occur. Therefore, we should 
anticipate preoperatively the level of functioning after discharge.13 The targets of treatment 
for elderly patients should extend beyond the in-hospital period, and continued attention 
should be given to comorbidity and complications in the post-hospital period.
The prolonged impact of the perioperative period could also have a profound effect on func-
tional status and quality of life. For elderly patients these issues should be evaluated with care, 
especially when they have limited life expectancies. However, for the majority of patients, age 
per se is not a contraindication for surgery, not least because surgery for colorectal cancer is 
often the best way to ensure palliation.
cOnclusiOn
This study can help to comprehend the challenge of treating elderly colorectal cancer patients. 
When survival data for colorectal cancer are corrected for expected death from other causes 
and first-year mortality, age differences disappear. Therefore, decreased survival in the elderly 
is mainly due to differences in early mortality. Only for stage III disease did elderly patients 
fare worse, probably as a result of less extensive adjuvant treatment. The overall difference 
between the younger and elderly age groups is that, within the elderly group, there is an 
excess mortality of about 10% the first year. Further studies are necessary to elucidate the 
aetiology of these differences and whether they may be modifiable. This study implies that, in 
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treating elderly stage I–III colorectal cancer patients, the focus should be on the perioperative 
process and the first postoperative year.
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Preoperative radiotherapy has proven to reduce local recurrences after curative surgery for 
rectal cancer. Radiotherapy is generally well tolerated, although postoperative morbidity and 
mortality was increased in some patients. Current study was undertaken to analyse whether 
the interval between preoperative radiotherapy and surgery influences postoperative mortal-
ity and recurrence for two cohorts.
Methods 
All Dutch patients included in the TME-trial receiving radiotherapy for resectable rectal cancer 
were included in this study (n=642). The verification set consisted of all patients receiving 
short course radiotherapy for resectable rectal cancer in two radiotherapy clinics in the Neth-
erlands (n=600). Univariate and multivariable survival analyses for overall survival, disease-
free survival, local recurrence-free survival, and non-cancer related survival were calculated.
Results 
Patients aged 75 years and older treated during the TME-trial showed a worse overall and non-
cancer-related survival when surgically treated 4-7 days after the last fraction of radiotherapy. 
No differences in survival between the interval groups were found in the verification set.
Conclusion 
Present study found that elderly patients aged 75 years and older operated 4-7 days after the 
last fraction of radiotherapy had a higher chance of dying due to non-cancer-related causes 
during the TME-trial as compared to patients with an interval of 0-3 days. In the verification 
set similar differences could not be confirmed, which could be due to awareness of the clini-
cians who avoided delayed surgery after radiotherapy since the results have been presented 
during congresses. A longer than recommended interval between radiotherapy and surgery 
should be avoided. Besides, the verification set suggests that radiotherapy duration of 7 days 
is acceptable.
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intrODuctiOn
In the treatment of rectal cancer, local recurrences are a major problem, occurring in 15-45% 
of the rectal cancer patients without TME surgery and radiotherapy.1-4 These local recurrences 
often have severe disabling symptoms and are difficult to treat. To reduce local recurrences 
after curative surgery, several studies have used either preoperative or postoperative 
radiotherapy.5,6 In a large Swedish trial, short course preoperative RT has proven to be more 
effective compared to postoperative radiotherapy with conventional surgery.7 The TME-trial 
and the CR07 trial showed, additionally, that with total mesorectal excision (TME) surgery, 
preoperative radiotherapy improved local control even further.8,9 Preoperative radiotherapy 
has been given in varying regimens, either short course (25 Gy in 5 fractions during one week) 
or long course combined with chemotherapy (45-50 Gy during five weeks).10,11 Radiotherapy 
is generally well tolerated, although postoperative morbidity and mortality is increased in 
some patients.8,12-17 The increased postoperative mortality may be contributed to the use 
of anterior-posterior beams, resulting in large irradiated volumes, from the earlier trials.12,14  
A more recent study has shown that short course radiotherapy has significant impact on the 
perioperative leukocyte response.18 Short course radiotherapy followed by surgery after 5 or 
more days since the last fraction of radiotherapy was significantly correlated with leukopenia 
or falling leukocytes rates on day one postoperatively. The patients with an abnormal leu-
kocyte response developed sepsis more often (31% versus 13% in patients with a normal 
leukocyte response), and had an increased risk of death within 90 days after surgery compared 
to patients with a normal leukocyte response, suggesting that surgery should occur within 5 
days after the last day of radiotherapy. 
This study was undertaken to analyse whether the interval between preoperative radiotherapy 
and surgery, or the duration of radiotherapy (5 or 7 days) influences the outcome of patients 
regarding one year postoperative mortality and five year local recurrence free survival and 
disease free survival for two cohorts; patients from the TME-trial from 1996-1999 (DUT-KWF-
CKVO-9504, EORTC-40971, EU-96020) and patients from a more recent cohort from 2000 
until 2010 as a verification set. 
PAtients AnD methODs
Patients and follow-up
Dataset from the TME-trial
From January 1996 until December 1999 1861 patients with resectable rectal cancer without 
evidence of distance disease were randomly assigned to TME preceded by 5×5 gray radio-
therapy or TME alone. There was no age limitation. For this subset analysis, only Dutch patients 
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receiving preoperative radiotherapy are included (n=642), since the follow-up of the Dutch 
patients has been more thorough and complete.
Verification set
From January 2000 until July 15th 2010, all patients receiving short course preoperative radio-
therapy for resectable rectal cancer without evidence of distant metastases followed by TME 
surgery at Leiden University Medical Center and Catherina Hospital Eindhoven were included 
retrospectively. Information on the patients’ characteristics, such as gender and date of birth, 
as well as tumour characteristics, location (according to the International Classification of 
Diseases for Oncology (ICD-O)), histology, stage (clinical and pathological TNM classification 
5th edition), grade, and primary treatment, were obtained from the medical records. The vital 
status was obtained either directly from the patients’ medical record or through linkage of the 
hospital with the municipal population registry which records information on their inhabit-
ants’ vital status. Exclusion criteria were: patients without information available on their vital 
status (n=2), patients without information on the date of radiotherapy or surgery (n=30), and 
missing data on the age (n=2). 
For both datasets, stage was based on pathological TNM classification. For patients in whom 
pathological stage was unknown, clinical stage was used. Patients were divided in two age 
groups (<75 years and ≥75 years). The majority of the patients were operated 1, 2, 3, 4, or 
5 days after the last fraction of radiotherapy. To compare the effect of the interval, we have 
divided the patients into four groups. Patients operated within 3 days since the last day of 
radiotherapy, from 4 until 7 days, from 8 until 27 days, and from 28 days or more (in line with 
one of the arms of the Stockholm III trial19). 
Radiotherapy duration has been divided into two groups: 5 days (Monday till Friday) or 7 days 
of radiotherapy (with a weekend included). Overall treatment time (OTT, as shown in figure 
1) has been divided into two groups: OTT ≤10 days (with the exception of a radiotherapy 
duration of 8 days) or OTT >10 days (as shown in table 1 with the light grey shaded area).  A 
radiotherapy duration of 8 days was in violation with the protocol and has therefore been 
included as an OTT>10 days. An interval between radiotherapy and surgery ≥8 days (dark 
shaded grey area in table 1) has been excluded from the OTT analyses since this was in viola-
tion with the recommendations.
 
Interval between radiotherapy and surgery 
(0 till 185 days) 
Radiotherapy duration 
(5 till 8 days) 
Overall treatment time (radiotherapy duration + interval between radiotherapy and surgery) 
figure 1: Relation between duration of radiotherapy, interval between radiotherapy and surgery, 
and overall treatment time
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When patients received radiotherapy for 5 days, from Monday till Friday, surgery was either 
performed on Monday (within 3 days since the last fraction of radiotherapy), or later in that 
week (from 4 until 7 days since the last fraction of radiotherapy).
Statistical analyses
All analyses were performed with STATA 10. Differences between the groups were tested with 
a Chi-Squared test. Follow-up was calculated as the time from surgery to death or date of last 
contact. Overall survival, disease-free survival, local recurrence-free survival, and non-cancer 
related survival (including death due to postoperative complications) were calculated, by 
using Kaplan-Meier survival curves, for both univariate and multivariable survival analyses. 
Overall survival and non-cancer related mortality were truncated at one year, since recently 
a study has shown that postoperative mortality can be increased up to one year after surgery 
due to differences in comorbidities and fragility.20 Disease-free survival and local recurrence-
free survival were truncated at five years, since recurrences or metastases are not expected 
to occur often within one year after surgery. Univariate and multivariable survival analysis 
was performed using a Cox proportional hazard model. Statistical significance was defined as 
table 1a: Relation between radiotherapy duration and the interval between radiotherapy and 
surgery during the TME-trial
interval between radiotherapy and surgery












5 - 2 12 204 172 99 38 12 4 3 546 (85.0%)
6 - 3 5 1 5 2 - 1 - - 17 (2.6%)
7 - 18 27 8 3 3 1 1 1 1 63 (9.8%)
8 1 6 4 2 1 1 1 - - - 16 (2.5%)
total 1 29 48 215 181 105 40 14 5 4 642
The area is light shaded grey area in case of OTT >10 days, and the dark shaded grey area has been excluded 
from the OTT analyses. Both were in violation with the protocol. Radiation duration of 8 days was in violation 
with the protocol and these patients were therefore included in the OTT > 10 days.
table 1b: Relation between radiotherapy duration and the interval between radiotherapy and 
surgery during the verification set (2000 until 2010)
interval between radiotherapy and surgery












5 - 2 3 179 61 2 7 6 5 10 275 (45.8%)
6 - 1 - 2 - - - - - - 3 (0.5%)
7 1 86 116 16 14 19 4 9 13 23 301 (50.2%)
8 1 14 4 - - - - - - 2 21(3.5%)
total 2 103 123 197 75 21 11 15 18 35 600
The area is light shaded grey area in case of OTT >10 days, and the dark shaded grey area has been excluded 
from the OTT analyses. Both were in violation with the recommendations. Radiation duration of 8 days was in 
violation with the protocol and these patients were therefore included in the OTT > 10 days.
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p<0.05. All analyses are done separately for the group of patients from the TME trial and the 
verification set.
results
Dataset from the TME-trial
Patients
A total of 642 patients from the TME-trial were included in this study. The median follow-up 
since surgery of these patients was 9.1 years (range 0.01-13.7 years). The median age of the 
patients at time of surgery was 65.1 years (range 26.6-89.0 years).
Radiotherapy duration and interval between radiotherapy and surgery
Table 1a demonstrates the relationship between the duration of radiotherapy and the interval 
between the last fraction of radiotherapy and surgery for patients during the TME-trial. Most 
patients received radiotherapy from Monday till Friday, so 5 days continuously (85.0%). For 
the other patients the radiotherapy duration was 6 days (2.6%), 7 days (9.8%), or 8 days 
(2.5%); including a weekend and/or bank holiday. Surgery within 3 days of the last fraction of 
radiotherapy was performed in 293 patients of the 642 patients, an interval of 4 to 7 days was 
the most common (340/642). Intervals of 8 until 27 days and 28 days or more occurred less 
often (5 and 4 patients, respectively). 
In table 2a the characteristics of the patients divided into the four interval groups are shown. 
There were no significant differences between the four interval groups in age and gender dur-
ing the TME-trial (p=0.5 and p=0.2, respectively). Pathological stage was lower in the patients 
with an interval of ≥8 days as compared to patients with an interval of <8 days (p<0.001), but 
no difference was detected between the group of patients with an interval of 0-3 days and 
4-7 days (p=0.3), neither when the interval of 28 days and more only was excluded (p=0.4).
Survival
Due to small numbers in the interval group of 8 until 27 days and 28 days or more, these 
patients (n=9) were excluded for survival analysis. 30-day mortality analyses showed no 
significant difference between an interval of 0-3 days and 4-7 days for all ages combined 
(30-day mortality for interval of 
0-3 days was 2.1% and for the interval of 4-7 days 4.7%, p=0.08). Neither difference in one 
year overall survival between an interval of 0-3 days and 4-7 days was found for all ages com-
bined (HR 1.67; 95% CI 0.94-2.96; p=0.08). However, the one year overall survival showed an 
age disparity (figure 2a). Where patients younger than 75 years of age showed no difference in 
one year overall survival between both intervals (HR 1.11; 95% CI 0.54-2.30; p=0.8), patients 
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figure 2b: Comparison of one year non-cancer related mortality per interval group stratified for 
age group (TME-trial)
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≥75 years showed worse survival for the 4-7 days interval compared to those with 0-3 days 
interval (HR 3.58; 95% CI 1.32-9.71; p=0.01). Adjusted for age, gender, and stage these dif-
ferences remained significant (HR 3.65; 95% CI 1.31-10.16; p=0.01). The difference between 
the two interval groups in elderly patients arose within the first month, which suggested 
non-cancer-related mortality (including postoperative complications), as confirmed in figure 
2b (HR 2.92; 95% CI 1.05-8.12; p=0.04). No significant differences were found for both age 
groups between the two interval groups in five year disease-free survival (HR 1.00; 95% CI 
0.71-1.39; p=0.9 for patients <75 years and HR 2.07; 95% CI 0.90-4.79; p=0.09 for patients 
≥75 years), neither for the five year local-recurrence free survival (HR 0.79; 95% CI 0.37-1.67; 
p=0.5 for patients <75 years and HR 3.98; 95% CI 0.41-38.34; p=0.2 for patients ≥75 years). 
Verification set
Patients
A total of 600 patients receiving radiotherapy between 2000 and 2010 were included in this 
verification set. The median follow-up since surgery of these patients was 4.3 years (range 
0-11.4 years). Median age of these patients at time of surgery was 67.2 years (range 26.5-94.5 
years).
Radiotherapy duration and interval between radiotherapy and surgery
In this cohort most patients received radiotherapy during 5 days (45.8%) or 7 days (50.2%) 
(table 1b). The remaining patients received radiotherapy during 6 days (0.5%) or 8 days (3.5%). 
Most patients (425/600) were operated on 0-3 days after the last fraction of radiotherapy. 
The interval of 4-7 days, 8-27 days, and ≥28 days were less common (112/600, 18/600, and 
35/600 patients, respectively). Over time there was an increase in patients who were oper-
ated on more than 28 days after the last fraction of radiotherapy (from 2.9% in 2000, to 
10.7% in 2009; p<0.001). 
As shown in table 2b, in the verification set elderly patients of 75 years and older more often 
had an interval of ≥28 days, and less often ≤3 days(p=0.006). Furthermore, with a longer 
interval between the last fraction of radiotherapy and surgery, there was a decrease in patho-
logical stage (p<0.001). The pooled rate of pathological complete response in patients with an 




The 30-day mortality for all ages combined was 1.7% for an interval of 0-3 days, 1.6% for an 
interval of 4-7 days and 2.9% for an interval of 28 days or more, which was not statistically 
different (p=0.9). Both the 30-day mortality and the one year overall survival of the patients 
table 2a: Clinical characteristics of patients of the TME-trial
interval between radiotherapy and surgery
≤3 days 4-7 days 8-27 days ≥28 days p-value
n % n % n % n %
Age 0.5
<75 years 237 45.1 279 53.1 5 1.0 4 0.8
≥75 years 56 47.9 61 52.1 0 0.0 0 0.0
sex 0.2
Male 185 44.3 228 54.5 4 1.0 1 0.2
Female 108 48.2 112 50.0 1 0.5 3 1.3
stage <0.001
In situ 3 30.0 5 50.0 0 0.0 2 20.0
I 102 48.2 106 50.0 2 0.9 2 0.9
II 94 49.5 96 50.5 0 0.0 0 0.0
III 94 40.9 133 57.8 3 1.3 0 0.0
total 293 45.6 340 53.0 5 0.8 4 0.6
table 2b: Clinical characteristics of patients of the verification set
interval between radiotherapy and surgery
≤3 days 4-7 days 8-27 days ≥28 days p-value
n % n % n % n %
Age 0.006
<75 years 336 72.7 95 20.6 12 2.6 19 4.1
≥75 years 89 64.5 27 19.6 6 4.3 16 11.6
sex 0.1
Male 272 74.3 64 17.5 10 2.7 20 5.5
Female 153 65.4 58 24.8 8 3.4 15 6.4
stage <0.001
In situ 4 57.1 0 0.0 0 0.0 3 42.9
I 140 70.4 38 19.1 5 2.5 16 8.0
II 120 67.2 37 22.2 8 3.9 12 6.7
III 159 76.0 43 19.2 5 2.9 4 1.9
Unknown 2 33.3 4 66.7 0 0.0 0 0.0
total 425 70.8 122 20.3 18 3.0 35 5.9
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figure 3a: Comparison of one year overall survival per interval group stratified for age group 
(verification set)
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figure 3b: Comparison of one year non-cancer related mortality per interval group stratified for 
age group (verification set)
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from the verification set did not show the age disparity found in the dataset from the TME trial 
(figure 3a). Due to small numbers, patients with an interval of 8 until 27 days between radio-
therapy and surgery (n=18) were excluded form survival analysis. There was no significant 
difference found between the interval of 0-3 days compared to 4-7 days both for patients <75 
years (HR 0.65; 95% CI 0.14-2.93; p=0.6) and patients ≥75 years (HR 0.59; 95% CI 0.13-2.66; 
p=0.5). This remained after adjusting for age, gender, and stage.  Similarly, no differences in 
overall survival were found between the interval of 0-3 days and ≥28 days in neither patients 
<75 years (HR 3.70; 95% CI 0.82-16.72; p=0.09), nor in patients ≥75 years (HR 0.97; 95% CI 
0.22-4.38; p=0.9).
The non-cancer-related survival of younger and elderly patients showed no significant dif-
ferences between the interval of 0-3 days compared to 4-7 days either (HR 0.40; 95% CI 
0.05-3.13; p=0.4, for patients <75 years, and HR 1.08; 95% CI 0.22-5.36; p=0.9, for patients 
≥75 years, respectively) (figure 3b). Besides, no differences were found in five year disease-
free survival (HR 0.93; 95% CI 0.57-1.52; p=0.8, 4-7 day interval compared to 0-3 days for 
patients younger than 75 years, HR 0.77; 95% CI 0.29-2.05; p=0.6, 4-7 day interval compared 
to 0-3 days for patients of 75 years and older). Furthermore, no differences were found in 
five year local-recurrence free survival, (HR 0.27; 95% CI 0.04-2.06; p=0.2, HR 0.89; 95% CI 
0.19-4.29; p=0.9, for younger and elderly patients with an interval of 4-7 days compared to 
0-3 days, respectively). 
Duration of radiotherapy
Since the TME-trial the radiotherapy treatment was more often interrupted with a weekend, 
which increased the duration of radiotherapy from 5 days (85.0% in the TME trial) to 7 days 
(50.2% in the verification set). When radiotherapy during 5 days and during 7 days were com-
pared in the verification set, no differences were found in one year overall survival (HR 0.75; 
95% CI 0.37-1.52; p=0.4), one year non-cancer-related mortality (HR 0.91; 95% CI 0.39-2.10; 
p=0.8), or five year local-recurrence free survival (HR 0.89; 95% CI 0.39-2.01; p=0.8). Further-
more, no differences in overall survival, non-cancer-related survival, or local-recurrence free 
survival were found in patients aged <75 years, neither in patients aged ≥75 years.
Overall treatment time
Since both the duration of the radiotherapy and the interval between radiotherapy and surgery 
have changed over time, overall treatment time (OTT, as explained in figure 1), could have been 
a factor influencing mortality. However, in the verification set OTT was not associated with one 
year overall survival, one year non-cancer-related survival, or five year local-recurrence free 
survival (HR 0.24; 95% CI 0.03-1.75; p=0.2, HR 0.35; 95% CI 0.085-2.62; p=0.3, and HR 1.31; 
95% CI 0.45-3.87; p=0.6, respectively). When the analyses have been done separately for 
each age group (<75 years and ≥75 years), no differences were found either. 
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DiscussiOn
In this study we analysed the impact of the interval between the last fraction of short course 
radiotherapy and surgery on one year survival and long term recurrence, both in the TME-trial 
and in a verification set. Results from the TME-trial showed that elderly patients with a pro-
longed interval (4-7 days) between the end of radiotherapy and surgery had higher one year 
overall and non-cancer related mortality. In the verification set this could not be confirmed.
Although the results of the TME cohort derived from a randomised controlled trial, we have 
to interpret these results with caution, since these analyses have not been evaluated in a 
randomised setting. Therefore the finding may be simply a random finding.  Another possible 
explanation for the results found may be that surgery was postponed in patients with a poor 
condition, after consultation by the anaesthetist, which would result in bias. Elderly patients 
are expected to have a poor condition more often, which would explain that the results were 
only found in patients ≥75 years. Because most patients were seen by the anaesthetist during 
admission prior to surgery, postponement of surgery by the anaesthetist should then result 
in a longer interval between admission and surgery for the longer interval group. However, 
no difference was found, with a similar median time between admission and surgery in both 
interval groups (2 days). Furthermore, no differences were found in age, gender, stage (see 
table 2a), WHO performance scores (data not shown), and toxicity (data not shown) between 
the two interval groups. Even though, comorbidities were not administered during the TME 
trial, and might explain differences between both interval groups. 
For this reason we tried to confirm the above mentioned findings in a separate retrospectively 
collected verification set. In this verification set, no differences were found in one year overall 
survival and non-cancer-related survival between the interval groups. Several possible reasons 
could explain this. Firstly, over time perioperative care might have improved, resulting in less 
postoperative mortality. 30-day mortality was 2.1% in the interval of 0-3 days and 4.7% in 
the interval of 4-7 days, compared with 1.7% in the interval of 0-3 days, 1.6% in the interval 
of 4-7 days and 2.9% in the interval of 28 days or more in the verification set; suggestion that 
perioperative care has improved. Finally, another possibility is that due to awareness of the 
clinicians for the higher postoperative mortality, since the TME results have been presented 
on several congresses, elderly patients were less often treated with an interval between 4 
till 7 days between radiotherapy and surgery in the verification set. The results showed that 
indeed fewer patients were operated on 4 till 7 days after the last fraction of radiotherapy, 
indicating that awareness of the physicians might have been present.  Besides, the finding 
that there has been a shift in radiotherapy duration from mainly 5 days in the TME-trials to 7 
days in the verification set, suggests that this was done in order to prevent logistical problems. 
During the TME trial most patients received radiotherapy from Monday till Friday, followed by 
surgery in the next week. The knowledge of possible worse outcome after an interval of more 
than three days might have triggered radiation oncologists to decrease the interval between 
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the end of radiotherapy and surgery, with nowadays only 20% of patients having an interval 
of 4-7 days (122 out of 600 patients), which was over 50% during the TME-trial (340 out of 
642 patients). This resulted in a shift in approach; approximately 10% of the patients had 
a radiotherapy duration of 7 days during the TME-trial, whereas this was over 50% in the 
verification set. The present study therefore analysed the relation between overall treatment 
time and postoperative mortality and non-cancer-related mortality, demonstrating no differ-
ence, neither for the whole group, nor for the elderly. This suggests that including a weekend 
in radiotherapy treatment is safe.
Several other studies have studied the influence of the interval between radiotherapy and 
surgery. Recently the interim analyses of the Stockholm III trial have been published. In these 
interim analyses an increase in postoperative complications for patients surgically treated 
11-17 days since the start of radiotherapy compared to patients with a shorter interval was 
reported. Differences in postoperative mortality were not significant due to small numbers.19 
Similar, Hartley et al21 found in a retrospective population-based cohort that patients with an 
overall treatment time < 10 days had a decreased risk of complications. Additionally, Hartley 
et al 22 published that the ratio between preoperative and postoperative neutrophil leucocyte 
count was significantly higher in patients without complications. Even though, they did not 
find an association between the neutrophil ratio and the overall treatment time. Fokstuen et 
al18 found clear indications that the differences between the interval groups are related to the 
perioperative leukocyte response. Patients with an abnormal leukocyte response developed 
sepsis more often and had an increased risk of death within 90 days after surgery. Besides, a 
longer than recommended interval also appeared to be detrimental for postoperative death 
independently of leukocyte response. 
From the above can be concluded that there are several indications in the literature that the 
increased postoperative mortality after a longer interval between radiotherapy and surgery 
could be caused by an impaired immune response, possibly reflected in the perioperative 
leucocyte count of the patient.
Currently a Swedish trial studies delayed surgery after short course radiotherapy, because 
clear indications have been found that short course radiotherapy could cause downstaging 
after an interval between radiotherapy and surgery of at least four weeks.19,23,24 Almost 
certainly due to these results and the currently running trial, delayed surgery was used more 
often in the verification set, mainly in elderly patients. In our study there were also indica-
tions that delayed surgery induces downstaging, as patients with delayed surgery had a lower 
pathological stage. Furthermore, the verification set showed no differences in short term 
survival between direct surgery after radiotherapy (interval of 0-3 days or 4-7 days) compared 
to delayed surgery (interval of 28 days or more), which is in line with the results shown in the 
interim analyses of the Stockholm III trial.19 Possibly, the leukocyte response has normalized 
at the time those patients are operated on.
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cOnclusiOn
In conclusion, there are several indications that the interval between radiotherapy and surgery 
influences postoperative outcome. Results from the verification set demonstrate that avoiding 
a longer interval between radiotherapy and surgery and including a weekend in the radio-
therapy treatment seems safe, both for postoperative mortality as for oncological outcome. 
Therefore we recommend to limit the interval to 3 days and accept a radiotherapy duration of 
7 days. If logistically impossible, postponement surgery after more than four weeks seems an 
option, although results on oncological outcome have to be awaited.
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The EURECCA (European Registration of Cancer Care) consortium is currently formed by nine 
independently founded national colorectal audit registrations, of which most already run for 
many years. The cumulative experience of EURECCA’s participants could be used to identify 
a ‘core dataset’ that covers all important aspects needed for high quality auditing and at the 
same time lacking needless data items that only consumes administrative effort. The aim of 
this study is to compare the data items used by the nine registries participating in EURECCA to 
identify a core dataset and explore options for future research.
Methods
All colorectal outcome registrations participating in the EURECCA project were asked to supply 
a list with all the data-items they score. Items were scored ‘present’ if they appeared literally 
in a registration or in case they could be calculated using other items in the same registration. 
The definition of a ‘shared data-item’ was that at least eight of the nine participating registries 
scored the item. 
Results
The number of registered data items varied between 254 (Belgium) and 83 (Norway). Among 
the 45 variables were patient data, data about preoperative staging, surgical treatment, pre- or 
postoperative radio- and/or chemotherapy, and follow-up. Items about tumour recurrence or 
quality of life were scored too little to become shared data items. 
Conclusion 
A total of 45 items were collected by 8 or more of the participating registries and subsequently 
met the criteria for a shared data-item.
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intrODuctiOn
In 2006, colorectal cancer caused over 200,000 deaths in Europe, making it the second most 
common cause of cancer related death, while its incidence is still increasing.1 In developing 
countries, the rise in incidence is even higher, while they have the worst outcome.2-4 Although 
surgery is the cornerstone for curative treatment, there is great variability in outcomes among 
surgeons and institutions. 
Quality of health care has a high priority on the political agenda of most European countries. 
Universal health care improvement initiatives, such as the development of a preoperative sur-
gical checklist by the World Health Organization, reflect the contemporary global commitment 
to prioritizing high quality care within surgery.5 
Surgical quality assurance program, also called surgical audit, is a quality instrument that 
collects detailed clinical data from different health care providers, which can be adjusted for 
baseline risk and subsequently fed back to individual hospitals or surgeons. Major improve-
ments have been achieved with national audits.6-8 However, although all the national audits 
achieved excellent results, differences in treatment and outcome remain between European 
countries and cannot be easily explained.9 To reduce those differences by identifying and 
spreading best practice, the European CanCer Organisation (ECCO) initiated an international, 
multidisciplinary, outcome-based quality improvement program: European Registration of 
Cancer Care (EURECCA). The goal is to create a multidisciplinary European registration struc-
ture for patient, tumour, and treatment characteristics linked to outcome registration. Many 
important topics that are unanswered by randomised controlled trials could be researched 
using the data of EURECCA project. The EURECCA project makes use of existing national audit 
registrations and started with colorectal cancer, but in the future other solid tumour types, 
such as breast cancer, gastric cancer, and oesophageal cancer, will follow. 
Unfortunately, clinical auditing comes with a price. Despite rapid development in medical 
information technology, clinical auditing still is a considerable administrative burden from 
medical professionals. A beautifully designed but very detailed registry that turns out to be 
too time consuming to complete is worthless. Therefore, it is important only to register those 
items that really matter. When a new audit is set up, dedicated professionals might be tempted 
to develop a very complete, although unnecessary large dataset. Instead of reinventing the 
wheel, a ‘core dataset’ distilled from existing audits could save much energy.
The EURECCA consortium is currently formed by nine independently founded national colorec-
tal audit registrations, most of whom already run for many years. The cumulative experience 
of EURECCA’s participants could be used to identify a ‘core dataset’ that covers all important 
aspects needed for high quality auditing and at the same time lacking needless data items 
that only consumes administrative effort. Even more important than being used as a template 
for other audits, an EURECCA core set will give the consortium insight in what research can be 
performed in the near future. 
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The objective of this study is to compare the data items used by the nine registries participat-
ing in EURECCA to identify a core dataset and explore options for future research within the 
EURECCA project.
 PAtients AnD methODs
All colorectal outcome registrations participating in the EURECCA project were asked to supply 
a list with all the data-items they score. These data-items were entered in a database and 
assigned to a main category and a subcategory. Items were scored ‘present’ if they appeared 
literally in a registration or in case they could be calculated using other items in the same 
registration. Secondly, the type of data (categorical, number, yes/no, free text) was scored. 
Software used for data input and analyses was SPSS 17 (PASW, Chicago). After all the items 
were entered in the database, a report was sent back to the national data managers to check 
for errors or incompleteness’. The corrected lists were returned and processed in the database. 
In the corrected and completed database, shared data items between the registries were 
identified as well as resemblances in data type and categories. The definition of a ‘shared 
data-item’ was that only one registry was allowed not to score the item, so at least eight of the 
nine participating registries scored the item.
results
All nine participating EURECCA registries (table 1) supplied lists with all recorded data items, 
which were entered into a database and checked for accuracy as described in the methods 
section. The number of registered data items varied between 254 (Belgium) and 83 (Norway) 
(figure 1). A total of 45 items were collected by 8 or more of the participating registries and 
subsequently met the criteria for a shared data-item (table 2). Among the 45 variables were 
patient data such as date of birth, gender, cancer type and ASA score. Furthermore, variables 
to score the use of endoscopy, rectal ultrasound, CT or MRI scan for preoperative staging met 
the shared data item criteria together with cT-stage and cM-stage. Items about the surgical 
treatment that met the criteria for a shared data item included date of surgery, main proce-
dure, open or laparoscopic, the creation of an anastomosis and/or stoma and the important 
postoperative complication; anastomotic leakage. Eight or more out of the nine participating 
registries scored pTNM stage, radicality and distance of the tumour to the surgical resection 
plane. Registrations of administered pre- or postoperative radio- and or chemotherapy were 
also shared data items. Regarding follow-up, death status and date of death were shared data 
items. Items about tumour recurrence or quality of life were scored too little to become shared 
data items. 
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Figure 1 shows the number of recorded data-items scored by all nine EURECCA participants on 
the Y-axis and the number of years since first registration on the X-axis. There was no relation 
between time since first registration and the number of scored data items.
table 1: The EURECCA consortium
name country number of included patients
(mid 2011)
Dutch surgical colorectal Audit (DscA) The Netherlands 25,000






norwegian colorectal cancer Project Norway 26,500
swedish colorectal cancer registry Sweden 41,000
Danish colorectal cancer Database Denmark 36,500
national bowel cancer Audit Program (nbOcAP) United Kingdom 200,000
Project on cancer of the rectum (PrOcAre) Belgium 4,500
spanish tme project Spain 7,500
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The 
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Italy Sweden Denmark Norway 
figure 1: Number of recorded data-items for all EURECCA participants, including time since first 
registration in years
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table 2: Data items shared by ≥8/9 registrations
category Data item
Patient: administrative data Patient number
Cancer type (rectal, colon)
Neoadjuvant therapy (type: none, RT, CT, RCT)





Radiotherapy: type (preop / postop) and duration (long- / short- 
course)
Patient: preoperative medical condition ASA score
Preoperative staging: colonoscopy, location tumour, 
biopsy, complications
Endoscopy: lower limit from anal verge (cm)
Endoscopy: y/n
Preoperative staging: imaging CT scan
Ultrasound rectal
MRI scan
MRI - cT stage
Preoperative staging: final preoperative staging, 
mDt, other
cM Clinical metastases: y/n
Final preop diagnosis: cT-stage
Final preop diagnosis: cM-stage
neoadjuvant treatment: type, technique, dose, etc Preoperative chemotherapy
Preoperative radiotherapy
Operation: type, technique, anastomosis, stoma, etc Operation: y/n
Operation: date
Main procedure (ICD10 or translatable into)
Surgery: stoma (none, decompressive, permanent, loop, endtype)
Surgical access for resection: (laparotomy / laparoscopy / converted 
laparoscopy / local excision)
Surgery: Anastomosis
Resection of adjacent organ
Operation: complications Postoperative anastomotic leakage






Tumour stage (TNM 6th edition)
Lymph nodes with metastases
Lymph nodes in total
Distance to surgical resection plane (CRM)
Radicality operation (R0, R1, R2)
Location distant metastases (liver, lung, peritonuem, omentum, 
ovary, lymp node)
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DiscussiOn
After comparing the datasets of EURECCA’s nine participating registries, a list of 45 data items 
could be identified as a shared, core dataset. A strong variation between the number of data 
items collected by different registries was found, ranging between 83 by Norway and 254 by 
Belgium. Despite the fact that the oldest registry (Norway) used the fewest data items, there 
was no relation between time since first registration and slimness of the dataset. 
Although many important items can be mentioned that are not listed in the core dataset, the 
most vital variables about patient, disease, preoperative staging, operation, pathology and 
survival are all part of the core dataset. Furthermore, data about pre- and postoperative adju-
vant treatment are also part of the core dataset. 
Worldwide and also within Europe, there are many differences in the use of (neo)adjuvant 
treatment for cancer. For instance, for rectal cancer with an unthreatened circumferential 
resection margin, many patients will receive short course (5×5 Gy) preoperative radiotherapy 
while others will get long course radiochemotherapy and sometimes this is administered 
postoperatively. Using the shared data items in combination with the impressive and unprec-
edented amount of patients supplied by EURECCA, an inventory about differences in (neo)
adjuvant treatment can be made and linked to other data such as anastomotic leakage, surgi-
cal radicality and long term survival. The EURECCA core dataset offers enough patient data to 
perform statistical corrections for patient and tumour factors, necessary for a fair comparison 
between different treatments.
While the share of elderly in the incidence of colorectal cancer is increasing every year, elderly 
are remarkably enough excluded from most clinical trials concerning colorectal cancer. Again, 
the extensive data of EURECCA’s core dataset should be able to answer vital questions about 
the optimal treatment for elderly. Differences in treatment can be identified as well as differ-













In conclusion, a valuable core data set is identified. This study shows a lean and easy to 
register core dataset that can help starting clinical audits setting up their database and help 
minimize administrative burden for existing audits. Most importantly, vital research questions 
will be answered in the near future using the power of EURECCA’s merged data.
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Several studies have shown remarkable differences in colorectal cancer survival across Europe. 
Most of these studies lacked information about stage and treatment. This study compared 
short term survival as well as differences in tumour stage and treatment strategies between 
five European countries: Norway, Sweden, Denmark, Belgium, and the Netherlands.
Methods
For this retrospective cohort study all patients aged 18 years or older with adenocarcinoma 
of the rectum without distant metastases and operated upon with a rectal resection from 
Norway, Sweden, Denmark, Belgium (PROCARE), and the Netherlands diagnosed in 2008 
and 2009 were included. Differences in preoperative treatment between the countries were 
compared using univariate and multivariable logistic regression. One year univariate relative 
survival and one year multivariable relative excess risk (RER) were compared between the five 
countries.
Results
The use of preoperative short course radiotherapy and chemoradiation varied widely across 
the countries. The one year relative survival was significantly better for patients from Sweden 
compared with the Netherlands. When stratified for age groups, these differences were only 
present in the patients aged 75 years and older.
Conclusion
Large variation in the use of preoperative radiotherapy and chemoradiation was found 
between the countries. Even though, there was little variation in relative survival between 
the countries, except Sweden, which had a significant better one year RER among the elderly 
patients after adjustment. The differences in survival are expected to be caused by differences 
in perioperative care, selection of patients, and especially management of elderly patients. 
The effects of preoperative treatment are expected to be seen on long term follow-up.
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intrODuctiOn
Several studies have shown remarkable differences in colorectal cancer survival across 
Europe.1,2 Although the mean European five year relative survival between 1995 and 1999 
was 54.0%, it ranged from 38.8% to 59.9% between the countries.3 The variation in outcome 
could be explained by case mix variation, differences in socioeconomic status and variation in 
registration. More importantly, many countries have their own guidelines resulting in variation 
in treatment plans. Potentially easy modifiable factors could be stage at diagnosis (by screen-
ing) and treatment plans (by adjusting guidelines). Since the stage of disease at diagnosis is 
one of the most important prognostic factors, this should always be taken into account when 
comparing the survival of cancer patients. The differences in treatment strategies may lead 
to differences in survival.4-6 Currently, it is unknown which country has a better treatment 
strategy compared with the other countries.
In the last two decades clinical audits have been initiated in several European countries to 
improve the outcome of rectal cancer patients. These clinical audits have not only successfully 
identified best practice and underperforming hospitals, but also achieved amongst others, a 
rise in survival, nationally.7-9 However, variation in outcome between the European countries 
remains.10 The EUropean REgistration of Cancer CAre (EURECCA) project was initiated by the 
European CanCer Organisation (ECCO) in order to decrease these differences and to improve 
cancer care through Europe.10,11 This project has the aim to generate the best care for all 
cancer patients by combining national audit structures.
Most of the previous studies concerning European survival differences lacked information 
about stage of disease and treatment strategies within countries and therefore, results should 
be interpreted with caution. The present study was undertaken to compare preoperative treat-
ment of rectal cancer patients including the differences in tumour stage between five Euro-
pean countries included in the EURECCA-project: Norway (NO), Sweden (SE), Denmark (DK), 
Belgium (BE), and the Netherlands (NL). The five included countries had the data available, the 
data was accessible, and similar health care systems were present. Furthermore, short term 
survival (30 day and 1 year) will be compared. Variation in both preoperative treatment and 
survival are to be expected.
PAtients AnD methODs
Patients and follow-up
Patients with rectal cancer (ICD-1O C20) were extracted from national (clinical) cancer regis-
tries from NO (Norwegian Colorectal Cancer Registry), SE (Swedish Colorectal Cancer Registry), 
DK (Danish Colorectal Cancer Group database), BE (PROCARE) and the NL (Netherlands Cancer 
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cancer registry. The inclusion criteria slightly differ among the countries; the Norwegian 
Colorectal Cancer Registry included all rectal cancer patients, the Swedish Colorectal Can-
cer Registry included only patients with an adenocarcinoma of the colon or rectum and no 
patients with premalignant tumours, the Danish Colorectal Cancer Group database included 
Danish patients (no residents of Greenland and Faroe Islands, nor foreigners without a civil 
registration number) aged 18 years and older, diagnosed at a surgical department, without 
metachronous colorectal cancer, the Netherlands Cancer Registry did not have any exclusion 
criteria, and in PROCARE the registration of patients was voluntary, besides, PROCARE only 
included patients with adenocarcinoma of the rectum and no premalignant tumours. From all 
countries patients diagnosed in 2008 and 2009 were included. Inclusion criteria in the pres-
ent study were: patients aged 18 years and older with adenocarcinoma of the rectum without 
distant metastases, operated upon with a rectal resection (including Hartmann procedure, Low 
Anterior Resection, Abdominoperineal resection, and proctocolectomy with or without pouch 
construction), known age, stage of disease and treatment strategy, and a vital status known at 
date of follow-up (either date of death, or last date of linkage with the municipal or national 
population registries). All countries link their data with the municipal or national population 
registry. The last date of linkage was at least December 31st 2010, except for DK, which was 
November 25th 2010. The inclusion of patients is shown in the flowchart (figure 1). A total of 
10,296 patients from the five countries were included in this study.
Tumour stage was based on pathology reports (pathological stage). In case pathological stage 
was not available, clinical stage was used. Clinical stage is based on the results of echoen-
doscopy and magnetic resonance imaging (MRI). If neither pathological nor clinical stage was 
registered, patients were defined as having an unknown stage and excluded. Clinical stage 
was not registered in Denmark. Preoperative treatment was divided into four groups: no pre-
operative treatment, preoperative radiotherapy, preoperative chemoradiation, and unknown 
treatment. Patients were categorized in three age groups (<65 years, 65-74 years, and ≥75 
years).
Statistical analyses
Differences in the characteristics between the countries were calculated using a chi-squared 
test. Univariate and multivariable logistic regressions were performed to compare the use of 
preoperative treatment between the countries, and to compare the 30-day mortality between 
the countries. Follow-up was calculated from the day of surgery until death or the last day of 
follow-up. One year univariate relative survival analyses were made using the Hakulinen defi-
nition12 as the ratio of the survival observed among the patients and the survival that would 
have been expected based on the corresponding (age, gender, and year) general population. 
National life tables were used to estimate expected survival. Expected survival was estimated 
with Ederer II method.13 With relative survival the excess mortality has been modelled, there-
fore, multivariable models can be estimated as Relative excess risks of death (RERs). RERs were 
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estimated using a multivariable generalized linear model with a Poisson distribution, based 
on collapsed relative survival data, using exact survival times. Multivariable analyses were 
adjusted for age (in one year groups, used as continuous variable in the model), gender, and 
stage. Follow-up was truncated at 30 days, or 1 year, respectively. Stratified multivariable RER 
analyses were performed for the three age groups. Sensitivity analyses have been performed, 
excluding BE from the analyses, to compare whether this would change the outcomes. In all 
analyses, a p-value of <0.05 was considered to be statistically significant. 
results
Characteristics
In attachment 1, an overview of the trends in incidence and mortality of the included countries 
is presented. A total of 16,401 patients diagnosed with rectal cancer in 2008 and 2009 have 
been identified in the five clinical cancer registries. The median age of the patients was 67 
years in NL, 70 years in SE, 70 years in DK, 70 years in NO, and 69 years in BE. About 20% 
of the patients from each country did not receive a resection of the tumour (NL 20.1%, SE 
17.0%, DK 24.6%, NO 20.8%, and BE 17.0%). Non-resected patients were slightly older than 
the complete group; 71 years in NL, 75 years in SE, 75 years in DK, 77 years in NO, and 73 
years in BE. 
A total of 10,296 patients from the five countries were included in this study. Table 1 shows 
the characteristics. The country with the highest number of included patients was NL with 
4107 (38.9%), followed by SE with 2433 patients, 1510 patients from DK, 1170 from NO, 
and the remaining 1076 from BE. Patients from NL had a younger age when compared to 
the patients of the other countries (p<0.001). No difference in gender distribution was found 
between the five countries. Both the clinical and the pathological stage distribution differed 
between the countries (p<0.001 for both), the differences for pathological stage remained 
statistically significant when patients with no residual tumour (ypT0 after preoperative treat-
ment) was excluded (p<0.001). 
Preoperative treatment
All countries used preoperative treatment, either radiotherapy or chemoradiation, for rectal 
cancer patients. However, in DK 71.5% of the patients did not receive any preoperative treat-
ment, compared to 69.3% in NO, 33.4% in BE, 33.1% in SE, and 14.2% in NL (p<0.001) (table 
1).
Overall, the proportion of patients receiving preoperative radiotherapy varied by country 
(p<0.001), with NL and SE reporting high rates of radiotherapy (52.8% and 52.3%, respec-
tively). BE, NO, and DK had low rates (14.7%, 9.7%, and 5.6%, respectively) (table 1). 












































































































































































































































































































































































































































































































































































Figure 2 shows the use of radiotherapy for each country organized by clinical stage. In NL 
radiotherapy is applied in a high amount for every stage (decreasing from 75.4% at stage I, 
to 28.5% at stage III), while the use of radiotherapy varied among the stages in SE (stage I 
37.2%, stage II cT3 cN0 65.70.2%, stage II cT4 cN0 37.9%, and stage III 61.0%). The use of 
preoperative radiotherapy was low in NO (from 3.0% in stage I to 17.7% in stage III). In BE the 
administration of radiotherapy alone is not very common, except for clinical stage II cT3 cN0, 
where 22.1% of the patients received preoperative radiotherapy.
Stratified for age group (see figure 3), NL, BE, NO, and DK used preoperative radiotherapy alone 
more frequently with increasing age: 47.8% of patients aged <65 years received radiotherapy 
in NL, 10.6% in BE, in NO 9.2%, and in DK 4.1%; when the patients were aged ≥75 years, they 
received radiotherapy in 61.1% of the patients in NL, 19.7% of the cases in BE, in 9.6% of the 
cases in NO, and in 7.4% of the cases in DK. In SE this percentage was more stable and high 
over the age groups: it changed from 53.1% to 46.8%. For DK, BE, and NL the differences in 
the use of radiotherapy between patients <65 years and patients ≥75 years remained after 
adjustment for gender and stage (OR 1.85; p=0.03 for DK, OR 1.95; p=0.002 for BE, and OR 
1.62; p<0.001 for NL). In NO the use of radiotherapy remained stable with increasing age after 
adjustment (OR 1.00; p=0.9). In SE the use of radiotherapy decreased with increasing age (OR 
0.79; p=0.02).
Overall, BE had the highest usage of chemoradiation (51.9%), followed by NL (33.0%), DK 
(22.4%), and NO (21.0%). SE used preoperative chemoradiation the least often (14.2%)(table 
1). Figure 2 also shows the proportion of patients that received chemoradiation in each coun-


































































































































































figure 2: The use of preoperative treatment per country organised by clinical stage
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with higher clinical stages in each country, whereas stage II cT4 cN0 was treated comparable 
with stage III. 
As shown in figure 3, stratified for age group, less chemoradiation was administered with 
increasing age for all countries (p<0.001 for each country). In DK and SE it decreased from 
27.9% and 24.6% in patients aged <65 years to 14.3% and 4.0% in patients aged ≥75 
years, respectively. In NL and NO 41.9% and 31.2% of the patients aged <65 years received 
chemoradiation, while 16.4% and 8.6% of the patients ≥75 years received chemoradiation, 
respectively. In BE the percentage decreased from 63.8% to 33.3%. After adjustment for gen-
der and stage, the use of chemoradiation remained decreased with increasing age group for 
each of the countries (OR 0.28; p=<0.001 for NL, OR 0.13; p<0.001 for SE, OR 0.43; p<0.001 
for DK, OR 0.21; p<0.001 for NO, and OR 0.30; p<0.001 for BE).
Survival
The 30-day mortality rate was 2.5% in NL, 1.9% in SE, 3.0% in DK, 1.7% in NO, and 1.5% in 
BE, which did not differ significantly between the countries (p=0.08). After adjustment for age, 
gender, and stage, SE, NO, and BE had a significant lower 30-day mortality rate as compared to 
NL (OR 0.58; 95%CI 0.41-0.83; p=0.003, OR 0.53; 95% CI 0.32-0.87; p=0.012, OR 0.52; 95% 
CI 0.30-0.89; p=0.017, respectively). Whereas the 30-day mortality was comparable between 
DK and NL (OR 0.99; 95%CI 0.69-1.43; p=0.9).
In figure 4 the relative survival according to country is shown. The relative survival at one year 
varied little between the countries: in NL one year relative survival was 95.6%, in SE 96.1%, 






































































































figure 3: The use of preoperative treatment per country organised by age group
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adjustment, SE had a significantly better relative survival at one year compared with NL (RER 
0.66; 95% CI 0.49-0.89; p=0.007) (table 2).
When stratified for age group, the differences in survival, adjusted for age, gender, and stage, 
between the countries were only present in the patients aged 75 years and older (table 2). 
SE had a significant better one year relative survival (RER 0.61; 95% CI 0.41-0.90; p=0.013) 
compared with NL. 
The sensitivity analyses did not show differences.
DiscussiOn
Major findings in this study were the large differences in the proportion of patients receiving 
preoperative radiotherapy or chemoradiation between the countries. The one year relative 
survival was significantly better for patients from SE as compared to NL. When stratified for 
age groups, the differences in multivariable relative survival were only present in the patients 
aged 75 years and older.
Patients from NL were younger in comparison with other countries. When the datasets were 
compared without the selection criteria and therefore including all patients, the median age of 
the patients remained younger in the Netherlands (67 years in NL, 69 years in BE, and 70 years 
















figure 4: Graphic depiction of one year relative survival by country


















































































































































































































































































































lower stage at diagnosis, as would be expected if the difference would be a result of screening. 
Brenner et al. have reported the age distribution in several European registries for colorectal 
cancer.14 Compared to NO and SE, less elderly patients from NL were included in this study. 
A possible explanation could be that the Dutch population is younger compared to the other 
countries, which is shown by Eurostat.15 Another possibility is that the age distribution for 
rectal cancer within the countries was different, resulting in less elderly patients within NL as 
compared to SE, DK, NO, and BE, supported by the evidence from the ECO-website (European 
Statistics by the European Commission).16
The variation in the administration of both radiotherapy and chemoradiation is striking, as in 
DK less than 30% of the patients were treated preoperatively, in NL, on the other hand, over 
85% of patients received preoperative treatment. In BE, DK and NO preoperative chemoradia-
tion was preferred, while in NL and SE preoperative radiotherapy was mostly administered. 
Besides variation in treatment, also variations between the guidelines are present (attach-
ment 2). An interesting research proposal would be to compare whether the (preoperative) 
treatment given by each of the countries was in accordance to the guidelines. Unfortunately, 
detailed information is needed, such as distance from the anal verge and threatened meso-
rectal fascia, are often not registered. Including these variables by the registries would make 
a comparison of the guideline adherence, including a comparison of the outcome of these 
treatment strategies, possible.
Although the results of the analyses showed that NO uses both radiotherapy alone and chemo-
radiation as preoperative treatment, this might be a flaw in the registration manner. Norwegian 
guidelines advise the use of chemoradiation as preoperative treatment. Since all guidelines 
are evidence-based, variation was expected to be minimal. However, it seems that the same 
literature can be interpreted in different ways. Besides, the difference in time of development 
of the guidelines could be another explanation. The Dutch and the Swedish guidelines are 
relatively old, and arise from the results of the Dutch TME-trial, in which the patients were 
randomised between total mesorectal excision (TME) surgery with and without preoperative 
radiotherapy.17 Since during that trial, MRI staging was not standard, preoperative staging was 
less accurate. Nowadays, MRI staging is widely incorporated in all five countries included. 
Recently, the Mercury trial has shown that with MRI staging, T3 and N0 patients should not 
always receive preoperative treatment.18 This suggests that overtreatment was present based 
on the knowledge we have today in a high percentage of the patients included in the cur-
rent study. Indications on overtreatment were also found in the most recent results from the 
TME-trial.19 Van Gijn et al. showed that preoperative radiotherapy significantly improved the 
cancer-specific survival in patients operated with a negative circumferential resection margin, 
but this benefit was offset by an increase in other causes of death, resulting in an equal overall 
survival compared with surgery alone. Similar data has been found in Sweden before the TME-
era, indicating that radiotherapy can harm.20 
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The wide-ranging variation in preoperative treatment could have an effect on short- and long 
term survival. Unadjusted survival did not differ significantly between the countries. After 
adjustment for age, gender, and stage, SE, NO, and BE had lower 30-day mortality as compared 
to NL. It has been shown before that DK has an inferior short term survival as compared to 
other European countries.21,22 SE had a significant better one year RER as compared to NL, 
after adjustment for several confounders. It is known that SE in general has a high quality 
health care with nationwide quality assurance programs, which might have contributed to the 
current results in short term survival.23 But, the health care structure of SE is comparable with 
NO and DE. Another explanation could be the use of tobacco and alcohol. 
As preoperative treatment is expected to have an effect on both the curative resection as well 
as on disease recurrence, it is expected to find the effects of the differences in treatment on 
recurrence and therefore, long term survival.24 Unfortunately, long term survival was not avail-
able at the time of the study for these incidence years. Although, it is difficult to distinguish 
between the effect of perioperative care (defined as the general care before, during, and after 
surgery, such as treatment of comorbidities, fast-track regimens, and anaesthesiologic care) 
and the effect of preoperative treatment on survival, it is to be expected that perioperative 
care will probably result in survival differences within one year, since recurrences rarely occur 
within the first postoperative year. Patients who die within the first postoperative year are 
most likely to die because of non-cancer related disease. Differences found at conditional five 
year survival (under the condition of surviving the first postoperative year) will probably be 
due to preoperative and postoperative treatment, such as radiotherapy, chemoradiation, and 
chemotherapy, and quality of surgery.25 The present study showed that the differences found 
in multivariable RER, when stratified according to age group, was only present in the group 
of patients aged 75 years and older. Elderly patients are a heterogeneous group of patients, 
which might vary among the countries due to differences in selection of patient which will be 
assessed fit enough for certain treatments as well as differences in perioperative approach. 
Therefore, the differences found in RER adjusted for several confounders in the current study 
between the countries in elderly patients are probably more related to differences in surgery, 
perioperative care, and differences in fitness of the elderly patients at time of surgery rather 
than to preoperative treatment. Unfortunately, information on perioperative care and fitness 
of the patients was not available in the present study. Nevertheless, at one year differences in 
survival between the countries can already be found, suggesting that survival can be improved 
in all countries.
Long term follow-up is vital, since it could show whether differences in treatment strategies 
also result in survival benefit. Currently, within the EURECCA consortium is ongoing on the dif-
ferences in survival between the countries for the elderly patients persist in long term survival. 
Furthermore, the administration of adjuvant chemotherapy in rectal cancer patients is being 
investigated. Possibly, due to the shorter life expectancy of elderly patients, the decrease 
in (local) recurrences of due to preoperative radiotherapy and chemoradiation should be 
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carefully weighed against the treatment-related morbidity and mortality caused. One of the 
goals of the EURECCA consortium is to define multidisciplinary European guidelines for the 
treatment of colorectal cancer. During a consensus meeting in December 2012, the experts 
from all disciplines involved in the care for patients with colon and rectal cancer used the 
Delphi method in order to develop diagnostic and treatment algorithms, as a first initiative to 
achieve multidisciplinary European guidelines.26
Strengths and limitations
Several limitations are present in this study. Unknown is to what extent the differences in 
characteristics are caused by time of diagnoses, leading to differences in stage at diagnosis, 
by variation in case-mix, especially comorbidities, and by registration. In the case of NL, 
patients are defined as clinical unknown stage when no MRI is available. Besides, DK did not 
register preoperative (clinical) TNM stage, and neither collected information about patients 
without residual tumour postoperatively (ypT0). But since DK had a very low administration 
of preoperative treatment, large differences in clinical and pathological TNM stage would not 
be expected. The use of staging by MRI is widely used in all five countries, which made pre-
operative staging more reliable. Differences in administration of preoperative treatment and 
survival could be partly explained by differences in performance status and comorbidities. 
Unfortunately, these case-mix variables were not available in this study.
Another limitation is the selection bias probably present in the PROCARE database, which is 
based on voluntary participation of both hospitals and clinicians. That the group of patients in 
PROCARE indeed is better as compared to all patients within Belgium is shown when compar-
ing the results of PROCARE with the Belgium Cancer Registry. The median age nationally was 
slightly higher (70 years as compared to 69 in PROCARE) and patients from PROCARE were 
less often diagnosed with stage IV (15.2% in the Belgium Cancer Registry, as compared to 
12.6% in PROCARE). Even though, we have chosen to include these patients in the present 
manuscript, since PROCARE is an important initiative and should therefore be stimulated. 
Recently, the Belgium government has decided that PROCARE is indeed very important, and 
in the next one and a half year, it should become mandatory to participate for all hospitals 
including all patients in Belgium. On the other hand, we understand that the voluntary base 
of PROCARE at this moment might induce bias. We have performed sensitivity analyses, which 
did not resulted in changes in the outcome of the results overall.
The strength of the current study is the large number of patients included in this study, with 
detailed information. To our knowledge this is the first study comparing five countries with 
detailed information on both rectal cancer treatment. All registries except for Belgium are 
national (clinical) cancer registries, with an estimated inclusion of over 95% of cases. For 
Belgium, a registration bias cannot be excluded since registration was based on voluntary 
participation. 
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cOnclusiOn
A large variation in administration of preoperative treatment has been found between NO, 
SE, DK, BE, and NL. After adjustment for age, gender, and stage, Sweden had a significant bet-
ter relative survival for patients aged ≥75 years at one year compared to the Netherlands. 
The differences in one year relative survival are expected to be caused by differences in 
perioperative care, selection of patients, and fitness of elderly patients. By comparing these 
items between the countries, which will be a next step of the EURECCA-project, differences 
in survival of elderly patients could be elucidated. To properly investigate this, randomized 
controlled trials (RCT’s) may be considered. RCT’s, however, are costly and time consuming and 
will not yield practice changing results within years from the start. Furthermore, older patients 
are underrepresented if not excluded from RCT’s. International comparison of specific treat-
ment protocols could serve as a good alternative to select ‘best practices’ and improve the 
risk/benefit ratio in the treatment of rectal cancer patients. This comparative effectiveness 
research can bridge the knowledge gap specifically in older cancer patients, who are by 
nature, heterogeneous in patient characteristics and treatment patterns.27
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Attachment 1: Trends in incidence and mortality of the included countries
Incidence (ESR) Mortality (ESR)
Men Women Trend over time
(incidence from 2000-2007†)
Men Women Trend over time
(mortality from 2000-2007‡)
























































ESR: European Standardised rates
NA: Not applicable, no information available
† The incidence rates of 2000 until 2007 for each country, except for Belgium, they are 2004 until 2007
‡ The mortality rates of 2000 until 2007 for each country, except for Belgium, they are 2004 until 2006 
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Attachment 2: Guidelines for rectal cancer treatment per country
country Guidelines
the netherlands t1 n0:
t2-4: 
Only TME surgery.
Preoperative radiotherapy followed by TME surgery.
In case of high, small tumours, there might be chosen not to give preoperative radiotherapy.
In case of positive circumferential resection margin (CRM) or more than 4 lymph nodes positive, there 
might be chosen for preoperative chemoradiation.





No preoperative treatment, only TME surgery
In case of no involved margins, preoperative short course 
 
radiotherapy is indicated, followed by TME surgery.
With compromised margins preoperative chemoradiation is 
indicated followed by TME surgery.





Low (≤5 cm from the anal verge), mid (5-10 cm from the anal verge), and high (11-15 
cm from the anal verge) tumours receive no preoperative treatment. Low and mid 
tumours receive TME surgery, while high tumours receive PME surgery.
Low and mid (CRM ≤5 mm) tumours receive preoperative chemoradiation, mid (CRM 
>5mm) and high tumours receive no preoperative treatment.
Low and mid tumours receive preoperative chemoradiation, while high tumours 
receive no preoperative treatment.
In selected cases preoperative radiotherapy and postoperative chemotherapy might be administered.
norway t1-2 n0:
t3:
No preoperative treatment, only TME surgery.
<3 mm from the CRM preoperative chemoradiation, in case of >3 mm from the CRM, 
no preoperative treatment. Followed by TME surgery.
t4 or n+ outside the mesorectum: Preoperative chemoradiation followed by TME surgery.
Short course preoperative radiotherapy might be an alternative for old and fragile patients. In case of 
no preoperative treatment and perforation of the tumour or postoperative CRM ≤1mm, postoperative 




No preoperative treatment, only TME surgery
Low tumour (≤5 cm from the anal verge) preoperative chemoradiation, mid and high 
tumours (5.1-15 cm from the anal verge) short course preoperative radiotherapy, or 
when the CRM<2mm preoperative chemoradiation followed by TME surgery.
Preoperative chemoradiation followed by TME surgery.
In case of postoperative stage of II or III adjuvant chemotherapy is advised (or a combination of 
chemoradiation with chemotherapy in case when patients did not receive preoperative treatment).
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Short course external beam radiotherapy decreases local recurrences in patients with rectal 
cancer. However, improvements should be weighed against treatment-related morbidity. The 
present study compared long term outcome in rectal cancer patients treated with either pre-
operative short course radiotherapy (5×5 Gy) or chemoradiotherapy (CRT) in the Netherlands 
and a new treatment with possibly less side-effects, high dose rate endorectal brachytherapy 
(HDREBT), in Canada.
Methods
In total, 134 patients treated with preoperative 5×5 Gy radiotherapy (n=52) or CRT (n=82), 
and 141 patients treated with preoperative HDREBT (26 Gy over 4 days) were included. Cox 
proportional hazard models were used to estimate hazard ratios (HR) with 95% confidence 
intervals (CIs) adjusted for potential confounders between the countries. Endpoint was five 
year overall survival. Besides, competing-risks regression models were used to assess Sub 
Hazard Ratios (SHR) for local recurrence and cancer-specific mortality between the treatment 
strategies, with death as competing risk.
Results
A statistically significant reduction of five year overall survival was observed in patients 
treated with HDREBT, compared to patients treated with 5×5 Gy or CRT (HR 0.42, 95% CI 
0.20-0.90, p=0.03). With death as competing risk, the SHR for five year local recurrence was 
0.56 (95% CI 0.14-2.30, p=0.42), and the SHR for five year cancer-specific mortality was 0.60 
(95% CI 0.17-2.16, p=0.44).
Conclusion
In the present study, no significant differences in local recurrence and cancer-specific mortal-
ity were observed. However, superior overall survival was observed for patients treated with 
HDREBT, possibly due to lower treatment-related toxicities. This finding needs to be formally 
tested in randomized controlled trials.
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intrODuctiOn
Colorectal cancer is the third most common cancer in men and the second in women world-
wide.1 Approximately one third of these malignancies occur in the rectum, making the global 
rectal cancer incidence approximately 400,000/year.1 
In the past two decades, several improvements in rectal cancer treatment have been achieved. 
Whereas five year local recurrence rates were up to 27% until the beginning of the nineties 
after surgery2, the introduction of total mesorectal excision (TME) decreased five year local 
recurrence rates to 5-11%3-5. The TME-trial showed that the addition of preoperative external 
beam irradiation further decreased these rates to 5.6%.5 However, the improvement in local 
control should be weighed against the risk of side-effects due to short-course external beam 
irradiation.6,7 Acute as well as late side-effects occur, including more postoperative complica-
tions (48% in patients treated with preoperative short-course radiotherapy (RT) versus 41% 
in patients not treated with RT8, and more faecal incontinence after five years (62% versus 
38%, respectively)8,9.
In an attempt to reduce treatment-related toxicity, high dose rate endorectal brachytherapy 
(HDREBT) has been explored as a neoadjuvant treatment in patients with resectable rectal 
cancer.10-15 The five year local recurrence rate was 5% and toxicity patterns seemed to be 
favourable as compared to external beam.10,15 Importantly, to our knowledge, no studies 
(either randomized or observational) have compared the long term effects of these therapies. 
Given these findings, the objective of this study is to compare the overall survival, cancer-
specific mortality, and local recurrence in patients with clinical T3 rectal cancer treated with 
either short term preoperative radiotherapy or chemoradiotherapy (CRT) in the Netherlands, 
to HDREBT as routinely used in Canada.
PAtients AnD methODs
Patients
All patients included in the current study had clinical T3 (cT3) rectal cancer based on MR 
Imaging.  From the Catharina Hospital in the Netherlands, 134 consecutive patients with 
cT3 rectal cancer based on MR Imaging were included, 52 were treated with short-course 
radiotherapy (5×5 Gy) followed by TME surgery, while the remaining 82 were preoperatively 
treated with long-course radiotherapy 25×1.8-2 Gy combined with chemotherapy followed by 
TME surgery. From the Jewish General hospital and McGill University Health Center in Canada, 
141 consecutive patients were included. All these patients were treated with preoperative 
HDREBT with a daily dose of 6.5 Gy during 4 days, followed by TME surgery after 4-8 weeks. 
Included patients from both hospitals were surgically treated between 2005 and 2010.
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According to the Dutch rectal cancer treatment guidelines, cT3 patients should receive pre-
operative short-course radiotherapy. When the circumferential margin (CRM) is threatened or 
patients have N2 disease, patients should receive a combination of long-course radiotherapy 
and chemotherapy (CRT).16 Patients included from Canada received HDREBT. 
None of the included patients had distant metastases at the time of diagnosis. TME surgery 
was performed to all patients. Age, gender, clinical N-stage, pathological T-stage, pathologi-
cal N-stage, and year of surgery were collected from all the included patients. Patients were 
divided into three age groups (<65 years, 65-74 years, and ≥75 years).
Follow-up was measured from date of surgery to last date of follow-up or date of death, or to 
the date of local recurrence. The primary outcome was death from any cause. The secondary 
outcomes were local recurrence, regardless of the status of the systemic disease, and cancer-
specific mortality. Local recurrence was defined as evidence of tumour within the pelvic or 
perineal area, confirmed by imaging or pathology. Cancer-specific mortality was defined as 
death due to rectal cancer, as defined by the treating physician. As an additional secondary 
analysis, the overall survival of the Dutch patients treated with either 5×5 Gy or CRT was 
compared.
Statistical analyses
Descriptive statistics were used to describe the characteristics of the patients from the Neth-
erlands treated with 5×5 Gy or CRT, and Canada treated with HDREBT. Kaplan-Meier curves 
were constructed comparing overall survival between the countries. Cox proportional hazard 
models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the 
overall survival when comparing the countries. All models were adjusted for age (as a con-
tinuous variable), gender, cN-stage, and year of surgery. Competing-risks regression models 
were used to assess Sub Hazard Ratios (SHR) for local recurrence and cancer-specific mortality 
between the treatment strategies, with death as competing risk.17 Statistical significance was 
defined as p<0.05. All analyses were performed with STATA 12. 
results
A total of 275 patients with cT3 rectal cancer were included. Table 1 shows the characteristics 
of included patients. No significant differences between patients treated with 5×5 Gy or CRT, 
and treated with HDREBT were present, except clinical N-stage (cN-stage), in which patients 
treated with 5×5 Gy or CRT had more often signs of lymph node metastasis. In the Nether-
lands, elderly patients were more likely to have received 5×5 Gy than chemoradiotherapy in 
line with current clinical guidelines. Besides, elderly patients are more often female.
Table 2 shows the postoperative T and N (pT and pN) staging per country. Patients treated with 
HDREBT had lower pT stages as compared with patients treated with 5×5 Gy or CRT (p<0.001), 
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<65 years 65 48.5 68 48.2
65-74 years 45 33.6 42 29.8
≥75 years 24 17.9 31 22.0
Gender 0.35
Male 90 67.2 102 72.3
Female 44 32.8 39 27.7
clinical t-stage
cT3 134 100.0 141 100.0
clinical n-stage 0.04
Negative 65 48.5 90 63.8
Positive 66 49.3 49 34.8
Unknown 3 2.2 2 1.4
Year of surgery 0.33
2005 22 16.4 25 17.7
2006 16 12.0 28 19.9
2007 29 21.6 23 16.3
2008 28 20.9 20 14.2
2009 24 17.9 29 20.6
2010 15 11.2 16 11.3
total 134 48.7 141 51.3







ypT0 15 11.2 45 31.9
1 4 3.0 13 9.2
2 37 27.6 42 29.8
3 72 53.7 39 27.7
4 2 1.5 2 1.4
Unknown 4 3.0 0 0.0
Pathological n-stage 0.11
0 83 61.9 103 73.1
1 36 26.9 24 17.0
2 15 11.2 14 9.9
total 134 48.7 141 51.3
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with a higher percentage of pathological complete responses (ypT0) (11.2% in patients 
treated with 5×5 Gy or CRT, as compared with 31.9% in patients treated with HDREBT) and 
fewer pathological T3-stage (53.7% patients treated with 5×5 Gy or CRT, 27.7% patients 
treated with HDREBT). The pN-stage on the other hand, did not differ significantly between 
both countries (p=0.11), although patients treated with HDREBT seemed to have slightly more 
pathological positive lymph nodes (73.1%, compared with 61.9% in patients treated with 
5×5 Gy or CRT).
Figure 1 shows the five year overall survival for the countries. Comparing the five year overall 
survival between patients treated with 5×5 Gy or CRT and patients treated with HDREBT 
unadjusted for baseline imbalances showed a HR of 0.56 (95% CI 0.27-1.16, p=0.12). After 
adjustment for potential confounders, patients treated with HDREBT had a significant better 
five year overall survival (HR 0.39, 95% CI 0.16-0.93, p=0.03). When comparing five year 
cancer-specific mortality between the countries, 6/134 patients treated with 5×5 Gy or CRT 
died due to the rectal cancer, and 4/141 patients treated with HDREBT (HR 0.59, 95% CI 
0.16-2.08, p=0.41). Five-year local recurrence was 5/134 in the patients treated with 5×5 Gy 
or CRT and 2/141 in the patients treated with HDREBT (HR 0.54, 95% CI 0.13-2.28, p=0.41). 
When death was taken into account as competing risk, the SHR for five year cancer-specific 
mortality was 0.60 (95% CI 0.17-2.16, p=0.44), and the SHR for five year local recurrence was 











141 115 84 57 39 16Canada
134 101 74 49 26 12The Netherlands
Number at risk
0 1 2 3 4 5
Years since surgery
The Netherlands Canada
figure 1: Kaplan-Meier of overall survival (event = death due to all causes)
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There was no difference in five year overall survival between Dutch patients treated with 5×5 
Gy radiotherapy and Dutch patients treated with CRT after adjustment (HR 1.18, 95% CI 0.32-
4.35, p=0.80).
DiscussiOn
In this study, a comparison was made between the current standard preoperative therapy 
in the Netherlands (5×5 Gy or CRT) and a newer therapy used in Canada, HDREBT. Overall 
survival was better for patients treated with HDREBT. Cancer-specific mortality and local 
recurrence were comparable, although this comparison is based on few events, making the 
study underpowered to detect relevant differences. Overall, the results of this study suggest 
that HDREBT could be a safe alternative to CRT or 5×5 Gy in the treatment of patients with 
rectal cancer. 
Findings from the present study add important new observations, which to our knowledge, 
have not been previously investigated. The results show that overall survival was better for 
patients treated with HDREBT, as compared with patients treated with 5×5 Gy or CRT. Besides, 
only a few patients had a local recurrence or died due to rectal cancer in both countries. 
The results of this study should be interpreted with caution, since the data are observational 
and type of preoperative treatment has not been randomised. The study’s conclusions there-
fore rely on the assumption of no unmeasured confounding. We have tried to deal with the 
potential of confounding by design and by analysis. We used a design in which the level of 
comparison was between two countries. The comparison at country level emulates the prin-
ciples of an instrumental variable analysis18,19, which deals with (unmeasured) confounding 
because the instrument (in this case country) is at least partially unrelated to prognosis. In 
other words: we made the assumption that the cT3 patients treated in the Netherlands and in 
Canada where to a certain extent comparable. As a direct country comparison will not circum-
vent confounding completely, we also adjusted for important baseline differences between 
the countries. Moreover, differences in age, gender, cN-stage, and year of surgery were found 
when comparing the two countries at baseline. These variables were adjusted for in the 
analysis. Clinical N-stage was significantly different between patients treated with 5×5 Gy or 
CRT and HDREBT when compared preoperative (p=0.004), but after surgery, no significant dif-
ferences in N-stage between both countries were found. Differences in preoperative N-stage 
could be due to difference in staging by the radiologists as accuracy of positive lymph nodes 
identification in rectal cancer lacks.20,21 In addition, the differences preoperatively could be 
decreased or adjusted due to the type of preoperative treatment used within the country, 
since preoperative treatment involves radiation on lymph nodes. Even though, the type of 
preoperative treatment was based on the cT-stage and in lesser extent on cN-stage. 
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Unexpectedly, the overall survival between the countries was significantly better for patients 
treated with HDREBT. We hypothesize that HDREBT is associated with lower non-cancer related 
deaths in comparison with external beam radiotherapy. This is an important observation as the 
long term results from the Dutch trial suggested that despite the improved cancer-specific 
survival provided by radiation therapy, these benefits were nullified by an increase in other 
causes of death.22 One of the main causes was secondary cancer.22 Several other studies on 
prostate cancer have also shown that secondary malignancies are less common after HDREBT 
as compared to external beam radiation.23-26 Furthermore, in the current study no difference 
between both countries is present until 4 years since surgical treatment, which suggests that 
short term outcome does not differ between both treatment strategies, as also shown in a 
comparison between patients from Canada and Sweden.27 
An ypT0 stage has been achieved more often for patients treated with preoperative HDREBT as 
compared with the treatment strategy from the Netherlands. Since 5×5 Gy is often followed by 
immediate surgery and downstaging is not the aim of this short course of radiation, this could 
explain the differences in downstaging. CRT on the other hand is followed by surgery after at 
least 6 weeks, similar to HDREBT, which would expect the same percentage of downstaging. 
However, HDREBT does induce more downstaging as compared with CRT as the mean dose 
given to the tumour bed was 26 Gy in 4 days, which is a much higher radiobiological dose than 
45-50 Gy in 25-28 fractions.28-30 
HDREBT was introduced as an attempt to reduce radiation treatment-related toxicity. The initial 
results showed that all patients treated with preoperative HDREBT had an acute proctitis grade 
2, except one percent of patients who had an acute proctitis grade 3 and required a blood 
transfusion. None of the patients had to be hospitalized for treatment-related toxicity.10 A 
comparison between Sweden and HDREBT showed that the postoperative complications were 
similar between patients treated with HDREBT, 5×5 Gy and without preoperative treatment, 
except HDREBT had a higher rate of cardiovascular complications, but there was no increase 
in the postoperative deaths.27 This could possibly be explained by the higher Charlson 
comorbidity score in the Canadian population (data not shown).  Furthermore, a comparison 
of hormonal profile collected prospectively in 119 male patients with rectal cancer treated 
with either conventional CRT or HDREBT showed that HDREBT allows better hormonal spar-
ing, less hypogonadism.31 And finally, interim analyses of an on-going study show that both 
faecal incontinence and urinary incontinence are lower in patients treated with HDREBT in 
comparison with patients treated with external beam radiotherapy.32 All these studies suggest 
that treatment-related toxicity may indeed be reduced.
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cOnclusiOn
Overall, HDREBT seems to be a realistic alternative in the treatment of patients with rectal 
cancer, whereas postoperative complications, local recurrence rates and the rates of death 
due to rectal cancer were low in all countries. These findings could have profound clinical 
implications and strongly propose a randomized controlled trial in consideration of the pos-
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In 2008, colorectal cancer was the third most common cancer in men (663 000 cases) and 
the second in women (571 000 cases) worldwide. Nowadays, these numbers are even higher. 
Incidence rates vary 10-fold worldwide, the highest rates being estimated in developed 
countries, such as in the Netherlands. Differences between developed and less developed 
countries are probably due to an unfavourable pattern in lifestyle and an aging population in 
developed countries.1,2 The incidence of colorectal cancer increases with higher age, with the 
highest incidence between 70 and 79 years of age. In the coming years the population will 
age further and it is estimated that by 2020 26% of the Dutch population will be 65 years or 
older.3 Incidence rates are substantially higher in men than in women, although stabilising in 
men and still increasing in women in the past decade.4 The difference between the incidence 
in males and females is probably at least partly due to differences in lifestyle pattern. In the 
Netherlands, approximately 13,000 patients are diagnosed with colorectal cancer yearly, and 
five year survival is 58% for colon cancer patients and 59% for rectal cancer patients.5
Diagnostic assessment and staging
Colorectal cancer is a curable disease when detected and treated in time. To optimise the 
outcome of colorectal cancer patients, accurate diagnosis and staging are important. This 
provides an opportunity for screening, which is already advised in the US and the UK and is 
being implemented in many other European countries.6,7 In the end of 2009 the Dutch Health 
Council advised the government that mass screening in the Netherlands should be conducted 
using biannual immunochemical faecal occult blood test for men and women aged 55 to 75 
years.8 The introduction of the screening will be between 2013 and 2019. In patients with 
a positive test result at screening, optimal diagnostics (especially colonoscopy) will follow, 
and, if necessary, treatment. The aim of the screening is reduced colorectal cancer mortal-
ity by detecting cancers at an earlier stage. Screening will probably result in an increased 
workload for both gastroenterologists and pathologists, and possibly also surgeons, due to 
increased finding of adenomatous polyps. Besides, costs will increase due to the screening 
itself, as well as, the treatment of patients with a positive screening. Screening could, on the 
long term, result in decreased costs of colorectal cancer treatment, when tumours are found 
at an earlier stage. Therefore, fewer patients would be diagnosed with an advanced stage of 
disease, needing more extensive treatment. Overall, screening could improve outcome, but 
the effectiveness of screening remains under discussion, as is also the case in for example 
breast cancer and prostate cancer.9 In breast cancer and prostate cancer the incidences have 
increased due to the introduction of screening, and have not returned to prescreening levels. 
Besides, the relative fraction of early stage cancer has increased, while the incidence of more 
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advanced tumours has not decreased. Therefore, results of the introduction of screening 
should be analysed carefully in order to achieve optimal results.
Once the diagnosis is established, the extent of the primary tumour, regional lymph nodes, as 
well as distant metastases should be determined, also called staging, to provide a framework 
for discussing therapy and prognosis. Besides, uniform staging provides a common language 
with which doctors can communicate about a patient’s case, and to compare treatment 
strategies and outcomes.10 National clinical guidelines state that for diagnostic assessment 
of colorectal cancer all patients should undergo physical examination, colonoscopy for colon 
cancer and endoscopy for rectal cancer, and imaging procedures of the abdomen, liver, and 
thorax. Furthermore, all patients need to be discussed in a multidisciplinary meeting.11 Based 
on the results of diagnostic assessment, the stage is determined. There are different types of 
staging; clinical staging, based on the physical examination, imaging tests, and biopsies of 
affected areas, and pathological staging, which can only be done in patients who have had 
surgery to remove the tumour. In pathological staging, both the information of clinical staging 
and the surgery are combined. Finally, since nowadays colorectal cancer patients more often 
are treated with neoadjuvant treatment, restaging is become more common and is used to 
determine the extent of the disease after neoadjuvant treatment.
Currently, the Tumour, Nodes, and Metastasis (TNM) staging system is considered the most 
robust tool for prediction of prognosis and for decisions on the delivery of treatment. The 
objectives of the TNM system have been stated as: to aid in the planning of treatment; to 
give some indication of prognosis; to assist in assessing the effects of treatment; to help with 
the exchange of information between treatment centres; and to contribute to the continuing 
investigation of human cancers.12 Since the knowledge of cancer is continually expanding, the 
TNM system is revised every few years. Unfortunately, these revisions may cause problems, 
since modification of a component of the system could lead to the upstaging or downstaging 
of the disease, resulting in a change in treatment. Besides, changes in the TNM system can also 
lead to an inability to compare results from new trials with older trials, or even worse, when 
the changes occur during an ongoing trial.13 As a result of the variation in definition of tumour 
deposit between the TNM5, TNM6 and TNM7, and their reproducibility and use in special 
situations, such as after neoadjuvant treatment, the Netherlands decided to continue applying 
the TNM5.11,14 Additional information needed for optimal staging, such as the R-classification, 
has not been included in the newer TNM versions. On the other hand, an improvement of the 
TNM6 as compared to the TNM5 is the distinction between stage IIA and stage IIB colon cancer 
patients, since the patients with a T4 N0 M0 from stage IIB do indeed have worse prognosis 
than those classified as T3 N0 M0. These stage IIB patients, defined as high risk, are often 
treated with adjuvant chemotherapy. However, other patients with stage II are also defined 
as high risk, and should therefore receive adjuvant chemotherapy. These patients have 
extramural vascular invasion or extensive extramural spread, inadequately sampled nodes 
(less than 10), perforation, and/or poorly differentiated histology.15 These details cannot be 
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identified by the TNM-system or are compromised. In addition, it is recommended to describe 
which TMN version is used and whether there are tumour deposits present, and describe their 
characteristics.11 Furthermore, additional details such as needed to confirm high risk, should 
be described. Perhaps in the future, a different staging system could be developed including 
possible gene mutations, which could lead to more individually based treatment and progno-
sis. On the other hand, the desire is to keep the staging system simple. 
Treatment of colon cancer
Surgical resection is the cornerstone of curative treatment for colon cancer. The resection 
rates remain high among all colon cancer patients, due to the fact that resection is the only 
possible curative option in the treatment of colon cancer.16 Unfortunately, resection alone 
will not cure all patients. Both high risk stage II patients and stage III patients should receive 
adjuvant chemotherapy according to the guidelines to improve their outcome.11 In the current 
thesis, it is demonstrated that the use of adjuvant chemotherapy for stage III has increased 
during the past two decades, which is in line with most other European countries.17,18 Elderly 
patients with stage III colon cancer receive adjuvant chemotherapy less often. There are several 
reasons why elderly patients are less likely to receive adjuvant chemotherapy, as described 
in this thesis; they include the presence of comorbidities, frailty, the absence of supportive 
caregivers, and a decrease in patients’ general condition and cognitive ability.19,20 In addition, 
elderly patients seem to be less willing to accept the negative side-effects of chemotherapy, 
resulting in more frequent patient refusal.21 In general, medical oncologist agree with the 
recommendations in the national guidelines for adjuvant chemotherapy for the relatively 
young and healthy patients with stage III colon cancer, but their opinion differs widely on 
recommendations for patients who are older and sicker.22 Consequently, the likelihood of the 
older patients to receive adjuvant chemotherapy depends on the attitude and opinion of the 
medical oncologist treating the patient. However, fit elderly colon cancer patients may benefit 
equally from adjuvant chemotherapy without increased toxicity.23,24 
Over time, the optimal combination of chemotherapy has been extended. Moertel et al. were 
the first to show a decrease in recurrences and improved survival with the use of fluorouracil 
and levamisole in stage III colon cancer patients.25 Afterwards, several studies have shown that 
levamisole can be replaced by folinic acid, whereas low dose folinic acid is as effective as high 
dose. Besides, it was shown that adjuvant chemotherapy for half a year achieves similar results 
in terms of relapse and improvement of survival as chemotherapy for one year.26,27 In 2004 
the MOSAIC-trial was published, which randomised between fluorouracil and folinic acid with 
or without oxaliplatin. The addition of oxaliplatin showed a significant improve in disease-free 
survival and overall survival for stage III colon cancer patients.28 Recently, subgroup analyses 
of two studies have shown that the elderly patients are less likely to benefit from the addi-
tion of oxaliplatin.29,30 Furthermore, a meta-analysis of recent trials showed no difference 
between oral or intravenous fluorouracil, and one trial included in the meta-analysis showed 
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a trend towards an advantage in disease-free survival for oral fluorouracil (capecitabine).31 
Therefore, elderly patients more often receive fluorouracil in combination with folinic acid, or 
capecitabine as monotherapy17,20, which is in line with the advice of the Dutch guidelines.11 
In general, five year survival has improved for all colon cancer patients over time.32 For stage 
III colon cancer patients the five year relative survival improved approximately 7% in the past 
18 years, which is thought to be at least in part attributable to the increased use of adjuvant 
chemotherapy.17 Besides adjuvant chemotherapy, also stage-migration and improved peri-
operative care, defined as care before, during, and the first days after surgery, have possibly 
attributed to this improvement in survival. In an attempt to further improve outcome of these 
patients, treatment can be individualized. To prevent both overtreatment and undertreatment 
of certain subgroups, which includes elderly colon cancer patients and patients with comor-
bidities, a geriatric assessment might be helpful in decision making. Overall, the selection of 
patients receiving adjuvant chemotherapy should be objectified in prospective studies and 
discussed. Furthermore, to compare the outcome of patients treated with and without adju-
vant chemotherapy, recurrence and quality of life should be important outcomes. Survival will 
be less informative, since the patients not treated with adjuvant chemotherapy are expected 
to have inferior survival due to the decreased fitness of them in comparison with patients who 
do receive adjuvant chemotherapy.
Treatment of rectal cancer
There are four major goals to achieve in the treatment of patients with rectal cancer; local con-
trol, long term survival, preservation of the anal sphincter, bladder and sexual function, and 
optimal quality of life.33 Treatment of rectal cancer has been subject of research for the past 
two decades. The Dutch TME-study from 1996 to 1999 was the first study to achieve quality 
control on radiotherapy, surgery, and pathology.34 With the change in pathology approach, 
the extent of the disease in each patient became clearer. Besides, this trial had quality control 
on surgical procedure, implementing a new surgical technique, the total mesorectal excision 
(TME). The goal of this surgical technique is to remove the rectum along with its blood ves-
sels and surrounding lymph nodes within an intact visceral fascial that envelopes around 
the mesorectal fat and thereby obtaining a negative circumferential resection margin which 
is associated with improved local control.35 Another improvement of the TME technique as 
compared to the traditional blunt dissection is that the autonomic nerves can be preserved, 
and therefore urinary and sexual function as well. However, surgery alone still resulted in 
unacceptable rates of locoregional recurrences. The Dutch TME-trial reported reduced local 
recurrences by implementing short course preoperative radiotherapy. The ten year follow-up 
of the Dutch TME trial, showed indeed a decrease in local recurrence for patients treated with 
preoperative radiotherapy followed by TME-surgery (5%), as compared to patients treated 
with only TME-surgery (11%, p<0.001).34 Even though, the overall survival did not differ 
between both groups. The interval between preoperative radiotherapy and surgery, however, 
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remains a subject of research. As also described in this thesis, patients during the TME-trial 
aged 75 years or older who had an interval of 4-7 days had a significant worse overall and 
non-cancer-related survival as compared to patients in the same age group with an interval 
of 0-3 days.36-38 Furthermore, a current trial is investigating whether an interval of more than 
four weeks could induce downstaging, without worse survival. The interim analyses of this 
trial show that the compliance was acceptable and severe acute toxicity was uncommon.38 
There are several indications in the literature that the increased postoperative mortality after 
a longer interval between radiotherapy and surgery could be caused by an impaired immune 
response, possibly reflected in the perioperative leucocyte count of the patient.39,40
In case of suspected mesorectal fascia involvement, short course radiotherapy followed by 
immediate surgery is not a good option. Hypofractioned preoperative radiotherapy followed 
by immediate surgery has not shown to lead to downstaging of the tumour.41 Therefore, 
radical resection cannot be achieved in those patients. Long course, or hyperfractionated, 
radiation followed by delayed surgery after 4-12 weeks reduces tumour size, which increased 
the change of a complete resection. Several phase II studies have shown that the addition of 
chemotherapy to long course radiotherapy results in downsizing and downstaging.42-45 The 
Dutch guidelines advise the use of long course radiotherapy in combination with fluorouracil 
based chemotherapy, also called chemoradiation, for patients with suspected mesorectal 
fascia involvement, and therefore a possible positive circumferential resection margin (CRM), 
or in case the patient has four or more lymph nodes which are suspected to be tumour 
positive.11 The addition of oxaliplatin might be associated with even a higher pathological 
complete response rate46,47, but is associated with more acute toxicity.48 Overall, neoadju-
vant short course radiotherapy alone followed by direct surgery compared to neoadjuvant 
chemoradiation followed by delayed surgery enhances pathological response and thereby 
improves radical resections in stage II and III rectal cancer. Survival, both disease-free survival 
and overall survival, was comparable between both treatment groups.49 Besides, the effects 
of neoadjuvant chemoradiation on functional outcome and quality of life are not completely 
clear. For that reason, future trials should be addressed on that topic. Throughout Europe, 
several countries prefer chemoradiation over short course radiotherapy as neoadjuvant treat-
ment even when mesorectal fascia involvement is not suspected. The differences of the use of 
neoadjuvant treated among rectal cancer patients from five European countries was striking, 
as described in this thesis.
Current Dutch guidelines advice neoadjuvant short course radiotherapy for all rectal cancer 
patients, with the exception of T1 N0 and small tumours located high in the rectum. The use of 
neoadjuvant chemoradiation is advised for patients with suspected mesorectal fascia involve-
ment. Since toxicity is common after neoadjuvant chemoradiation for rectal cancer patients 
with a high risk for recurrence, a new study, the RAPIDO trial, is aiming to decrease the toxicity 
and improve survival with an experimental treatment. In this study the intervention arm will 
be short term radiotherapy (5 days), followed by six cycles of chemotherapy, to decrease the 
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size of the rectal tumour and to treat possible (micro)metastases. The smaller tumour will then 
be removed by surgery. The intervention arm will be compared with standard of care. The clini-
cians can optionally give adjuvant chemotherapy. Since the beginning of 2013 the accrual of 
this study is ongoing, with an aim of 850 patients to participate in the study. The datacenter at 
Leiden University Medical Center is the organising center. Besides centers in the Netherlands, 
also centers from Norway, Sweden, Slovenia, and Spain are participating.50 
In another attempt to reduce treatment-related toxicity from short course radiotherapy, high 
dose rate endorectal brachytherapy (HDREBT) has been explored as a neoadjuvant treatment 
in patients with resectable rectal cancer.51-55 A study of Vuong et al. has shown that the five 
year local recurrence rate was 5% and toxicity patterns seemed to be favourable as compared 
to external beam radiotherapy (only grade 2 and in one percent of the patients grade 3 proc-
titis).53 In this thesis, a comparison of the long term results between cT3 rectal cancer patients 
from the Netherlands treated with short course radiotherapy or chemoradiation, compared 
with cT3 rectal cancer patients from Canada treated with high dose rate endorectal brachy-
therapy has been described. No significant differences in local recurrence and cancer-specific 
mortality were observed. However, superior overall survival was observed in patients from 
Canada possibly due to a decrease in treatment related toxicities. Overall, HDREBT seems to 
be a realistic alternative in the treatment of rectal cancer patients, and the results are a strong 
rationale for a randomised controlled trial. 
Another relatively new approach to treat locally advanced rectal cancer is to apply intraopera-
tive radiotherapy boost to a specific area. This treatment allows the deliverance of a radia-
tion boost, biologically comparable to an additional 30–40 Gy fractionated irradiation, to a 
well-defined volume under direct vision, with a possibility to shield or remove dose-sensitive 
structures. However, the equipment needed is expensive and the logistics are complex. The 
results of a pooled analyses show that the outcome of these patients is promising.56
Even though colon and rectal cancer are treated as different entities, they are comparable in 
some aspects, as they appear similar macroscopically. Besides, metastatic colorectal cancer 
shows similar response to chemotherapy both for colon and rectal cancer. Adjuvant chemo-
therapy is standard of care for stage III colon cancer. Adjuvant chemotherapy for rectal cancer 
is still subject of research. Although it is assumed that the effects of postoperative adjuvant 
chemotherapy are similar in rectal cancer to the results achieved in colon cancer, there is little 
evidence to support this. Recently, a Cochrane review has indicated that the evidence supports 
adjuvant chemotherapy for rectal cancer patients treated without neoadjuvant radiotherapy 
or chemoradiation.57 For rectal cancer patients treated with neoadjuvant treatment sufficient 
evidence is lacking. There have been some trials on this subject, but the results have not been 
published yet. The results of three individual trials are expected to be published in 2013 and 
2014. An individual patient meta-analysis will be performed with the patients from a Dutch 




Despite potentially curative surgery and the use of (neo)adjuvant chemotherapy and/or radia-
tion therapy, more than 40% of patients who present with stage II or III disease will have a 
disease recurrence following primary therapy.58 The aim of follow-up after primary treatment 
is to diagnose local and distant recurrences, and second primaries when the patient is still 
asymptomatic and potentially eligible for curative treatment. There is considerable variability 
among physicians in the use of follow-up studies after potentially curative resection of CRC59-
63 and in the guidelines from major societies.64-69 Multiple surveillance strategies have been 
published at costs ranging from a few hundred to several thousand dollars per patient.70,71 
A survival benefit from such an approach has in fact been shown in three separate meta-
analyses.72-74 However, several comments can be made on those studies; first, the selection of 
patients are not consistent, and second, the standard treatment arm of these studies had more 
intensive follow-up as compared to our current guidelines. Overall, the optimal frequency 
and duration of surveillance is difficult to determine due to the heterogeneity of programmes 
assessed in the studies. 
Elderly patients often have several comorbid conditions at time of colorectal cancer diagno-
ses. The presence of these concomitant diseases have an impact on both crude and relative 
survival, which is not purely due to differences in the treatment of these patients.16 Because of 
this, there is discussion about the follow-up of elderly colorectal cancer patients. Whereas in 
young patients they might die of the recurrence of disease, elderly patients and patients with 
comorbidities perhaps need less intense or no follow-up since they might probably not die 
of the recurrence. In Denmark patients over 75 years of age rarely are followed after surgery. 
Old age and comorbidities
The fastest growing part of the population in Western countries are people aged 65 years 
or older, and the highest incidence of colorectal cancer is among those between 70 and 80 
years old. In recent years the focus on elderly colorectal cancer patients has increased. It is 
important to realise that the elderly population forms a very heterogeneous group of patients. 
Not only can chronological age be very different from biological age, but also the definition 
of elderly varies widely from ≥65 years to ≥80 years in different studies. Chronological age 
alone is therefore not the primary influence on outcome. The combination of comorbidities 
present and a decreased physical reserve to recover from adverse events that may occur, may 
rather determine the outcome of elderly patients.23,75 This is also referred to as biological age. 
Hence chronicle age itself should not be a contraindication for more aggressive or adjuvant 
treatment. Comorbidities, on the other hand, are of critical importance in the care of a patient. 
The presence of comorbidity effects treatment decisions22,76-78, and the prognosis79-83. As the 
prevalence of comorbid conditions is increasing among colorectal cancer patients, individu-
alised care becomes more important. In order to accomplish improved personalised medicine, 
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more knowledge about and attention to the role of comorbidity in colorectal cancer in both 
research and care is needed.81,84
Besides age-related treatment differences, several studies have shown age-related differences 
in relative survival as well. In this thesis it was reported that although the survival of elderly 
colon cancer patients (75 years and older) has improved over the time period of 1990 to 2005, 
the survival-gap as compared to midde-aged patients(younger than 65 years) remains. There 
might be two explanations for the differences in relative survival among aged and elderly 
patients. First of all, elderly might still be undertreated, resulting in worse survival. This can 
probably not be completely prevented, since frailty and comorbidities could impede the use 
of chemotherapy, radiotherapy or a combination of both. Secondly, elderly patients have a 
higher risk of excess mortality. In this thesis, we show that the differences in survival are most 
apparent in the first postoperative year, probably due to a prolonged impact of the insult of 
surgery in elderly patients.85
In order to improve the survival of elderly colorectal cancer patients, in the future there 
should be more focus on non-cancer related survival, such as treatment of comorbidities. In 
this way the balance in physiological recourses could be optimised. Due to the heterogeneity 
of elderly colorectal cancer patients, there is hardly any clinical trial data on elderly patients 
and evidence based treatment guidelines specifically for the elderly are currently lacking.86,87 
As elderly patients are characterized by a large variation in health status, recent developments 
should focuss on geriatric screening instruments to predict the tolerance to treatment88-90, 
followed by multidisciplinary treatment, focussing on the perioperative care of not only 
colorectal cancer itself, but also the comorbid conditions.
Quality assurance 
Quality control on surgery, radiotherapy, and pathology has been introduced in trials, followed 
by incorporation in the general care.91,92 Furthermore, there have been several improvements 
by introducing high volume clinics.93,94 As an alternative to volume based referral, hospitals 
and surgeons can also improve their results by learning from their own outcome statistics and 
those from colleagues treating a similar patient group. An audit is a quality instrument that 
collects detailed clinical data from different healthcare providers, which can be adjusted for 
baseline risk and subsequently fed back to individual hospitals or surgeons. In this way, ‘best 
practices’ can be identified, communicated, and broadly adopted. After case-mix adjustments, 
a fair judgement can be made on the quality of cancer treatments. Hospitals and surgeons can 
be faced with their own results compared to those of colleagues treating the same patient 
category. Another important advantage is the fact that audit registries include the entire 
patient population which makes it possible to perform research on patient groups that are 
usually excluded from clinical trials (such as elderly patients and patients with comorbidities). 
Although all these national and regional audit structures have achieved excellent results, dif-
ferences in outcome between European countries remain which cannot be easily explained. 
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A joined international network has been initiated to generate the best care for all cancer 
patients, founded as the European Registration of Cancer Care (EURECCA). EURECCA was initi-
ated in colorectal cancer, but has expended to Upper GI, breast, and hepatic, pancreatic, and 
biliary cancer. The initiative and the first results of a comparison between treatment strategies 
for rectal cancer are described in this thesis. Next, the selection of patients receiving adjuvant 
chemotherapy in colon stage II and rectal cancer will be compared across the countries. In the 
future EURECCA wants to expand to other cancer types, and the ultimate goal would be to 
achieve an European audit with feedback to the countries, hospitals, and clinicians about their 
results in comparison with other countries, after case-mix adjustment. 
cOnclusiOn AnD future PersPectives
For the past two decades both colon and rectal cancer have been a subject of research. This 
resulted in several diagnostic and treatment improvements for both colon and rectal can-
cer, which led to improved outcome. Even though, several further improvements are to be 
expected in the coming decades. First of all, screening will be initiated in the Netherlands, 
possibly leading to a detection of more early tumours, which might need a different approach. 
Secondly, elderly patients and patients with comorbidities, which will be a growing group of 
patients in the next ten years, will probably need different care since not all treatments will 
be tolerated and fewer side effects might be accepted. Furthermore, the past five to ten years 
have led to significant advances in the understanding of biological, molecular, genetics, and 
pathogenesis. Genetic based tumour markers will lead to further characterised cancer, and 
will be accompanied by tailored treatment. Already the genetic testing for KRAS, and several 
other similar RAS mutations, are being implemented clinically to determine which patients 
should undergo treatment with monoclonal antibodies against EGFR. In parallel with these 
advances in understanding colorectal cancer, DNA sequencing has increased exponentially. 
By examining tumours and identifying common genetic mutations and molecular pathway 
perturbations, cancer development will be better understood. This will allow the development 
of more accurate screening tests, diagnostic tests, and identification of new and specialised 
treatments. Overall, these advances will lead to more complex treatment strategies which 
need to be individualised based on patient- and tumour characteristics. 
Trials are important to answer specific research questions, but for individualised patient care 
trials will probably not provide the needed information. Large population based datasets 
can provide the needed information by identifying the optimal treatment strategy for certain 
subgroups. An audit is a quality instrument that collects detailed clinical data from different 
healthcare providers, which can be adjusted for baseline risk and subsequently fed back to 
individual hospitals or clinicians. The audit structure will include all patients. Audits have 
achieved excellent results on national level. A next step will be to combine these national 
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audits. The combined audit structure will provide a network in which ‘best practices’ can be 
compared and identified, including for certain subgroups. 
To achieve optimal care for all patients, multidisciplinary care is the only way. Current and 
future research will lead to advances in colorectal cancer screening, diagnosing, treatment, 
and outcome. By comparing multidisciplinary audit structures across countries, optimal treat-
ment strategies within subgroups can be identified. Furthermore, optimal communication 
between clinicians and between patient and clinician will be the optimal strategy to achieve 




In the Western World, colorectal cancer is a major health problem. The incidence is high and 
expected to grow even further in the upcoming years.5 Besides, the incidence increases with 
increasing age, which makes it a disease of the older patient. Together, it is anticipated that 
the number of elderly patients with colorectal cancer will grow during the coming years, 
while there are no specific clinical guidelines for the elderly. Evidence from population-based 
studies clearly demonstrates that older patients are more often inadequately staged, undergo 
fewer elective operations95 and are less likely to receive adjuvant chemotherapy and/
or radiotherapy than their younger counterparts96-100. Current guidelines are derived from 
(randomised) trials in which elderly patients or patients with severe comorbidity are excluded 
or underrepresented.100,101 
PArt i cOlOrectAl cAncer; treAtment AnD survivAl
Over the past two decades the treatment of colon cancer has changed substantially. Moertel 
et al25 have shown that adjuvant chemotherapy has a beneficial effect on survival. The guide-
lines in the Netherlands have changed in 1997 and adjuvant chemotherapy is now advised 
for all patients diagnosed with stage III colon cancer, regardless of the age of a patient. Since 
the adjustment of the guidelines, the use of adjuvant chemotherapy has increased. The aim of 
Chapter 2 was to describe the time trends in the use and costs of adjuvant chemotherapy. A 
total of 24,111 patients diagnosed with stage III colon cancer between 1990 and 2008 were 
included in this retrospective cohort study. Both the administration (from 9.5% in 1990 to 
61.8% in 2008) and the estimated medicine costs of chemotherapy (from € 38,467 in 1990 
to € 3,876,150 in 2008) increased during the study period. Elderly patients received less 
adjuvant chemotherapy as compared to younger patients. Multivariable analyses showed that 
the relative survival improved for all patients receiving adjuvant chemotherapy (RER 0.93; 
95% CI 0.92-0.94). In contrast, relative survival remained stable for patients, younger than 80 
years, who did not receive chemotherapy (RER 1.00; 95% CI 1.00-1.01). In patients aged 80 
years and older treated without chemotherapy, relative survival improved during the study 
period (RER 0.98; 95% CI 0.97-0.99). Concluding, the administration of chemotherapy, the 
costs of chemotherapy and the survival of patients with stage III colon cancer increased over 
time. Whereas the costs and administration of chemotherapy increased extensively, relative 
survival improved to a lesser extent. For patients treated with adjuvant chemotherapy relative 
survival improved equally in all age groups.  
Even though the Dutch guidelines advise to treat all stage III colon cancer patients with 
adjuvant treatment, a large proportion of these patients are not treated adherent to this 
guideline. The percentage of patients not receiving adjuvant chemotherapy increases with 
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age. In Chapter 3 factors associated with not receiving adjuvant chemotherapy were studied 
as well as causes of death and recurrences of this population. A total of 348 consecutive 
stage III colon cancer patients diagnosed between 2000 and 2009 from two hospitals in the 
mid-western region of the Netherlands were included. Most patients were between 70 and 79 
years of age (35.6%) and slightly more women were included (51.4%). Just over half of the 
patients received adjuvant chemotherapy (50.6%). After adjustment for several confound-
ers, elderly patients and patients with one or more comorbidities were less likely to receive 
adjuvant chemotherapy. Patients who did not receive adjuvant chemotherapy died earlier, 
and more often due to other causes than the primary tumour. Adjuvant chemotherapy is 
prescribed in order to prevent recurrence of disease. Patients need to be alive to develop a 
recurrence. Therefore a so-called competing risk analyses has been performed, with death as 
competing risk in order to develop a recurrence. Patients who did and who did not receive 
adjuvant chemotherapy had a comparable cumulative incidence of recurrence, when death 
was taken into account as a competing risk. This study showed that the selection of patients 
who are eligible for adjuvant chemotherapy is of great importance in order to decrease recur-
rences. Further research should focus on objectifying the selection of the patients treated 
with and without adjuvant chemotherapy. Besides, decreasing recurrences in both patients 
treated with and without adjuvant chemotherapy, and optimising the quality of life of these 
patients should be a focus of further research. 
Recently, the EUROCARE working group has shown that the survival of colon cancer patients 
has improved between 1988 and 1999. When they compared the five year relative survival 
between elderly (70-85 years) and middle-aged patients (55-69 years), survival improved 
in both age groups, although in lesser extent in the elderly, resulting in a survival gap.102 
Chapter 4 aimed to describe treatment and compare survival rates over time (1991-2005) 
between middle-aged (<65 years), aged (65-74 years), and elderly (≥75 years) colon cancer 
patients in the mid-western region of the Netherlands, to assess whether the survival gap has 
increased over time. A total of 8926 patients with invasive colon cancer were included in the 
present study. Over time no treatment changes occurred for stage I and II, while the use of 
chemotherapy increased for stage III and IV. Surgical procedures were less often performed 
for stage IV over time. Survival differences between middle-aged and elderly patients were 
present and the survival gap from the EUROCARE was thereby confirmed. Nevertheless, the 
differences between both age groups remained stable over time, which means that the gap 
between middle-aged and elderly patients did not increase. 
The survival of elderly colon cancer patients is worse as compared to younger patients. Similar 
results have been found for elderly rectal cancer patients. Chapter 5 included all stage I-III 
colorectal cancer patients diagnosed between 1991 and 2005 in the mid-western region of 
the Netherlands (n=9397). As expected, both overall and relative survival of elderly patients 
(aged 75 years or older), was worse as compared to patients younger than 65 years. These 
‘age related’ differences disappeared in conditional relative survival, under the condition 
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that the patients should have survived the first postoperative year. Only in stage III disease, 
elderly patients had a worse conditional relative survival than young patients, probably due to 
differences in the use of adjuvant treatment. In conclusion, elderly colorectal cancer patients 
that survive the first year, have the same cancer related survival as younger patients. So, 
decreased survival in the elderly is mainly due to differences in early mortality. Treatment of 
elderly colorectal cancer patients should therefore focus on perioperative care and the first 
postoperative year.
As in colon cancer, the treatment of rectal cancer has changed substantially in the past two 
decades. Surgical resection has been improved by Phil Quirke and Bill Heald in 1986.35,103 
Between 1987 and 1990, the Swedish rectal cancer trail has shown that preoperative short 
course radiotherapy decreases recurrence rates (27% in surgery only compared with 11% for 
patients treated with preoperative radiotherapy followed by immediate surgery).104 The Dutch 
TME trial showed that with standardised total mesorectal excision (TME) surgery, preoperative 
radiotherapy still improves local control.34 Since the introduction of preoperative radiotherapy, 
the interval between short course radiotherapy has been discussed as this could result in 
differences in outcome. Chapter 6 addresses the impact of the interval between preopera-
tive short course radiotherapy and surgery on outcome of rectal cancer patients in two time 
periods, during the TME trial and a more recent verification set. A total of 642 patients from 
the TME trial were included, and 600 patients from the verification set from two radiotherapy 
clinics in the Netherlands. During the TME trial, patients aged 75 years and older had a worse 
overall and non-cancer-related survival when surgically treated 4 to 7 days after the last frac-
tion of radiotherapy. No differences in survival between the interval groups were found in the 
verification set. Several trials have found similar results.40,105 The results in the verification 
set may be different due to awareness of the clinicians, who avoided delayed surgery after 
radiotherapy since the results have been presented during congresses. Therefore, a longer 
than recommended interval between radiotherapy and surgery should be avoided.
PArt ii internAtiOnAl cOmPArisOns in cOlOrectAl cAncer 
treAtment AnD survivAl
Randomised controlled trials, systematic reviews, and meta-analyses are seen as the highest 
level of evidence. Unfortunately, randomised controlled trials are costly, time consuming, sub-
groups may be underrepresented in trials, and certain research questions remain unanswered 
by randomised clinical trials. Another option to identify optimal treatment is comparing 
treatment strategies. When all factors except the treatment strategy are comparable between 
regions or countries, the region or country can be seen as a pseudo randomisation, and the 
prognosis of different treatment strategies can then be compared. Overall, trials are important 
to answer specific research questions, but for individualised patient care trials might not 
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provide the needed information. In that case, large population based datasets can provide 
information about the optimal treatment of subgroups, such as elderly and patients with 
comorbidities. Audits might provide the detailed clinical information to compare treatment 
strategies and the results can be fed back to hospitals and clinicians, who can thereby further 
improve their outcome. 
Major improvements have been achieved with national audits.106-108 However, although all 
the national audits achieved excellent results, differences in treatment and outcome remain 
between European countries.109 To reduce the differences between the countries by identify-
ing and spreading ‘best practice’, an international, multidisciplinary, outcome-based quality 
improvement program has been initiated: European Registration of Cancer Care (EURECCA).110 
The EURECCA project makes use of existing national audit registrations and started with 
colorectal cancer, but also other solid tumour types, such as breast cancer, gastric cancer, 
oesophageal cancer, and hepato bilary (HPB) cancer and pancreatic cancer, have recently 
been initiated. Chapter 7 describes the ‘core dataset’ of EURECCA colorectal. A total of 45 
shared data items are identified.  Among the 45 shared data items were patients’ data, data 
about preoperative staging, surgical treatment, preoperative and postoperative treatment, 
and follow-up. The first EURECCA analyses are described in Chapter 8. The aim of this study 
was to compare the use of preoperative treatment for rectal cancer patients between Norway, 
Sweden, Denmark, Belgium and the Netherlands. Several studies have shown differences in 
colorectal cancer survival, but most of these studies lacked of details about stage and treat-
ment. All rectal cancer patients without distant metastases and operated on with a rectal 
resection from Norway, Sweden, Denmark, Belgium, and the Netherlands were included 
(n=10,296). The use of preoperative radiotherapy and chemoradiation varied widely across 
the countries. The variation in one year relative survival did not very much. Sweden had a 
significant better one year relative survival after adjustment for age, gender, and stage as 
compared to the Netherlands. When stratified for age group, only patients aged 75 years or 
older from Sweden had a better one year relative survival after adjustment. The differences 
in one year survival are expected to be caused above all by differences in perioperative care, 
selection of patients, and especially management of elderly patients, and not by differences in 
the use of preoperative treatment. Effects of preoperative treatment will probably be visible 
in long term survival, unfortunately, this is not available yet.
In Chapter 9 a new preoperative treatment for rectal cancer, high dose rate endorectal brachy-
therapy (HDREBT), used in a specialised clinic in Canada has been compared with standard 
of care in a specialised clinic in the Netherlands. In the Netherlands short course external 
beam radiotherapy and chemoradiation are standard of care. Short course external beam 
radiotherapy improved survival and decreased recurrences in rectal cancer, but improvements 
should be weighed against treatment related morbidity. High dose rate endorectal brachy-
therapy (HDREBT) is a targeted form of radiation therapy. Since the comparison of treatment 
would include biases such as confounding by indication and selection bias, this study has 
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compared treatment strategies from two specialised clinics. In total 141 patients from Canada 
treated with preoperative HDREBT, 26 Gy over 4 days, and 134 Dutch patients treated with 
either preoperative 5×5 Gy radiotherapy (n=52), or chemoradiation (n=82) were included, all 
diagnosed with a clinical T3 rectal carcinoma based on MRI-imaging. A statistically significant 
difference in five year overall survival was observed, with patients treated with HDREBT hav-
ing better survival than patients from the Netherlands after adjustment (HR 0.42, 95% CI 
0.20-0.90). Again patients should be alive in order to develop a recurrence at five years or to 
die due to the rectal cancer. Therefore, competing risk analyses have been performed for five 
year local recurrence and cancer-specific mortality. With death as competing risk, there were 
no significant differences in five year local recurrence and five year cancer-specific survival 
between the treatment strategies. Concluding, HDREBT seems to be a realistic alternative in 
the treatment of rectal cancer patients. The difference in five year overall survival between 
both countries might be possibly due to treatment related toxicities. These findings could 
have profound clinical implications and strongly suggest a randomised controlled trial in 
which the treatments can be compared.
Due to the research performed in the past and the ongoing research, more and more sub-
groups are being identified with screening, increasing age of the patients and the presence of 
comorbidities among the patient, besides, research in the past ten years has led to significant 
advances in the understanding of biology, molecular background, genetics, and pathogenesis 
of colorectal cancer. In the future, patient care has to become more multidisciplinary. Every 
involved specialism should be included in the audit structures. By comparing multidisciplinary 
audit structures across countries, optimal treatment strategies for subgroups can be identi-
fied. Besides optimal treatment strategies, the opinion of the patient should be incorporated 
achieving optimal personalised medicine.
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summArY in Dutch (neDerlAnDse sAmenvAttinG)
In de westerse wereld is colorectaal carcinoom een belangrijk gezondheidsprobleem. De inci-
dentie is hoog en zal naar verwachting nog verder toenemen in de komende jaren.1 Daarnaast 
stijgt de incidentie met toenemende leeftijd, waardoor het voornamelijk een ziekte van de 
ouderen is. Samen leidt dit tot een verdere toename van het aantal oudere patiënten met 
colorectaal carcinoom in de komende jaren. Echter, leeftijdsspecifieke behandelrichtlijnen 
zijn niet beschikbaar. Bewijs uit ‘population-based’ onderzoek laat duidelijk zien dat oudere 
patiënten vaker inadequaat gestageerd worden2, minder vaak electieve operaties ondergaan 
en minder vaak pre- of postoperatief worden behandeld met chemotherapie of radiotherapie 
in vergelijking met jongere patiënten3-7. Huidige richtlijnen zijn gebaseerd op (gerandomis-
eerde) trials, oudere patiënten en patiënten met comorbiditeit worden vaak geëxcludeerd of 
ondervertegenwoordigd in trials.8 
Deel i cOlOrectAAl cArcinOOm; behAnDelinG en OverlevinG
Over de afgelopen 20 jaar is de behandeling van het coloncarcinoom aanzienlijk veranderd. 
Begin jaren 1990 hebben Moertel e.a.9 laten zien dat adjuvante chemotherapie een gunstig 
effect heeft op de overleving. De richtlijnen in Nederland zijn daarop in 1997 aangepast en 
adjuvante behandeling met chemotherapie wordt nu geadviseerd voor alle patiënten met 
stadium III coloncarcinoom, ongeacht de leeftijd van de patiënt. Het doel van Hoofdstuk 2 was 
het beschrijven van de tijd trends in het gebruik en de kosten van adjuvante chemotherapie. 
In totaal 24.111 patiënten met stadium III coloncarcinoom gediagnosticeerd tussen 1990 
en 2008 zijn geïncludeerd in deze retrospectieve cohort studie. Zowel de het gebruik (van 
9,5% in 1990, naar 61,8% in 2008), als de geschatte medicijnkosten van chemotherapie 
(van €38,467 in 1990, naar €3.876.150 in 2008), zijn toegenomen over de studieperiode. 
Met toenemende leeftijd werd er minder chemotherapie gebruikt. Multivariabele analyses 
van de relatieve overleving lieten een verbetering zien voor alle patiënten behandeld met 
adjuvante chemotherapie (RER 0,93; 95% CI 0,92-0,94). Voor patiënten jonger dan 80 jaar 
die geen adjuvante chemotherapie kregen, daarentegen, bleef de relatieve overleving stabiel 
(RER 1,00; 95% CI 1,00-1,01). De relatieve overleving van patiënten ouder dan 80 jaar zonder 
adjuvante chemotherapie behandeld is toegenomen over de studieperiode (RER 0,98; 95% 
CI 0,97-0,99). Concluderend; het gebruik van adjuvante chemotherapie, de kosten van chemo-
therapie en de overleving van de patiënten met stadium III coloncarcinoom zijn over de tijd 
toegenomen. Waar het gebruik en de kosten van chemotherapie aanzienlijk zijn toegenomen, 
is de relatieve overleving in mindere mate verbeterd. Patiënten behandeld met adjuvante che-
motherapie hadden een gelijkmatige verbetering van de overleving in alle leeftijdsgroepen. 
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Ondanks dat de Nederlandse richtlijnen adviseren om alle patiënten met stadium III 
coloncarcinoom met adjuvante chemotherapie te behandelen, krijgt een groot deel van de 
patiënten geen aanvullende behandeling met chemotherapie. Het percentage patiënten wat 
niet behandeld wordt met adjuvante chemotherapie neemt toe met toenemende leeftijd. In 
Hoofdstuk 3 worden de factoren bestudeerd die geassocieerd zijn met het onthouden van 
adjuvante chemotherapie, daarnaast zijn ook de doodsoorzaken en de recidieven van deze 
populatie bestudeerd. In totaal 348 opeenvolgende patiënten met stadium III coloncarcinoom 
gediagnosticeerd tussen 2000 en 2009 van twee ziekenhuis in de mid-westerse regio van 
Nederland werden geïncludeerd. De meeste patiënten waren tussen 70 en 79 jaar oud 
(35,6%) en iets meer vrouwelijke patiënten werden geïncludeerd (51,4%). Net iets meer dan 
de helft van de patiënten hebben adjuvante chemotherapie gehad (50,6%). Oudere patiënten 
en patiënten met één of meer comorbiditeiten werden minder met adjuvante chemotherapie 
behandeld. Dit effect bleef zichtbaar na correctie voor mogelijke confounders. Patiënten die 
niet behandeld werden met adjuvante chemotherapie stierven vaker eerder, en meer als 
gevolg van complicaties en hartfalen. Adjuvante chemotherapie is een behandeling voor het 
voorkomen van recidieven na een in opzet curatieve operatie. Om een recidief te krijgen, moet 
een patiënt in leven zijn. Daarom is een zogenaamde ‘competing risk’ analyse uitgevoerd, 
waarbij dood een ‘competing risk’, ofwel concurrerend risico, is. Patiënten die geen adjuvante 
chemotherapie ontvingen hadden een vergelijkbare cumulatieve incidentie voor het krijgen 
van een recidief, wanneer dood als een concurrerend risico werd meegenomen. Deze studie 
toont aan dat de selectie van patiënten die geschikt zijn voor adjuvante chemotherapie van 
groot belang is om zo recidieven te voorkomen. Verder onderzoek zou zich moeten richten op 
het objectiveren van de selectie van de patiënten die wel en niet met adjuvante chemothera-
pie behandeld worden. Daarnaast moet het verminderen van recidieven in zowel patiënten 
die wel en niet behandeld zijn met adjuvante chemotherapie, en het optimaliseren van de 
kwaliteit van leven van deze patiënten een focus van verder onderzoek zijn.
Recentelijk heeft de EUROCARE working group laten zien dat de overleving van patiënten  met 
coloncarcinoom verbeterd is tussen 1988 en 1990. Echter, wanneer zij de relatieve vijf jaar 
overleving vergeleken tussen oudere patiënten (70 tot 85 jaar) en patiënten van middelbare 
leeftijd (55 tot 69 jaar), bleek dat de overleving van beide leeftijdsgroepen was verbeterd 
over de tijd, maar in mindere mate bij de oudere patiënten, waardoor een overlevingskloof 
is ontstaan.10 Hoofdstuk 4 had als doel om de behandeling en overleving over de tijd (1991-
2005) te beschrijven tussen jongere (<65 jaar), middelbare (65 tot 74 jaar), en oudere (≥75 
jaar) patiënten met coloncarcinoom in de mid-westerse regio van Nederland, om zo te bep-
alen of de overlevingskloof is toegenomen over de tijd. In totaal 8.926 patiënten met invasief 
coloncarcinoom zijn geïncludeerd in deze studie. Over de tijd vonden geen veranderingen in 
de behandeling van stadium I en II coloncarcinoom plaats, terwijl er een toename was in het 
gebruik van adjuvante chemotherapie voor stadium III en IV. Stadium IV patiënten werden 
over de tijd minder vaak geopereerd. Verschillen in de overleving tussen jongere en oudere 
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patiënten was aanwezig en daarmee was de overlevingskloof van de EUROCARE bevestigd. 
Desondanks, de verschillen tussen de leeftijdsgroepen bleven stabiel over de tijd, wat betek-
ent dat de kloof tussen jongere en oudere patiënten met coloncarcinoom niet is toegenomen.
De overleving van oudere patiënten met coloncarcinoom is slechter in vergelijking met jon-
gere patiënten. Vergelijkbare verschillen zijn gevonden bij oudere patiënten met rectumcar-
cinoom. Hoofdstuk 5 heeft alle stadium I-III colorectaal carcinoom patiënten gediagnosticeerd 
tussen 1991 en 2005 in de mid-westerse regio van Nederland geïncludeerd (n=9.397). Zoals 
verwacht, was zowel de overall als de relatieve overleving van oudere patiënten (75 jaar en 
of ouder) slechter in vergelijking met patiënten jonger dan 65 jaar. Deze leeftijd gerelateerde 
verschillen verdwenen bij conditionele relatieve survival, onder de conditie dat de patiënten 
het eerste jaar na de operatie overleefd moeten hebben. Alleen bij stadium III hadden oudere 
patiënten een slechtere conditionele relatieve survival, waarschijnlijk door de verschillen 
in het gebruik van adjuvante behandeling. Concluderend hebben oudere patiënten die 
het eerste postoperatieve jaar overleven een vergelijkbaar kanker-gerelateerde overleving 
als jongere patiënten. De lagere overleving van oudere patiënten is dus voornamelijk door 
verschillen in vroege mortaliteit. De behandeling van oudere colorectaal carcinoom patiënten 
moet zich daarom focussen op de perioperatieve zorg en het eerste postoperatieve jaar.
Net als voor het coloncarcinoom is de behandeling van het rectumcarcinoom aanzienlijk 
veranderd in de afgelopen 20 jaar. De chirurgische verwijdering is verbeterd mede door Phil 
Quirke en Bill Heald in 1986.11,12 De Zweedse rectumcarcinoom trial liet tussen 1987 en 1990 
zien dat preoperatieve radiotherapie een afname geeft van het aantal lokaal recidieven (27% 
in de groep alleen behandeld met chirurgie, vergeleken met 11% in de groep behandeld met 
preoperatieve radiotherapie direct gevolgd door chirurgie).13 De Nederlandse TME trial liet 
zien dat met gestandaardiseerde totale mesorectale excisie (TME) chirurgie, preoperatieve 
radiotherapie nog altijd lokale controle verbeterd.14 Sinds de introductie van kortdurende 
preoperatieve radiotherapie, wordt het interval tussen de radiotherapie en de chirurgie 
bediscussieerd, aangezien het interval mogelijk invloed zou kunnen hebben op de uitkom-
sten. Hoofdstuk 6 beschrijft de impact van het interval tussen kortdurende preoperatieve 
radiotherapie en chirurgie op de uitkomst van rectumcarcinoom patiënten gedurende twee 
tijdsperiodes, tijdens de TME trial en tijdens een meer recente verificatie set. In totaal waren 
642 patiënten van de TME trial geïncludeerd, en 600 patiënten van de verificatie set uit twee 
radiotherapeutische centra in Nederland waren geïncludeerd. Gedurende de TME trial hadden 
patiënten van 75 jaar en ouder een slechtere overall en niet-kanker-gerelateerde overlev-
ing wanneer ze 4 tot 7 dagen na de laatste fractie radiotherapie geopereerd werden. In de 
verificatie set werden geen verschillen in overleving tussen de verschillende interval-groepen 
gevonden. De resultaten in de verificatie set kunnen beïnvloed zijn door besef van de clinici 
aangezien de resultaten van de TME trial op verschillende congressen gepresenteerd zijn, 
waardoor vertraagde chirurgie na radiotherapie wellicht vermijd werd. Daarnaast hebben 
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verschillende andere trials vergelijkbare resultaten gevonden.15,16 Alles bij elkaar zou een 
langer dan geadviseerd interval tussen radiotherapie en chirurgie vermeden moeten worden.
Deel ii internAtiOnAle verGeliJkinGen vAn De behAnDelinG en 
OverlevinG vAn cOlOrectAAl cArcinOOm
Gerandomiseerde gecontroleerde trials, systematische reviews, en meta-analyses worden 
gezien als de hoogste ‘levels of evidence’. Helaas zijn gerandomiseerde gecontroleerde 
trials kostbaar, tijdrovend, sommige subgroepen zijn vaak ondervertegenwoordigd in trials, 
en bepaalde onderzoeksvragen blijven onbeantwoord door gerandomiseerde trials. Een 
andere optie om optimale behandeling te identificeren is het vergelijken van behandel-
ingsstrategieën. Wanneer alle factoren behalve de behandelingsstrategie vergelijkbaar zijn 
tussen regio‘s of landen, kan de regio of het land gezien worden als een pseudorandomisatie, 
waardoor de uitkomsten van de verschillende behandelingsstrategieën met elkaar vergeleken 
kunnen worden. Concluderend, zijn trials belangrijk om specifieke onderzoeksvragen te 
beantwoorden, maar bij geïndividualiseerde patiënten zorg kunnen trials niet de benodigde 
informatie geven. In dat geval, kunnen grote ‘population-based’ datasets ons wel informeren 
over de optimale behandeling van bepaalde subgroepen, zoals oudere patiënten of patiënten 
met comorbiditeit. Audits kunnen gedetailleerde klinische informatie bieden om daarmee 
behandelingsstrategieën te vergelijken en de resultaten kunnen terug gekoppeld worden aan 
de ziekenhuizen en specialisten, die daardoor hun uitkomsten verder kunnen verbeteren.
Grote verbeteringen zijn behaald met behulp van nationale audits.17-19 Landelijk hebben 
audits dan wel uitstekende resultaten bereikt, verschillen in de behandelingen en uitkomsten 
tussen de verschillende Europese landen blijven bestaan.20 Om de verschillen tussen de 
landen te minimaliseren door middel van het identificeren en verspreiden van ‘best practice’ 
is een internationaal, multidisciplinair, uitkomstgebaseerd kwaliteitsverbeteringsprogramma 
geïnitieerd: EUropean REgistration of Cancer Care (EURECCA).21 Het EURECCA-project gebruikt 
bestaande nationale audit registraties en is begonnen met colorectaal carcinoom registraties, 
daarnaast zijn andere solide tumoren, zoals mammacarcinoom, maagcarcinoom en oesopha-
guscarcinoom geïnitieerd, maar in de toekomst zullen onder andere HPB (hepatobilliare) carci-
nomen en pancreascarcinomen, volgen. Hoofdstuk 7 beschrijft de ‘core dataset’ van EURECCA 
colorectaal. In totaal 45 gedeelde variabelen zijn geïdentificeerd. Onder deze 45 variabelen 
vallen data-items over patiëntkarakteristieken, preoperatieve stadiëring, chirurgische behan-
deling, preoperatieve en postoperatieve behandeling, en follow-up. De eerste EURECCA-
analyses zijn beschreven in Hoofdstuk 8. Het doel van deze studie was het vergelijken van 
het gebruik van preoperatieve behandeling tussen Noorwegen, Zweden, Denemarken, België, 
en Nederland voor patiënten met een rectumcarcinoom. Diverse studies hebben verschillen 
in de overleving van colorectaal carcinoom patiënten tussen landen laten zien, maar bij de 
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meeste van die studies ontbrak informatie over stadium en behandeling. Alle patiënten met 
een rectumcarcinoom zonder afstandsmetastasen en geopereerd aan de tumor door middel 
van een rectumresectie uit Noorwegen, Zweden, Denemarken, België, en Nederland werden 
geïncludeerd (n=10.296). Het gebruik van preoperatieve radiotherapie en chemoradiatie 
varieerde sterk tussen de landen. De éénjaars overleving varieerde in minder mate. Zweden 
had een significant betere overleving in vergelijking met Nederland na correctie voor leeftijd, 
geslacht, stadium. Gestratificeerd naar leeftijdsgroep, hadden alleen de patiënten van 75 jaar 
en ouder uit Zweden een betere éénjaars overleving na correctie. Naar verwachting worden de 
verschillen in éénjaars overleving veroorzaakt door verschillen in perioperatieve zorg, selectie 
van patiënten, en in het bijzonder de behandeling van oudere patiënten, en niet zozeer door 
verschillen in het gebruik van preoperatieve behandeling.
In Hoofdstuk 9 is een nieuwe preoperatieve behandeling voor het rectumcarcinoom, ‘high 
dose rate endorectal brachytherapy’ (HDREBT), gebruikt in een gespecialiseerde kliniek 
in Canada, vergeleken met de standaard behandeling in een gespecialiseerde kliniek in 
Nederland. In Nederland zijn kortdurende preoperatieve radiotherapie en chemoradiatie 
de standaard zorg. Kortdurende radiotherapie verbeterde de overleving en verminderde het 
aantal recidieven, maar deze verbeteringen moeten worden afgewogen tegen de morbiditeit 
door de behandeling. HDREBT is een gerichte wijze van radiotherapie. In totaal 141 Canadese 
patiënten behandeld met preoperatieve HDREBT, 26 Gy over 4 dagen, en 134 Nederlandse 
patiënten behandeld met of preoperatieve 5×5 Gy radiotherapie (n=52), of chemoradiatie 
(n=82) werden geïncludeerd, allen hadden zij een cT3 rectumcarcinoom op basis van de MRI 
beelden. Geen verschillen in lokale recidieven en niet-kankergerelateerde overleving werden 
gevonden tussen Nederland en Canada (5 uit 134 versus 2 uit 141, en 6 uit 134 versus 4 
uit 141, respectievelijk). Een statistisch significant verschil in vijf jaar overall overleving was 
gevonden, waarbij patiënten uit Canada een betere overleving hadden dan de patiënten 
uit Nederland na correctie (HR 0,42; 95% CI 0,20-0,90, p=0,03). HDREBT lijkt daarmee een 
realistisch alternatief voor de behandeling van patiënten met rectumcarcinoom. De verschil-
len in vijf jaar overall overleving tussen beide landen zijn mogelijk door de behandeling 
gerelateerde toxiciteit. Deze bevindingen kunnen grote klinische implicaties hebben; echter 
een gerandomiseerde trial kan hier definitief antwoord op geven. 
Als gevolg van onderzoek uit het verleden en het lopende onderzoek, zullen in de toekomst 
een toenemend aantal subgroepen geïdentificeerd worden met screening, toenemende 
leeftijd van de patiënten en de aanwezigheid van comorbiditeiten bij patiënten, daarnaast 
heeft onderzoek in de afgelopen tien jaar ertoe geleid dat significante vooruitgang is geboekt 
in het begrijpen van de biologie, moleculaire achtergrond, genetica, en pathogenese van het 
colorectaal carcinoom. In de toekomst zal patiëntenzorg meer multidisciplinair worden. Ieder 
betrokken specialisme zou deel moeten nemen aan de auditstructuren. Door multidisciplinaire 
auditstructuren tussen landen te vergelijken kunnen optimale behandelingsstrategieën voor 
iedere subgroep geïdentificeerd worden. Naast optimale behandelingsstrategieën, zal ook de 
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mening van de patiënt opgenomen moeten worden, om zo optimaal ‘personalised medicine’ 
te bereiken.
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